



(51) International Patent Classification:

C07K 16/40 (2006.01) G01N 33/577 (2006.01)

A61K 39/395 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/SG2021/050061

(22) International Filing Date:

05 February 2021 (05.02.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

10202001139U 07 February 2020 (07.02.2020) SG

(71) Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH [SG/SG]; 1 Fusionopolis Way, #20-10, Connexis North Tower, Singapore 138632 (SG).

(72) Inventors: SUN, William; c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #07-01, Singapore 138669 (SG). TAN, Boon Ooi Patrick; c/o Genome Institute of Singapore, 60 Biopolis Street, Genome, #02-01, Singapore 138672 (SG). WANG, Huajing; c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #07-01, Singapore 138669 (SG). YAP, Thai Leong; c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #07-01, Singapore 138669 (SG). HONG, Shin Yee; c/o Institute of Bioengineering and Nanotechnology, 31 Biopolis Way, #07-01, Singapore 138669 (SG). WANG, Cheng-I; c/o Singapore Immunology Network, 8A Biomedical Grove, Level 3, Immunos Building, Singapore 138648 (SG). HUANG, Ching-Wen; c/o Singapore Immunology Network, 8A Biomedical Grove, Level 3, Immunos Building, Singapore 138648 (SG). LEE, Shuet Theng; c/o Experimental Drug Development Centre, 10 Biopolis Road, #05-01, Singapore 138670 (SG). WAN, Kah Fei; c/o Experimental Drug Development Centre,

10 Biopolis Road, #05-01, Singapore 138670 (SG). NG, Jian Duan Johnathan; c/o Experimental Drug Development Centre, 10 Biopolis Road, #05-01, Singapore 138670 (SG).

(74) Agent: DAVIES COLLISON CAVE ASIA PTE. LTD.; 10 Collyer Quay #07-01, Ocean Financial Centre, Singapore 049315 (SG).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(54) Title: ANTIGEN-BINDING MOLECULES AGAINST ALPPL2 AND/OR ALPP AND USES THEREOF

(G)



(57) Abstract: The invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI. It also relates to a pharmaceutical composition, an immunoconjugate and a chimeric antigen receptor comprising said antigen-binding molecules. The invention also relates to methods for reducing the expression or activity of ALPPL2 in a cancer cell and methods of treating a cancer in a subject.

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

ANTIGEN-BINDING MOLECULES AGAINST ALPPL2 AND/OR ALPP AND USES THEREOF

Field of Invention

The invention relates generally to the field of oncology. In particular, the invention relates to antigen-binding molecules that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI.

Background

Antibodies are attractive therapeutic agents due to their ability to bind to cell surface antigens and eliminate cancer cells. Clinically-approved antibody therapeutics include Herceptin and Rituxan, which are highly successfully drugs for treating various cancers, including blood and solid cancers. Antibody therapies work by, for example, recruiting effector cells (such as natural killer cells or T-cells) or by modulating the signalling pathway of a cancer cells. The antibodies may also be conjugated to toxins or radioisotopes to help eliminate cancer cells. The development of a successful antibody therapy requires targeting of cell surface antigens that are preferentially expressed on cancer cells. This is because the expression of the same surface antigen on normal healthy cells may lead to undesired side effects.

There is generally a lack of suitable tumor-associated antigens for targeted antibody therapy against cancer. Furthermore, it is a significant challenge to develop an effective therapy against such antigens to treat cancer.

Accordingly, it is generally desirable to overcome or ameliorate one or more of the above mentioned difficulties.

Summary

Disclosed herein is an antigen-binding molecule that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI, comprising:

- (a) a heavy chain variable region (V_H) comprising VHCDR1, VHCDR2 and

- VHCDR3 amino acid sequences; and
- (b) a light chain variable region (V_L) comprising VLCDR1, VLCDR2 and VLCDR3 amino acid sequences; wherein the combination of VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 amino acid sequences are shown in any of the rows in Table 1.

Disclosed herein is a chimeric molecule comprising an antigen-binding molecule as defined herein and a heterologous moiety.

Disclosed herein is an isolated polynucleotide comprising a nucleic acid sequence encoding the antigen-binding molecule or the chimeric molecule as defined herein.

Disclosed herein is a construct comprising a nucleic acid sequence encoding the antigen-binding molecule or the chimeric molecule as defined herein in operable connection with one or more control sequences.

Disclosed herein is a host cell that contains the construct as defined herein.

Disclosed herein is a pharmaceutical composition comprising the antigen-binding molecule or the chimeric molecule as defined herein, and a pharmaceutically acceptable carrier.

Disclosed herein is a method for reducing the expression or activity of ALPPL2 in a cancer cell, the method comprising contacting the cancer cell with an antigen-binding molecule or a chimeric molecule as defined herein.

Disclosed herein is a method for reducing or inhibiting proliferation, survival and viability of a tumor in a subject, the method comprising administering an antigen-binding molecule or a chimeric molecule as defined herein to the subject.

Disclosed herein is a method of treating cancer in a subject, wherein the method comprises administering an antigen-binding molecule or a chimeric molecule as defined herein to the subject.

Disclosed herein is an antigen-binding molecule or a chimeric molecule as defined herein for use in the treatment of cancer.

Disclosed herein is the use of an antigen-binding molecule or a chimeric molecule as defined herein in the manufacture of a medicament for the treatment of cancer.

Disclosed herein is a method of treating a disease or condition associated with the undesired expression of ALPPL2 in a subject, wherein the method comprises administering an antigen-binding molecule or a chimeric molecule as defined herein to the subject.

Disclosed herein is a kit for detecting cancer, the kit comprising an antigen-binding molecule or a chimeric molecule as defined herein.

Disclosed herein is a method of determining the likelihood of a cancer in a subject, wherein the method comprises detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 in the sample as compared to a reference indicates the likelihood of cancer in the subject.

Disclosed herein is a method of treating a cancer in a subject, wherein the method comprises a) detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 in the sample as compared to a reference indicates an increased likelihood of cancer in the subject; and b) treating a subject found to have an increased likelihood of cancer.

Disclosed herein is a method of identifying a subject who is likely to be responsive to treatment with an anti-ALPPL2 antibody, the method comprising detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 indicates that the subject is likely to be responsive to treatment with the ALPPL2 antibody.

Disclosed herein is a method of identifying and treating a subject who is likely to be responsive to treatment with an anti-ALPPL2 antibody, the method comprising a) detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 indicates that the subject is likely to be responsive to treatment with the ALPPL2 antibody; and b) treating the subject found likely to be responsive to treatment with the ALPPL2 antibody.

Disclosed herein is a method for preparing an antigen-binding molecule that specifically binds ALPPL2 but not ALPL or ALPI, the method comprising:

- a) immunizing an animal, preferentially a rabbit, with ALPPL2,

- b) isolating from the animal a B-cell that binds specifically to ALPPL2 but not ALPL or ALPI, and
- c) determining the amino acid sequence of the antibody that is expressed by the B-cell.

Brief Description of Drawings

Embodiments of the present invention are hereafter described, by way of non-limiting example only, with reference to the accompanying drawings in which:

Figure 1 shows that a list of criteria was set to select for candidate genes encoding cell membrane proteins. Placental-like alkaline phosphatase, ALPPL2 emerged as one of the top candidates for subsequent target validation.

Figure 2 shows the immunohistochemical staining of gastric cancer cell lines (top) and gastric tumour microarrays (bottom).

Figure 3 shows identification of ALPPL2/ALPP specific clones produced from rabbit B cells supernatant by ELISA and FACS (top), and affinity measurements of selected clones in single concentration by biolayer interferometry (bottom).

Figure 4 shows the comparison between ALPPL2 reactivity and ALPI reactivity of our humanized antibody and a comparable humanized antibody disclosed in prior art, as measured by ELISA (top) and surface plasmon resonance (bottom).

Figure 5 shows the IHC stains of formalin fixed, paraffin embedded (FFPE) sections by C36, C45 and C130 of different gastric cancer cell lines (A). IHC stains of FFPE - human gastric, ovarian, colorectal, pancreatic, testicular, mesothelioma and endometrial tumors microarrays by C36 with different H-score of IHC 1+, IHC 2+ and IHC 3+ (B). IHC stains of FFPE-normal tissues by C36. All normal tissues shows no C36 staining (negative) except placenta tissues that shows positive IHC2+ staining (C).

Figure 6 shows the cross-reactivity of select clones produced from rabbit B cells supernatant to rhesus macaque ortholog identified through FACS screen (A).

Recombinant humanized C4 and C36 clones binds to CHO cells over-expressed rhesus macaque ortholog but not WT CHO by FACS analysis (B).

Figure 7 shows retention of high ALPP/ALPPL2 affinity after humanization of select clones, as measured by surface plasmon resonance (SPR).

Figure 8 shows ADCC induction by humanized clones. ADCC induction as measured in coculture of high-expressing gastric cancer cell line MKN1 with Jurkats CD16A reporter cells (top row, left), and coculture of low-expressing gastric cancer cell line MKN74 with Jurkats CD16A reporter cells (top row, right). Potentiation of ADCC by C4 as measured by CellTiter-Glo assay of gastric cancer cell lines in coculture with primary NK cells (middle row, left), and coculture of ovarian and pancreatic cancer cell lines with Jurkats CD16A reporter cells (middle row, right). ADCC enhancement by Fc engineering of humanized C4 as measured in coculture of MKN74 with Jurkats CD16A reporter cells (bottom row).

Figure 9 shows ADC killing of gastric cancer cell lines as measured by CellTiter-Glo assay. Killing of high-expressing gastric cancer cell lines by humanized clones via vc-MMAF conjugated to the secondary antibody (top row). Killing of gastric cancer cell lines by humanized C4 (middle row, left) and C12 (middle row, right) conjugated with vc-MMAE. Killing of gastric cancer cell lines by humanized C4 (bottom row, left) and C12 (bottom row, right) via vc-MMAF conjugated to the secondary antibody.

Figure 10 shows potent killing of different cancer cell lines by T-cell engagers derived from the humanized clones, as measured by xCELLigence real-time cell analysis of the cancer cells in coculture with expanded human T-cells. C4 consistently demonstrated pM killing of gastric, ovarian and pancreatic cancer cell lines, regardless of target expression level.

Figure 11 shows potent killing of different cancer cell lines by T-cell engagers with different anti-CD3 variants, in different formats. Humanized Fab fragment is amenable to the production of potent T-cell engagers by different anti-CD3 pairings and in different formats.

Figure 12 shows reactivity of select clones to ALPPL2 but not ALPP and cancer cells killing potency by these clones after humanisation. FACS shows chimerized C53 and C78 bind ALPPL2 but not ALPP, whereas rabbit C4 binds both (A). ELISA shows chimerized C53 and C78 bind ALPPL2 but not ALPP (B). ADCC induction by chimerised clones as measured by co-culture of MKN74 with Jurkats CD16A reporter cells is shown (C). ELISA shows chimerized C53 and C78 cross-reacted to CHO cells overexpressing rhesus macaque ortholog identified through FACS (D). Humanized C53 shows the ALPPL2 specificity by ELISA (E) and co-culture of N87 with Jurkats CD16A reporter cells show that ADCC induction activity (F) is maintained after humanization. Humanized C53 demonstrated nM binding affinity towards ALPPL, but not ALPP determined by Biolayer Interferometry, whereas humanized C36 demonstrated similar binding affinity towards ALPPL2 and ALPP (G). Humanized C53 shows potent killing in N87 cells by T-cell engagers, as measured by xCELLigence real-time cell analysis of the N87 gastric cancer cells co-cultured with expanded human T-cells (H). Humanized C53 T-cell engager demonstrated similar pM killing as C36 T-cell engager.

Figure 13 shows binding profile of humanized C4, C36 and C53 to different isoform of human alkaline phosphatase family, cancer cell lines and normal immune cells. Humanized C4 and C36 show binding to human ALPPL2 and ALPP, but not to human ALPI and ALPL, whereas humanized C53 binds specifically to human ALPPL2, but not to human ALPP, ALPI and ALPL transiently expressed in 293T cells by FACS analysis (A). Different doses of humanized C36, C4 and C53 show binding to ALPPL2/ALPP positive cell line (NCI-N87) but not to negative cells line (MIAPaca-2). Humanized C53 has comparable binding affinity as commercial antibody (catalogue number: eBioScience #14-9870-82), and weaker binding affinity as compared to humanized C4 and C36 (B). Humanized C36, C4 and C53 show no binding to the naïve and CD3/CD28 beads + IL-2 activated human PBMCs (CD4+/CD8+ T cell, B cell, CD11b+ myeloid Mφ cells) (C). Humanized C36, C4 and C53 shows no binding to the T cell, B cells and myeloid Mφ cells (D).

Detailed Description

The present disclosure teaches antigen-binding molecules that specifically binds ALPPL2 and/or ALPP, but not ALPL or ALPI. The antigen-binding molecules may

bind to ALPPL2 and/or ALPP or a cell expressing ALPPL2 and/or ALPP with an affinity of between about 14 pM to about 10 nM.

Disclosed herein is an antigen-binding molecule that specifically binds ALPPL2 and/or but not ALPL or ALPI, comprising: (a) a heavy chain variable region (V_H) comprising VHCDR1, VHCDR2 and VHCDR3 amino acid sequences; and (b) a light chain variable region (V_L) comprising VLCDR1, VLCDR2 and VLCDR3 amino acid sequences; wherein the combination of VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 amino acid sequences are shown in any of the rows in Table 1.

Alkaline phosphatase, placental-like 2 (ALPPL2) is a member of the alkaline phosphatase (AP) family, consisting of two closely related isoforms expressed in placental trophoblasts (ALPPL2 and ALPP), and two widely expressed members ALPL (tissue-nonspecific, liver/bone/kidney) and ALPI (intestinal). In one embodiment, the antigen-binding molecule specifically binds to ALPPL2 and/or ALPP. In one embodiment, the antigen-binding molecule specifically binds to human ALPPL2 and/or human ALPP. In one embodiment, the antigen-binding molecules have enhanced efficacy due to the high affinity towards ALPPL2 and/or ALPP.

In one embodiment, the antigen-binding molecule does not have any detectable binding to ALPL or ALPI. In one embodiment, the antigen-binding molecule does not have any detectable binding to human ALPL or human ALPI. This may also be referred to as having a dissociation constant (K_d) of more than 10 nM, more than 100 nM, more than 1 μ M, more than 10 μ M, more than 100 μ M or more than 1 mM detectable binding to human ALPL or human ALPI. In one embodiment, the antigen-binding molecules have desirable therapeutic windows due to the lack of binding to ALPL or ALPI. In one embodiment, the antigen-binding molecules do not induce (or induce minimal) T-cell killing of normal cells.

Without being bound by theory, the inventors have isolated monoclonal antibodies against tumor-associated antigens, human placental-like alkaline phosphatases (ALPPL2) with high affinity (sub-nM K_d) and specificity (non-reactive to the closely related ALPL or ALPI), immunohistochemical activity (useful for development of companion diagnostics), cross-reactivity to non-human primate ortholog (useful for

toxicology studies). The inventors have humanized some clones by grafting the complementarity determining region (CDR) to a human IgG1 framework and showed these humanized antibodies retain high affinity to ALPPL2. The inventors have also shown that these naked humanized antibodies induced potent antibody-dependent cell cytotoxicity (ADCC) in coculture assay of Jurkats reporter and primary natural killer (NK) cells with gastric cancer cell lines. ADCC induction was also seen with ovarian and pancreatic cancer cell lines. The inventors have showed suitability of using these humanized antibodies as antibody-drug conjugates through cancer cell killing by primary conjugates and in a secondary assay. The inventors have also generated bispecific antibodies by heterodimerisation of these humanized antibodies with anti-CD3 antibodies. These bispecific antibodies functioned as potent T-cell engagers (TcE) and that achieved picomolar (pM) killing of gastric, ovarian and pancreatic cancer cell lines. Thus, these antibodies can be used as targeted therapy against tumors expressing ALPPL2 on the cell surface.

Table 1 shows the possible combinations of CDRs that can be present on an antigen-binding molecule.

	V _H	V _L
CDR1 CDR2 CDR3	FTISNNYWIC (SEQ ID NO: 1) WIGCIATGDGSTYY (SEQ ID NO: 2) RGAAGSSWTTYFDF (SEQ ID NO: 3)	QNIDNYLS (SEQ ID NO: 4) LLIYRASTLAS (SEQ ID NO: 5) QNNNGGSTFTGFP (SEQ ID NO: 6)
CDR1 CDR2 CDR3	FDFSSNGMC (SEQ ID NO: 7) WIACIYVDSSDNTNY (SEQ ID NO: 8) RGYGYVGSAMD (SEQ ID NO: 9)	QSINNELS (SEQ ID NO: 10) LLIYGASTLES (SEQ ID NO: 11) QSAYYSSSSYANT (SEQ ID NO: 12)
CDR1 CDR2 CDR3	FTISSIWIC (SEQ ID NO: 13) WIACIYAGSDGGSYY (SEQ ID NO: 14) RASNSWQYGYAGYGNKYDFNL (SEQ ID NO: 15)	ESISNLLA (SEQ ID NO: 16) VLIYKASALPS (SEQ ID NO: 17) QSYYGSSDTGNT (SEQ ID NO: 18)
CDR1 CDR2 CDR3	FSFSSSYWIS (SEQ ID NO: 19) WIACIAIGSSGTTY (SEQ ID NO: 20) RSGDGYTYVEL (SEQ ID NO: 21)	QSISSYLA (SEQ ID NO: 22) LLIYRASTLAS (SEQ ID NO: 23) QNYDIDDSNT (SEQ ID NO: 24)
CDR1 CDR2 CDR3	FSFSWIC (SEQ ID NO: 25) WIACIYAGSSAKTY (SEQ ID NO: 26) RASNYRYGVAGYADYTGYNL (SEQ ID NO: 27)	QSISSWLA (SEQ ID NO: 28) LLIYGTSTLAS (SEQ ID NO: 29) QNYGGSSGDA (SEQ ID NO: 30)
CDR1 CDR2 CDR3	FSFSSNYWIC (SEQ ID NO: 31) WIACIATGSSGSTYY (SEQ ID NO: 32) RGEYTYGYVEYAIVTQYYFDL (SEQ ID NO: 33)	QNIYSNLA (SEQ ID NO: 34) LLIYGASNLES (SEQ ID NO: 35) QSADYIGSAYNA (SEQ ID NO: 36)

CDR1 CDR2 CDR3	FSFSSSYMC (SEQ ID NO: 37) WIACIYTTYGGTWY (SEQ ID NO: 38) RSSISDVTYFNL (SEQ ID NO: 39)	QSISSNYLA (SEQ ID NO: 40) LLIYRASTLES (SEQ ID NO: 41) QSYDNNNYA (SEQ ID NO: 42)
CDR1 CDR2 CDR3	FTLSTYWVC (SEQ ID NO: 43) WIGCIDTVSSGDTYF (SEQ ID NO: 44) RRTGSGWTL (SEQ ID NO: 45)	QSVYNNNYLA (SEQ ID NO: 46) LLIYWASKLAS (SEQ ID NO: 47) LGAYVSNGWYFA (SEQ ID NO: 48)
CDR1 CDR2 CDR3	FSFSSYWTC (SEQ ID NO: 49) WLGCTDGGSSGDTYY (SEQ ID NO: 50) RNLITWDL (SEQ ID NO: 51)	ESVYNNNQLS (SEQ ID NO: 52) LLIYWASKLAS (SEQ ID NO: 53) AGYKSSITDGNA (SEQ ID NO: 54)
CDR1 CDR2 CDR3	FDFSTNIMC (SEQ ID NO: 55) WIACIYAGDGSTYY (SEQ ID NO: 56) RASTYWNYGAGYGYYPGYFNL (SEQ ID NO: 57)	QSIISALA (SEQ ID NO: 58) LLIYAASLAS (SEQ ID NO: 59) QTYAYSTKSNGSV (SEQ ID NO: 60)
CDR1 CDR2 CDR3	FSFSSGYDMC (SEQ ID NO: 61) WIACIYTGDSSTYY (SEQ ID NO: 62) REDVSSGDTYFNL (SEQ ID NO: 63)	EDIYSGLA (SEQ ID NO: 64) LLIYKASNLAS (SEQ ID NO: 65) QQGVYTYSNVDNT (SEQ ID NO: 66)
CDR1 CDR2 CDR3	FSFSSTYYMC (SEQ ID NO: 67) WIACIYTGSTGSTYY (SEQ ID NO: 68) RGDYTYAYAGGAHVNTNYFDL (SEQ ID NO: 69)	QNIYSNLA (SEQ ID NO: 70) LLIFGASNLES (SEQ ID NO: 71) QTADYSSSTDWGA (SEQ ID NO: 72)
CDR1 CDR2 CDR3	FDFSSNGMC (SEQ ID NO: 73) WIACIYVDSSDSTYY (SEQ ID NO: 74) RGYGYVGSAMD L (SEQ ID NO: 75)	QSISSNELS (SEQ ID NO: 76) LLIYGASTLES (SEQ ID NO: 77) QSAYYSSSSSYANT (SEQ ID NO: 78)
CDR1 CDR2 CDR3	FTLSTYWVC (SEQ ID NO: 79) WIGCIDTVSSGDTYF (SEQ ID NO: 80) RRTGSGWTL (SEQ ID NO: 81)	QSVYNNNYLA (SEQ ID NO: 82) LLIYWASKLAS (SEQ ID NO: 83) LGAYVSNGWYFA (SEQ ID NO: 84)
CDR1 CDR2 CDR3	FSFSSSYMC (SEQ ID NO: 85) WIACIYPDDGNTYY (SEQ ID NO: 86) RALAYYAYVDGGHSYAINDFDL (SEQ ID NO: 87)	QSVFSNDYFS (SEQ ID NO: 88) LLIYDASRLAS (SEQ ID NO: 89) QGTYYSSAWYNA (SEQ ID NO: 90)
CDR1 CDR2 CDR3	FDFSSNGMC (SEQ ID NO: 91) WIACIYVDSSDNTNY (SEQ ID NO: 92) RGYGYVGSAMD L (SEQ ID NO: 93)	QSISSNELS (SEQ ID NO: 94) LLIYGASTLES (SEQ ID NO: 95) QSAYYSSSSSYANT (SEQ ID NO: 96)
CDR1 CDR2 CDR3	IDFSSDYMC (SEQ ID NO: 97) WIACIYTGSDDTYY (SEQ ID NO: 98) RGGYGGKDL (SEQ ID NO: 99)	QSIGSLLA (SEQ ID NO: 100) LLIYWASTLAS (SEQ ID NO: 101) QCTYGSSGSSSYLNA (SEQ ID NO: 102)
CDR1 CDR2 CDR3	FDFSSNGMC (SEQ ID NO: 103) WIACIYVDSSDSTYY (SEQ ID NO: 104) RGYGYVGSAMD L (SEQ ID NO: 105)	QSISSNELA (SEQ ID NO: 106) LLIYGASTLES (SEQ ID NO: 107) QSAYYSSSSSYANT (SEQ ID NO: 108)
CDR1 CDR2 CDR3	FTLSTYWVC (SEQ ID NO: 109) WIGCIDTVSSGDTYF (SEQ ID NO: 110) RRTGSRWTL (SEQ ID NO: 111)	ESVYNNNYLS (SEQ ID NO: 112) LLIYQASTLAS (SEQ ID NO: 113) LGAFVSNGWYFA (SEQ ID NO: 114)

CDR1 CDR2 CDR3	FSFSSGYNIC (SEQ ID NO: 115) LIACIYSSSGSTYY (SEQ ID NO: 116) RGEAYYAYGYVGYAYYHGAFDP (SEQ ID NO: 117)	HSISKYFS (SEQ ID NO: 118) LLIYEASTLAS (SEQ ID NO: 119) QSYYYGTSSSYA (SEQ ID NO: 120)
CDR1 CDR2 CDR3	FSFSSSYMC (SEQ ID NO: 121) WIACIYAGSSGGTYY (SEQ ID NO: 122) RAFSYYYSDGYTGYAYGL (SEQ ID NO: 123)	QSISSYLA (SEQ ID NO: 124) LLIYRASTLAS (SEQ ID NO: 125) QGAYYSSSSSYG (SEQ ID NO: 126)
CDR1 CDR2 CDR3	FSFSGYDM (SEQ ID NO: 127) WIACIHSSSGTYY (SEQ ID NO: 128) RDFSYYTDDYISYVYATD (SEQ ID NO: 129)	QGSSLA (SEQ ID NO: 130) LLIYAASYLA (SEQ ID NO: 131) QSTYYSSSTDIRA (SEQ ID NO: 132)
CDR1 CDR2 CDR3	FSFSSYWIC (SEQ ID NO: 133) WIACIYAGSSGTYY (SEQ ID NO: 134) RAEYIDGYADYTYTTLTYFDL (SEQ ID NO: 135)	QIYNNLA (SEQ ID NO: 136) LLIYGASNLE (SEQ ID NO: 137) QSADLTSSINV (SEQ ID NO: 138)
CDR1 CDR2 CDR3	FSFNSNYWMC (SEQ ID NO: 139) WIGCILFGNTDTYY (SEQ ID NO: 140) RSVSGVGSANL (SEQ ID NO: 141)	ESVYNNNHLA (SEQ ID NO: 142) LLIYLASILDS (SEQ ID NO: 143) AGYKGITIDGSA (SEQ ID NO: 144)
CDR1 CDR2 CDR3	FDFSSYYWIC (SEQ ID NO: 145) WIACIYGGSSGTYY (SEQ ID NO: 146) RSLYTWRYADYAASTLNL (SEQ ID NO: 147)	QSVYNVNLLA (SEQ ID NO: 148) LLIYETSKLES (SEQ ID NO: 149) AGGYSSSKDNS (SEQ ID NO: 150)
CDR1 CDR2 CDR3	FSFSSSYFMC (SEQ ID NO: 151) WIACIYTG DGNNYY (SEQ ID NO: 152) RGGSYYAYGYAGYDYYPDAFDY (SEQ ID NO: 153)	QSISSYLS (SEQ ID NO: 154) LLIYRASTLAS (SEQ ID NO: 155) QSYYYSSSGSYG (SEQ ID NO: 156)
CDR1 CDR2 CDR3	FSFNSYYMC (SEQ ID NO: 157) WIACISGGSSDNTYY (SEQ ID NO: 158) RDIPRSGYFGCDL (SEQ ID NO: 159)	QNIYSNLA (SEQ ID NO: 160) LLIYGASNLES (SEQ ID NO: 161) QSTVYNSNYANT (SEQ ID NO: 162)
CDR1 CDR2 CDR3	FSFSSSYWIY (SEQ ID NO: 163) WIACIYTASRGSIYY (SEQ ID NO: 164) RGPDYTYGYIGDALTRLDL (SEQ ID NO: 165)	QSVYDNNWLA (SEQ ID NO: 166) LLIYAASTLSS (SEQ ID NO: 167) AGGYSSTSDIEDNT (SEQ ID NO: 168)
CDR1 CDR2 CDR3	FSFSSSYWIC (SEQ ID NO: 169) WIACIYAGSSGDTYY (SEQ ID NO: 170) RAEYIDGYADYTYTTLTYFDL (SEQ ID NO: 171)	ESINSWLA (SEQ ID NO: 172) LLIYSASTLAS (SEQ ID NO: 173) QSYYSFSRFA (SEQ ID NO: 174)
CDR1 CDR2 CDR3	FSFSSGYWIC (SEQ ID NO: 175) WIACIYTG VGATYY (SEQ ID NO: 176) RDFGGSSGFYFNL (SEQ ID NO: 177)	QSI SNALA (SEQ ID NO: 178) LLIYSASTLES (SEQ ID NO: 179) QNYYGSTSSSYGVA (SEQ ID NO: 180)
CDR1 CDR2	FSFSSSYMC (SEQ ID NO: 181) WIACIYAGSTFSTYY (SEQ ID NO: 182)	ESIYSNLA (SEQ ID NO: 184) LLIYLASTLAS (SEQ ID NO: 185)

CDR3	RSDSYYTYGYAGYAYAIFNL (SEQ ID NO: 183)	QSAYYSSSADIA (SEQ ID NO: 186)
CDR1 CDR2 CDR3	LDFSSSYWIC (SEQ ID NO: 187) WIGCIKTATETTVY (SEQ ID NO: 188) KTYADNGGYINL (SEQ ID NO: 189)	QNIYNNLA (SEQ ID NO: 190) LLIYGASNLES (SEQ ID NO: 191) QSADLTSSINV (SEQ ID NO: 192)
CDR1 CDR2 CDR3	FSFSSSYWIC (SEQ ID NO: 193) WIACIYTASRDSIYY (SEQ ID NO: 194) RGPYYSYAYIGDALTRLDL (SEQ ID NO: 195)	QSVYDNNWLA (SEQ ID NO: 196) LLIYEASKLAS (SEQ ID NO: 197) AGGYSSSSDIEDNT (SEQ ID NO: 198)
CDR1 CDR2 CDR3	FSFNSNYYMC (SEQ ID NO: 199) WIACIYTGIVVPTY (SEQ ID NO: 200) RDPYVGSSYIYNL (SEQ ID NO: 201)	QSVYNNNNLA (SEQ ID NO: 202) LLIYSASSLAS (SEQ ID NO: 203) AGYKTYSNNEA (SEQ ID NO: 204)
CDR1 CDR2 CDR3	FSFSSSYMC (SEQ ID NO: 205) WIACIYAGSSSTYY (SEQ ID NO: 206) RAGYIDSYVDYTYAAWYFDL (SEQ ID NO: 207)	ENIYSNLAW (SEQ ID NO: 208) LLIYGASNLES (SEQ ID NO: 209) QSADLSSINV (SEQ ID NO: 210)
CDR1 CDR2 CDR3	FSFSSSYMC (SEQ ID NO: 303) WIGCIYTGNDTWTY (SEQ ID NO: 304) RGLSPIDL (SEQ ID NO: 305)	ESIYNNNNLG (SEQ ID NO: 306) LLIYWASTLAS (SEQ ID NO: 307) AGYKSRTTDGSAF (SEQ ID NO: 308)
CDR1 CDR2 CDR3	FSFSSGYDMC (SEQ ID NO: 309) WIACIHSSSGTYY (SEQ ID NO: 310) RDFSYTDDYISYVYATDL (SEQ ID NO: 311)	QSIGSSLA (SEQ ID NO: 312) LLIYAASYLAS (SEQ ID NO: 313) QSTYYSSSTDIRA (SEQ ID NO: 314)

Table 2 shows the combinations of V_H and V_L sequences (CDR1, 2 and 3 underlined) in an antigen-binding molecule that are derived from the 36 antibody clones.

Clone ID	V _H	V _L
AB1C4	QSLEESGGDLVKPGPSLTLTCKASG <u>FTISNNYWICWVRQAPGKGL</u> <u>WIGCIATGDGSTYYASWAKGRFTI</u> SKTSSTTVTLQMTSLTAADTATYFCA <u>RGAAGSSWTYFDWGP</u> GPVTVSS (SEQ ID NO: 211)	DIVMTQTPASVEAAVGGTGTIKCQAG <u>QNIDNYLSWYQQKPGQPPK</u> <u>LLIYRASTLASGVPSRFKSGSG</u> TEFTLTISDLECAATAATYYC <u>QNNNGGSTFTGFP</u> GGGTEVVVK (SEQ ID NO: 212)
AB1C10	QSLEESGGDLVKPGASLTLTCTASG <u>FDSSNGMCWVRQAPGKGL</u> <u>WIACIYVDSSDNTNYASWVNGRFTI</u> SRTSSTTVTLQMTSLTAADTATYFCA <u>RGYGYVGSAMD</u> LWGQGLTVTVSS (SEQ ID NO: 213)	DIVMTQTPASVEAAVGGTGTIKCQAS <u>QSINNELSWYQQKPGQPPK</u> <u>LLIYGASTLES</u> GVPSRFKSGSG TEFTLTISDLECAATAATYYC <u>QSAYYSSSSSYANT</u> FGGGTEVVVK (SEQ ID NO: 214)
AB1C11	QSLEESGGDLVKPGASLTLTCKASG <u>FTISSIWICWVRQAPGKGL</u> <u>WIACIYAGSDGGSYYASWARGRFTI</u> SKTSSTTVTLQMTSLTAADTATYFCA <u>RASNSWQYGYAGYGNKYDYNL</u> WGP GTLVTVSS	FELTQTPSSVEAAVGGTGTINCAQAS <u>ESISNLLAWYQQKSGQPPK</u> <u>VLIYKASALPSGVSSRFKSGSG</u> TEFTLTISDLECAATAATYYC <u>QSYYGSSDTGNT</u> FGGGTEVVVK

	(SEQ ID NO: 215)	(SEQ ID NO: 216)
AB1C12	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSYWISWVRQAPGKGLE</u> <u>WIACIAIGSSGTTYASWAKGRFT</u> <u>ISKTSTTVTLQMTSLTAADTATYFCA</u> <u>RSGDGYTYVELWGPGLTVTVSS</u> (SEQ ID NO: 217)	<u>DVVMQTTPASVSEPVGTVTIKCQAS</u> <u>QSISSYLAWYQKPGQPPK</u> <u>LLIYRASTLASGVPSRFGSGSGTQF</u> <u>TLTISDLECADAAATYYC</u> <u>QNYDIDDSNTFGGGTEVVVK</u> (SEQ ID NO: 218)
AB1C13	<u>QEQLYESGGDLVKPEGSLTLTCTASG</u> <u>FSFSWICWVRQAPGKGLE</u> <u>WIACIYAGSSAKTTYASWAKGRFTI</u> <u>SKASSTTVTLQMTSLTAADTATYFCA</u> <u>RASNYRYGVAGYADYTGYNLWGP</u> <u>GTLTVTVSS</u> (SEQ ID NO: 219)	<u>FELTQTPASVEAAVGGTVTIKCQAS</u> <u>QSISSWLAWYHQKPGQRPK</u> <u>LLIYGTSTLASGVPSRFGSGSG</u> <u>TEFTLTISDLECADAAATYYC</u> <u>QNYGGSSSGDAFGGGTEVVVK</u> (SEQ ID NO: 220)
AB1C14	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSNYWICWVRQAPGKGLE</u> <u>WIACIATGSSGSTYYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RGEYTYGYVEYAIVTQYYFDLWGP</u> <u>GTLTVTVSS</u> (SEQ ID NO: 221)	<u>FEMTQTPSSVSAAVGGTVTINCQAS</u> <u>QNIYSNLAWYQKPGQRPK</u> <u>LLIYGASNLSEGVPSRFGSGSG</u> <u>TEYTLTISDLECDAAATYYC</u> <u>QSADYIGSAYNAFGGGTEVVVK</u> (SEQ ID NO: 222)
AB1C15	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSYYMCWVRQAPGKGLE</u> <u>WIACIYTTYGGTWYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTDADTATYFCA</u> <u>RSSISDVTFNLWGPGLTVTVSS</u> (SEQ ID NO: 223)	<u>DIVMTQTPASVEAAVGGTVTIKCQAS</u> <u>QSISSNYLAWYQKPGQPPK</u> <u>LLIYRASTLESGVPSRFGSGSG</u> <u>TGFTLTISDLECADAAATYYC</u> <u>QSYDNNNYAFGGGTEVVVK</u> (SEQ ID NO: 224)
AB1C17	<u>QEQLKESGGDLVKPGASLTLTCTASG</u> <u>FTLSTYWVCWVRQAPGKGLE</u> <u>WIGCIDTVSSGDTYFASWAKGRFTG</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RRTGSGWTLWGPGLTVTVSS</u> (SEQ ID NO: 225)	<u>LVMTQTPSPVSAAVGGTVTISCQSS</u> <u>QSVYNNNNYLWFQNPQPPK</u> <u>LLIYWASKLASGVPSRFGSGSG</u> <u>TQFTLTISDVQCDDAAATYYC</u> <u>LGAYVSNGWYFAFGGGTEVVVK</u> (SEQ ID NO: 226)
AB1C18	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSYWTWVRQAPGKGLE</u> <u>WLGCTDGGSGDTYYATWAKGRVAI</u> <u>SKTSSTTVTLQVTSMTAADTATYFCA</u> <u>RNLITWDLWGPGLTVTVSS</u> (SEQ ID NO: 227)	<u>IVMTQTPSSKSVPVGDVTINCQAS</u> <u>ESVYNNNNQLSWFQKPGQPPK</u> <u>LLIYWASKLASGVPSRFGSGSG</u> <u>TQFTLTISDVVCDDAAATYYC</u> <u>AGYKSSITDGNAFGGGTEVVVK</u> (SEQ ID NO: 228)
AB1C19	<u>QSLEESGGDLVQPEGSLTLTCKASG</u> <u>FDFSTNIMCWVRQAPGKGLE</u> <u>WIACIYAGDGSTYYASWVNGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RASYWNYGYAGYGYYPGYFNLWGP</u> <u>GTLTVTVSS</u> (SEQ ID NO: 229)	<u>DIVMTQTPASVEAAVGGTVTIKCQAS</u> <u>QSIISALAWYQKPGQPPK</u> <u>LLIYAASSTLASGVPSRFGSGSG</u> <u>TQFTLTISDLECADAAATYYC</u> <u>QTYAYSTKSNGSVFGGGTEVVVK</u> (SEQ ID NO: 230)
AB1C21	<u>QQQLVESGGGLVKPGASLTLTCKASG</u> <u>FSFSSGYDMCWVRQAPGKGLE</u> <u>WIACIYTGDSSTYYASWARGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>REDVSSGDYTFNLWGPGLTVTVSS</u>	<u>YDMTQTPASVEVTVGGTVTIKCQAS</u> <u>EDIYSGLAWYQKPGQRPK</u> <u>LLIYKASNLASGVPSRFGSGSG</u> <u>SGTEFTLTISGVECADAAATYYC</u> <u>QQGVTYSNVDNTFGGGTEVVVK</u>

	(SEQ ID NO: 231)	(SEQ ID NO: 232)
AB1C23	<u>Q</u>SLEESGGDLVKPGASLTLTCTASG <u>F</u>SFSSTYYMCWVRQAPGKGLE <u>W</u>IACIYTGSTGSTYYASWAKGRFTG SKTSSTTVTLQMTSLTAADTATYFCA <u>R</u>GDYTYAYAGGAHVTNYYFDLWGP GTLVTVSS (SEQ ID NO: 233)	LVMTQTPSSVSAAVGGTVTINCQAS <u>Q</u>NIYSNLAWYQQKPGQRPK <u>L</u>LIFGASNLESGVPSRFKGS GSG TEFTLTISDLECDAAATYYC <u>Q</u>TADYSSSTDWGAFGGGTEVVVK (SEQ ID NO: 234)
AB1C25	Q SLEESGGDLVKPGASLTLTCTASG FDFSSNGMCWVRQAPGKGLE <u>W</u>IACIYVDSSDSTYYASWVNGRFTI SRTSSTTVTLQMTSLTAADTATYFCA <u>R</u>GYGYVGSAMD L WGQGLTVTVSS (SEQ ID NO: 235)	DIVMTQTPASVEAAVGGTVTIKCQAS Q SISELNSWYQQKPGQRPK <u>L</u>LIYGASTLESGVPSRFKGS GSG TEFTLTISDLECDAAATYYC <u>Q</u>SAYYSSSSSYANTFGGGTEVVAA (SEQ ID NO: 236)
AB1C28	QEQLKESGGDLVKPGASLTLTCTASG <u>F</u>TLSTYWVCWVRQAPGKGLE <u>W</u>IGCIDTVSSGDTYFASWAKGRFTG SKTSSTTVTLQMTSLTAADTATYFCA <u>R</u>RTGSGWTL WGPGLTVTVSS (SEQ ID NO: 237)	LVMTQTPSPVSAAVGGTVTISCQSS <u>Q</u>SVYNNNYLAWFQQNPGQPPK <u>L</u>LIYWASKLASGVPSRFKGS GSG TQFTLTISDVQCDDAAATYYC <u>L</u>GAYVSNGWYFAFGGGIEVVVK (SEQ ID NO: 238)
AB1C29	QEHLEESGGGLVKPEGSLTLTCTASG <u>F</u>SFSSYYMCWVRQAPGKGLE <u>W</u>IACIYDSDGNTYYASWAKGRFTI SKTSSTTVTLQMTSLTAADTATYFCA <u>R</u>ALAYYAYVDGGHSYAINDFDLWGP GTLVTVSS (SEQ ID NO: 239)	QVLTQTPSSVSAAVGGTVTINCQSS <u>Q</u>SVFSNDYFSWYQQKPGQPPK <u>L</u>LIYDASRLASGVPSRFKGS GSG TQFTLTISGVQCDDAAATYYC <u>Q</u>GTYYSASWYNAFGGGTEVVVK (SEQ ID NO: 240)
AB1C31	Q SLEESGGDLVKPGASLTLTCTASG FDFSSNGMCWVRQAPGKGLE <u>W</u>IACIYVDSSDNTNYASWVNGRFTI SRTSSTTVLKMSTLTAADTATYFCA <u>R</u>GYGYVGSAMD L WGQGLTVTVSS (SEQ ID NO: 241)	DIVMTQTPASVEAAVGGTVTIKCQAS Q SISELNSWYQQKPGQRPK <u>L</u>LIYGASTLESGVPSRFKGS GSG TEFTLTISDLECDAAATYYC <u>Q</u>SAYYSSSSSYANTFGGGTEVVVK (SEQ ID NO: 242)
AB1C32	QEQLKESGGDLVKPGGLTLTCKASG <u>I</u>DFSSDYMCWVRQAPGKGLE <u>W</u>IACIYTGSSDDTYFASWAKGRFTI SKTSPTVALQMTSLTAADTATYFCA <u>R</u>GGYGGKDL WGPGLTVTVSS (SEQ ID NO: 243)	VVMTQTPASVEAAVGGTVTIKCQAS <u>Q</u>SIGSLLAWYQQKPGQPPN <u>L</u>LIYWASTLASGVPSRFKGS GSG TEFTLTISDLECDAAATYYC <u>Q</u>CTYGSSGSSSYLNAFGGGTEVVVK (SEQ ID NO: 244)
AB1C34	Q SLEESGGDLVKPGASLTLTCTASG FDFSSNGMCWVRQAPGKGLE <u>W</u>IACIYVDSSDSTYYASWVNGRFTI SKTSSTTVTLQMTSLTAADTATYFCA <u>R</u>GYGYVGSAMD L WGQGLTVTVSS (SEQ ID NO: 245)	NIVMTQTPSPVSGAVGGTVTIKCQAS Q SISELNSWYQQKPGQRPK <u>L</u>LIYGASTLESGVPSRFKGS GSG TEFTLTISDLECDAAATYYC <u>Q</u>SAYYSSSSSYANTFGGGTEVVVK (SEQ ID NO: 246)
AB1C35	QEQLKESGGDLVKPGASLTLTCTASG <u>F</u>TLSTYWVCWVRQAPGKGLE <u>W</u>IGCIDTVSSGDTYFASWAKGRFTG SKTSSTTVTLQMTSLTAADTATYFCA <u>R</u>RTGSRWTL WGPGLTVTVSS (SEQ ID NO: 247)	QVLTQTPSSVSAGVGGTVTINCQAS <u>E</u>SVYNNNYLSWYQQKPGQPPK <u>L</u>LIYQASTLASGVPSRFKGS GSG TQFTLTISDVQCDDAAATYYC <u>L</u>GAFVSNGWYFAFGGGTEVVVK (SEQ ID NO: 248)

AB1C36	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSGYNICWVRQAPGKGLE</u> <u>LIACIYTSSSGSTYYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTVADTATYFCA</u> <u>RGEAYYAYGYVGYAYYHGA</u><u>FDPWGP</u> <u>GTLVTVSS</u> (SEQ ID NO: 249)	<u>DIVMTQTPASVEAGVGGT</u><u>VTIKQAS</u> <u>HSISKYFSWYQQKIGQPPK</u> <u>LLIYEASTLASGVPSRFGSGSG</u> <u>TQFTLTISDLECADAAATYYC</u> <u>QSYYYGTSSSYAFGGGTEVVVK</u> (SEQ ID NO: 250)
AB1C39	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSYYMCWVRQAPGKGLE</u> <u>WIACIYAGSSGGTYYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RAFSYYYSDGYTGYAYGLWGP</u> <u>GTLVTVSS</u> (SEQ ID NO: 251)	<u>DIVMTQTPASVEAAVGGT</u><u>VTIKQAS</u> <u>QSISSYLAWYQQKPGQPPK</u> <u>LLIYRASTLASGVPSRFGSGSG</u> <u>TQFTLTISDLECADAAATYYC</u> <u>QGAYYSSSSSYGFGGGTEVVVK</u> (SEQ ID NO: 252)
AB1C45	<u>QERLEESGGGLVQPEGSLTLTCTASG</u><u>FSFSSYYMC</u> <u>WVRQAPGKGMWIGCIYTGNDDTWYASWAKGR</u> <u>FTVSKTSSTTVTLQMTSLTATDTATYFCARGLSPIDL</u> <u>WGPGLTVTVSS</u> (SEQ ID NO: 315)	<u>IVMTQTPSSKSVPGD</u><u>TVTINCQASEIYNNNNL</u> <u>GWYQQKPGQPPKLLIYWASTLASGVPSRFGSG</u> <u>SGTQFTLTISDVECDAAATYYCAGYKSRTDGS</u><u>AF</u> <u>GGGTEVVVK</u> (SEQ ID NO: 316)
AB2C53	<u>QEQLVESGGGLVQPEGSLTLTCTASG</u> <u>FSFSGYDMCWVRQAPGKGLE</u> <u>WIACIHSSSGTYYANWAKGRFTI</u> <u>SKTSSTTVTLQMTSLAADTATYFCA</u> <u>RDFSYTDDYISYVYATDWGP</u><u>GTLVTVSS</u> (SEQ ID NO: 253)	<u>AIEMTQTPASVSAAVGGT</u><u>VTIKQAS</u> <u>QGSSLAWYQQKPGQPPK</u> <u>LLIYAASYLASVPSRFGSGSG</u> <u>TEYTLTISGVQCADAAYYC</u> <u>QSTYYSSSTDIRAFGGGTEVVVK</u> (SEQ ID NO: 254)
AB2C78	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>EFSSYWICWVRQAPGKGLE</u> <u>WIACIYAGSSGTYYASWAKGRFTI</u> <u>SKTSSTTVTLQTTSLAADTATYFCA</u> <u>RAEYIDGYADYTYTTLYFDLWGP</u> <u>GTPVTVSS</u> (SEQ ID NO: 255)	<u>ALVMTQTPSSVSAAVGGT</u><u>VTINCQAS</u> <u>QIYNNLAWYQQKPGQPPK</u> <u>LLIYGASNLEGVPSRFGSGSG</u> <u>TEYTLTISDLECDAAAYYC</u> <u>QSADLTSSINVFGGGTEVVVK</u> (SEQ ID NO: 256)
AB2C102	<u>QQQLEESGGDLVQPGASLTLTCTASG</u> <u>FSFNSNYWMCWGRQAPGKGLE</u> <u>WIGCILFGNTDTYYANWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RSVSGVGSAWNLWGP</u><u>GTLVTVSS</u> (SEQ ID NO: 257)	<u>IVMTQTPSSKSVPGD</u><u>TVTINCQAS</u> <u>ESVYNNNHLAWYQQKPGQSPK</u> <u>LLIYLASILDGVPSPRFGSGSG</u> <u>TQFTLTISDVVCDDAAATYYC</u> <u>AGYKGITIDGSAFGGGTEL</u><u>VVK</u> (SEQ ID NO: 258)
AB2C103	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FESSYYWICWVRQAPGKGLE</u> <u>WIACIYGGSSGTYYATWAKGRFTI</u> <u>SETSSTTVTLQMTSLTAADMATYFCA</u> <u>RSLYTWRYADYAASTLNLWGP</u><u>GTLVTVSS</u> (SEQ ID NO: 259)	<u>AVLTQTPSPVSAAVGGT</u><u>VSISCQSS</u> <u>QSVYNNVNLAWYQQKPGQPPK</u> <u>LLIYETSKLESGVPSRFGSGSG</u> <u>TQFTLTISDVQCDDAAATYYC</u> <u>AGGYSSSKDNSFGGGTEVVVK</u> (SEQ ID NO: 260)
AB2C124	<u>QEQLVESGGGLVQPEGSLTLTCTASG</u> <u>FSFSSSYFMCWVRQAPGKGLE</u> <u>WIACIYTGDNNNYYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCS</u> <u>RGGSYAYGYAGYDYYPDAFDY</u><u>WGP</u> <u>GTLVTVSS</u> (SEQ ID NO: 261)	<u>DIVMTQTPASVEAVGGT</u><u>VTIKQAS</u> <u>QSISSYLSWYQQKPGQPPK</u> <u>LLIYRASTLASGVPSRFGSGSG</u> <u>TQFTLTISDLECADAAATYYC</u> <u>QSYYYSSSGSYGFGGGTEVVVK</u> (SEQ ID NO: 262)

AB2C127	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFNSYYMCWVRQAPGKGLE</u> <u>WIACISGGSSDNTYYASWAKGRFTT</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RDIPRSGYFGCDLWGPGLTVTVSS</u> (SEQ ID NO: 263)	<u>VVMTQTPASVSEPVGGTVTIKCQAS</u> <u>QNIYSNLAWYQQKPGQRPK</u> <u>LLIYGASNLESGVPSRFKGS</u> <u>TEYTLTISNLECADAAATYYC</u> <u>QSTVYNSNYANTFGGGTEVVVK</u> (SEQ ID NO: 264)
AB2C128	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSSYWYWRQAPGKGLE</u> <u>WIACIYTASRGSIIYASWTKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RGPDYTYGYIGDALTRLDLWGQGLTVTVSS</u> (SEQ ID NO: 265)	<u>AVLTQTPSPVSAAVGGTVSISCQSS</u> <u>QSVYDNNWLAWYQQKAGQPPK</u> <u>LLIYAASLTLASGVPSRFKGS</u> <u>IEFTLTISDVQCDDAAATYYC</u> <u>AGGYSSSDIEDNTFGGGTEVVVK</u> (SEQ ID NO: 266)
AB2C129	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSSYWICWVRQAPGKGLE</u> <u>WIACIYAGSSGDTYYASWAKGRFTI</u> <u>SKTSSTTVTLQTTSLTAADTATYFCA</u> <u>RAEYIDGYADYTYTLLYYFDLWGP</u> <u>GTPVTVSS</u> (SEQ ID NO: 267)	<u>DVMTQTPASVSEPVGGTVTINCQAS</u> <u>ESINSLAWYQQKPGQPPK</u> <u>LLIYASLTLASGVPSRFKGS</u> <u>IEFTLTISDLECADAAATYFC</u> <u>QSYYSFSRFAFGGGTEVVVK</u> (SEQ ID NO: 268)
AB2C130	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSGYWICWVRQAPGKGLE</u> <u>WIACIYTGVGATYYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RDEFGSSGFYFNLWGPGLTVTVSS</u> (SEQ ID NO: 269)	<u>FELTQTPSSVEAAVGATVTIKCQAS</u> <u>QSIENALAWYQQKPGQPPK</u> <u>LLIYASLTLASGVPSRFKGS</u> <u>TEFTLTISDLECADAAATYYC</u> <u>QNYYGSTSSSYGVAFGGGTEVVVK</u> (SEQ ID NO: 270)
AB2C131	<u>QSLEESGGDLVQPEGSLTLTCTASG</u> <u>FSFSSSYMCWVRQAPGKGLE</u> <u>WIACIYAGSTFSTYYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RSDSYYTYGYAGYAYAIENLWGP</u> <u>GTLTVTVSS</u> (SEQ ID NO: 271)	<u>LVMTQTPSSVSAAVGGTVTINCQAS</u> <u>ESIYSNLAWYQQKPGQPPK</u> <u>LLIYLASTLASGVPSRFKGS</u> <u>TEFTLTISDLECADAAATYYC</u> <u>QSAYYSSSADIAFGGGTEVVVK</u> (SEQ ID NO: 272)
AB2C133	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>LDSSSYWICWVRQAPGKGLE</u> <u>WIGCIKTATETTVYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYLC</u> <u>KTYADNGGYINLWGPGLTVTVSS</u> (SEQ ID NO: 273)	<u>LVMTQTPSSVSAAVGGTVTINCQAS</u> <u>QNIYNNLAWYQQKPGQRPK</u> <u>LLIYGASNLESGVPSRFKGS</u> <u>TEYTLTISDLECDAAATYYC</u> <u>QSADLTSSINLVFGGGTEVVVK</u> (SEQ ID NO: 274)
AB2C135	<u>QSLEESGGDLVKPGASLTLTCTASG</u> <u>FSFSSSYWICWVRQAPGKGLE</u> <u>WIACIYTASRDSIIYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RGPYYSYAYIGDALTRLDLWGQGLTVTVSS</u> (SEQ ID NO: 275)	<u>AVLTQTPSPVSAAVGGTVSISCQSS</u> <u>QSVYDNNWLAWYQQKPGQPPK</u> <u>LLIYEASKLASGVPSRFKGS</u> <u>TQFTLTISGVQCDDASTYYC</u> <u>AGGYSSSDIEDNTFGGGTEVVVK</u> (SEQ ID NO: 276)
AB2C136	<u>QEQLLEESGGDLVKPGASLTLTCTASG</u> <u>FSFNSNYMCWVRQAPGKGLE</u> <u>WIACIYTGIVVPTYASWAKGRFTI</u> <u>SKTSSTTVTLQMTSLTAADTATYFCA</u> <u>RDPYVGSSYIYNLWGPGLTVTVSS</u> (SEQ ID NO: 277)	<u>LVMTQTPSPVSAAVGSTVTISCQSS</u> <u>QSVYNNNNLAWYQQKPGQPPK</u> <u>LLIYSASSLASGVPSRFKGS</u> <u>TQFTLTISGVECDAAATYYC</u> <u>AGYKTYSNENAFGGGGTEVVVK</u> (SEQ ID NO: 278)
AB2C138	<u>QSLEESGGDLVKPGASLTLTCTASG</u>	<u>QVLTQTPSSVSEPVGGTVTINCQAS</u>

<u>FSFSSSYMCWVRQAPGKGLE</u> <u>WIACIYAGSSSTYYASWAKGRFTI</u> SKTSSTTVTLQTTSFTAADTATYFCA <u>RAGYIDSYVDYTYAAWYYFDLWGP</u> GTLVTVSS (SEQ ID NO: 279)	<u>ENIYSNLAWYHQKPGQRPK</u> <u>LLIYGASNLESGVPSRFKSGSG</u> TEYTLYHQTISDLECDAAATYYC <u>QSADLSSSINVFGGTEVVVK</u> (SEQ ID NO: 280)
---	---

Table 3 provides some examples of V_H, V_L sequences of humanized clones

	V _H	V _L
hC4	EVQLVESGGGLVQPGGSLRLSCAASG <u>FTISNNYICWVRQAPGKGLE</u> <u>WIGCIATGDGSTYYASWAKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RGAAGSSWTTYDFW</u> GQGTLTVSS (SEQ ID NO: 281)	DIQMTQSPSSLSASVGDRVITTCQAG <u>QNIDNYLSWYQQKPGKVPK</u> <u>LLIYRASTLASGVPSRFSGSGSG</u> TDFTLTISLQPEDVATYYC <u>QNNNGGSTFTGFP</u> GQGTKVEIK (SEQ ID NO: 282)
hC12	EVQLVESGGGLVQPGGSLRLSCAASG <u>FSFSSSYWISWVRQAPGKGLE</u> <u>WIACIAIGSGTTYASWAKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RSGDGYTYVELW</u> GQGTLTVSS (SEQ ID NO: 283)	DIQMTQSPSSLSASVGDRVITTCQAS <u>QSISSYLAWYQQKPGKVPK</u> <u>LLIYRASTLASGVPSRFSGSGSG</u> TDFTLTISLQPEDVATYYC <u>QNYDIDDSNTF</u> GQGTKVEIK (SEQ ID NO: 284)
hC15	EVQLVESGGGLVQPGGSLRLSCAASG <u>FSFSSSYMCWVRQAPGKGLE</u> <u>WIACIYTYGGTWYASWAKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RSSISDVTYFNLW</u> GQGTLTVSS (SEQ ID NO: 285)	DIQMTQSPSSLSASVGDRVITTCQAS <u>QSISSYLAWYQQKPGKVPK</u> <u>LLIYRASTLASGVPSRFSGSGSG</u> TDFTLTISLQPEDVATYYC <u>QSYDNNNYAF</u> GQGTKVEIK (SEQ ID NO: 286)
hC18	EVQLVESGGGLVQPGGSLRLSCAASG <u>FSFSSYWTWVRQAPGKGLE</u> <u>WLGCTDGGSSGDTYYATWAKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RNLITWDLW</u> GQGTLTVSS (SEQ ID NO: 287)	DIQMTQSPSSLSASVGDRVITTCQAS <u>ESVYNNNNQLSWYQQKPGKVPK</u> <u>LLIYWASKLASGVPSRFSGSGSG</u> TDFTLTISLQPEDVATYYC <u>AGYKSSITDGN</u> AFGQGTKVEIK (SEQ ID NO: 288)
hC31	EVQLVESGGGLVQPGGSLRLSCAASG <u>FDSSNGMCWVRQAPGKGLE</u> <u>WIACIYDSSDNTNYASWVNGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RGYGYVGSAMD</u> LWGQGTLTVSS (SEQ ID NO: 289)	DIQMTQSPSSLSASVGDRVITTCQAS <u>QSISSNELSWYQQKPGKVPK</u> <u>LLIYGASTLESGVPSRFSGSGSG</u> TDFTLTISLQPEDVATYYC <u>QSAYSSSSSYANT</u> FQGQGTKVEIK (SEQ ID NO: 290)
hC36	EVQLVESGGGLVQPGGSLRLSCAASG	DIQMTQSPSSLSASVGDRVITTCQAS

	<u>FSFSSGYNICWVRQAPGKGLE</u> <u>LIACIYTSSSGSTYYASWAKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RGEAYYAYGYVGYAYYHGAFDPWGQ</u> GTLVTVSS (SEQ ID NO: 291)	<u>HSISKYFSWYQQKPGKVPK</u> <u>LLIYEASTLASGVPSRFGSGSG</u> TDFTLTISLQPEDVATYYC <u>QSYYYGTSSSYAFGQGTKVEIK</u> (SEQ ID NO: 292)
hC53	EVQLVESGGGLVQPGGSLRLSCAA SG <u>FSFSSGYDMCWVRQAPGKGLE</u> <u>WIACIHSSSGTTYASWAKGRFTIS</u> RDNSKNTLYLQMNSLRAEDTAVYY CARD <u>FSYTDDYISVYYATDLWGQ</u> GTTLTVSS (SEQ ID NO: 317)	DIQMTQSPSSLSASVGDRVTITCQAS <u>QSIGSSLAWYQQKPGKVPKLLIYAASYLAS</u> GVPSRFGSGSGTDFTLTISLQPEDVATYY CQSTYYSSSTDIRAFGQGTKVEIK (SEQ ID NO: 318)
hC131	EVQLVESGGGLVQPGGSLRLSCAASG <u>FSFSSYYMCWVRQAPGKGLE</u> <u>WIACIYAGSTFSTYYASWAKGRFTISRDN</u> SKNTLYLQMNSLRAEDTAVYYCA <u>RSDSYTYGYAGYAYAIFNLWGQ</u> GTTLTVSS (SEQ ID NO: 293)	DIQMTQSPSSLSASVGDRVTITCQAS <u>ESIYSNLAWYQQKPGKVPK</u> <u>LLIYLASTLASGVPSRFGSGSG</u> TDFTLTISLQPEDVATYYC <u>QSAYYSSSADIAGQGTKVEIK</u> (SEQ ID NO: 294)

The antigen-binding molecules of the present invention may be in isolated, purified, synthetic or recombinant form. Suitable antigen-binding molecules may be selected from antibodies and their antigen-binding fragments, including monoclonal antibodies (MAbs), chimeric antibodies, humanized antibodies, human antibodies, and antigen-binding fragments of such antibodies. The antigen-binding molecules may be multivalent (e.g., bivalent) or monovalent. In some embodiments, the antigen-binding molecules comprise an Fc domain. In other embodiments, the antigen-binding molecules lack an Fc domain. In some embodiments, the antigen-binding molecules are monovalent antigen-binding molecules (e.g., Fab, scFab, Fab', scFv, one-armed antibodies, etc.).

By “antigen-binding molecule” is meant a molecule that has binding affinity for a target antigen. It will be understood that this term extends to immunoglobulins, immunoglobulin fragments and non-immunoglobulin derived protein frameworks that exhibit antigen-binding activity. Representative antigen-binding molecules that are useful in the practice of the present invention include antibodies and their antigen-binding fragments. The term “antigen-binding molecule” includes antibodies and antigen-binding fragments of antibodies.

The antigen-binding molecules as defined herein can be naked or conjugated to other molecules or moieties such as toxins, radioisotopes, small molecule drugs, polypeptides, etc.

The term “antibody”, as used herein, means any antigen-binding molecule or molecular complex comprising at least one complementarity determining region (CDR) that binds specifically to or interacts with a particular antigen. The term “antibody” includes full-length immunoglobulin molecules comprising four polypeptide chains, two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (*e.g.*, IgM). Each heavy chain comprises a heavy chain variable region (which may be abbreviated as HCVR or V_H) and a heavy chain constant region. The heavy chain constant region comprises three domains, C_H1 , C_H2 and C_H3 . Each light chain comprises a light chain variable region (which may be abbreviated as LCVR or V_L) and a light chain constant region. The light chain constant region comprises one domain (C_L1). The V_H and V_L regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with regions that are more conserved, termed framework regions (FR). Each V_H and V_L is composed of three CDRs and four FRs, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the invention, the FRs of an antibody of the invention (or antigen-binding portion thereof) may be identical to the human germline sequences, or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.

An antibody includes an antibody of any class, such as IgG, IgA, or IgM (or sub-class thereof), and the antibody need not be of any particular class. Depending on the antibody amino acid sequence of the constant region of its heavy chains, immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), *e.g.*, IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. The heavy-chain constant regions that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively. The subunit structures and three-dimensional configurations of different classes of immunoglobulins are well known.

As used herein, the term “complementarity determining regions” (CDRs; *i.e.*, CDR1, CDR2, and CDR3) refers to the amino acid residues of an antibody variable domain the presence of which are necessary for antigen-binding. Each variable domain typically has three CDR regions identified as CDR1, CDR2 and CDR3. Each complementarity determining region may comprise amino acid residues from a “complementarity determining region” as defined for example by Kabat (*i.e.*, about residues 24-34 (L1), 50-56 (L2) and 89-97 (L3) in the light chain variable domain and 31-35 (H1), 50-65 (H2) and 95-102 (H3) in the heavy chain variable domain; Kabat *et al.*, Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (1991)) and/or those residues from a “hypervariable loop” (*i.e.*, about residues 26-32 (L1), 50-52 (L2) and 91-96 (L3) in the light chain variable domain and 26-32 (H1), 53-55 (H2) and 96-101 (H3) in the heavy chain variable domain; Chothia and Lesk J. Mol. Biol. 196:901-917 (1987)). In some instances, a complementarity determining region can include amino acids from both a CDR region defined according to Kabat and a hypervariable loop.

A “humanized” antibody refers to an antibody comprising amino acid residues from non-human CDRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDRs correspond to those of a non-human antibody, and all or substantially all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody.

As used herein, a “chimeric” molecule is one which comprises one or more unrelated types of components or contain two or more chemically distinct regions which can be conjugated to each other, fused, linked, translated, attached via a linker, chemically synthesized, expressed from a nucleic acid sequence, etc. For example, a peptide and a nucleic acid sequence, a peptide and a detectable label, unrelated peptide sequences, and the like. In embodiments in which the chimeric molecule comprises amino acid sequences of different origin, the chimeric molecule includes (1) polypeptide sequences that are not found together in nature (*i.e.*, at least one of the amino acid sequences is heterologous with respect to at least one of its other amino acid sequences), or (2) amino acid sequences that are not naturally adjoined. For example, a “chimeric” antibody” as

used herein refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

As used herein, the term “antigen” and its grammatically equivalents expressions (*e.g.*, “antigenic”) refer to a compound, composition, or substance that may be specifically bound by the products of specific humoral or cellular immunity, such as an antibody molecule or T-cell receptor. Antigens can be any type of molecule including, for example, haptens, simple intermediary metabolites, sugars (*e.g.*, oligosaccharides), lipids, and hormones as well as macromolecules such as complex carbohydrates (*e.g.*, polysaccharides), phospholipids, and proteins. Common categories of antigens include, but are not limited to, viral antigens, bacterial antigens, fungal antigens, protozoa and other parasitic antigens, tumor antigens, antigens involved in autoimmune disease, allergy and graft rejection, toxins, and other miscellaneous antigens.

An “antigen-binding site” refers to the site, *i.e.*, one or more amino acid residues, of an antigenbinding molecule which provides interaction with the antigen. For example, the antigen binding site of an antibody comprises amino acid residues from the complementarity determining regions (CDRs). A native immunoglobulin molecule typically has two antigen binding sites, a Fab molecule typically has a single antigen binding site. An antigen-binding site of an antigen-binding molecule described herein typically binds specifically to an antigen and more particularly to an epitope of the antigen.

The terms “antigen-binding fragment”, “antigen-binding portion”, “antigen-binding domain” and “antigen-binding site” are used interchangeably herein to refer to a part of an antigen-binding molecule that participates in antigen-binding. These terms include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds an antigen to form a complex.

Antigen-binding fragments of an antibody may be derived, *e.g.*, from full antibody molecules using any suitable standard techniques such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and optionally constant domains. Such DNA is

known and/or is readily available from, *e.g.*, commercial sources, DNA libraries (including, *e.g.*, phage-antibody libraries), or can be synthesized. The DNA may be sequenced and manipulated chemically or by using molecular biology techniques, for example, to arrange one or more variable and/or constant domains into a suitable configuration, or to introduce codons, create cysteine residues, modify, add or delete amino acids, etc.

Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')₂ fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of the amino acid residues that mimic the hypervariable region of an antibody (*e.g.*, an isolated complementarity determining region (CDR) such as a CDR3 peptide), or a constrained FR3-CDR3-FR4 peptide. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, one-armed antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (*e.g.* monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression “antigen-binding fragment,” as used herein.

An antigen-binding fragment of an antibody will typically comprise at least one variable domain. The variable domain may be of any size or amino acid composition and will generally comprise at least one CDR which is adjacent to or in frame with one or more framework sequences. In antigen-binding fragments having a V_H domain associated with a V_L domain, the V_H and V_L domains may be situated relative to one another in any suitable arrangement. For example, the variable region may be dimeric and contain V_H-V_H, V_H-V_L or V_L-V_L dimers. Alternatively, the antigen-binding fragment of an antibody may contain a monomeric V_H or V_L domain.

In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting, exemplary configurations of variable and constant domains that may be found within an antigen-binding fragment of an antibody of the present invention include: (i) V_H-C_H1; (ii) V_H-C_H2; (iii) V_H-C_H3; (iv) V_H-C_H1-C_H2; (v) V_H-C_H1-C_H2-C_H3, (vi) V_H-C_H2-C_H3; (vii) V_H-C_L; (viii) V_L-C_H1; (ix) V_L-C_H2, (x) V_L-C_H3; (xi) V_L-C_H1-C_H2; (xii) V_L-C_H1-

C_H2-C_H3; (xiii) V_L-C_H2-C_H3; and (xiv) V_L-C_L. In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a full or partial hinge or linker region. A hinge region may consist of at least 2 (*e.g.*, 5, 10, 15, 20, 40, 60 or more) amino acids which result in a flexible or semi-flexible linkage between adjacent variable and/or constant domains in a single polypeptide molecule. Moreover, an antigen-binding fragment of an antibody of the present disclosure may comprise a homo-dimer or hetero-dimer (or other multimer) of any of the variable and constant domain configurations listed above in non-covalent association with one another and/or with one or more monomeric V_H or V_L domain (*e.g.*, by disulfide bond(s)). A multispecific antigen-binding molecule will typically comprise at least two different variable domains, wherein each variable domain is capable of specifically binding to a separate antigen or to a different epitope on the same antigen. Any multispecific antigen-binding molecule format, including bispecific antigen-binding molecule formats, may be adapted for use in the context of an antigen-binding fragment of an antibody of the present disclosure using routine techniques available in the art.

The term “variable region” or “variable domain” refers to the domain of an antibody heavy or light chain that is involved in binding the antigen-binding molecule to antigen. The variable domains of the heavy chain and light chain (V_H and V_L, respectively) of a native antibody generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, *e.g.*, Kindt et al., Kuby Immunology, 6th ed., W.H. Freeman and Co., page 91 (2007). A single V_H or V_L domain may be sufficient to confer antigen-binding specificity.

The term “constant domains” or “constant region” as used herein denotes the sum of the domains of an antibody other than the variable region. The constant region is not directly involved in binding of an antigen, but exhibits various immune effector functions.

The term “bispecific antigen-binding molecule” refers to a multi-specific antigen-binding molecule having the capacity to bind to two distinct epitopes on the same antigen or on two different antigens. A bispecific antigen-binding molecule may be bivalent, trivalent, or tetravalent. As used herein, “valent”, “valence”, “valencies”, or

other grammatical variations thereof, mean the number of antigen-binding sites in an antigen-binding molecule. These antigen recognition sites may recognize the same epitope or different epitopes. Bivalent and bispecific molecules are described in, *e.g.*, Kostelny *et al.*, 1992. *J Immunol* 148:1547; Pack and Plückthun, 1992. *Biochemistry* 31:1579, Gruber *et al.* 1994. *J Immunol* 5368, Zhu *et al.* 1997. *Protein Sci* 6:781, Hu *et al.*, 1996. *Cancer Res.* 56:3055, Adams *et al.*, 1993. *Cancer Res.* 53:4026, and McCartney *et al.*, 1995. *Protein Eng.* 8:301. Trivalent bispecific antigen-binding molecules and tetravalent bispecific antigen-binding molecules are also known in the art. See, *e.g.*, Kontermann RE (ed.), Springer Heidelberg Dordrecht London New York, pp. 199- 216 (2011). A bispecific antigen-binding molecule may also have valencies higher than 4 and are also within the scope of the present invention. Such antigen-binding molecules may be generated by, for example, dock and lock conjugation method. (Chang, C.-H. et al. In: Bispecific Antibodies. Kontermann RE (2011), *supra*).

The phrase “specifically binds” or “specific binding” refers to a binding reaction between two molecules that is at least two times the background and more typically more than 10 to 100 times background molecular associations under physiological conditions. When using one or more detectable binding agents that are proteins, specific binding is determinative of the presence of the protein, in a heterogeneous population of proteins and other biologics. Thus, under designated immunoassay conditions, the specified antigen-binding molecule binds to a particular antigenic determinant, thereby identifying its presence. Specific binding to an antigenic determinant under such conditions requires an antigen-binding molecule that is selected for its specificity to that determinant. This selection may be achieved by subtracting out antigen-binding molecules that cross-react with other molecules. A variety of immunoassay formats may be used to select antigen-binding molecules (*e.g.*, immunoglobulins) [such that they are specifically immunoreactive with a particular antigen. For example, solid-phase ELISA immunoassays are routinely used to select antibodies specifically immunoreactive with a protein (see, *e.g.*, Harlow & Lane, *Antibodies, A Laboratory Manual* (1988) for a description of immunoassay formats and conditions that can be used to determine specific immunoreactivity). Methods of determining binding affinity and specificity are also well known in the art (see, for example, Harlow and Lane, *supra*); Friefelder, “Physical Biochemistry: Applications to biochemistry and molecular biology” (W.H. Freeman and Co. 1976)).

In one embodiment, the antigen-binding molecule specifically binds to a cell expressing ALPPL2 with an affinity of between about 14 pM to about 10 nM.

“Affinity” or “binding affinity” refers to the strength of the sum total of non-covalent interactions between a single binding site of a molecule (*e.g.*, an antigen-binding molecule) and its binding partner (*e.g.*, an antigen). Unless indicated otherwise, as used herein, “binding affinity” refers to intrinsic binding affinity which reflects a 1:1 interaction between members of a binding pair *e.g.*, an antigen-binding molecule). The affinity of a molecule X for its partner Y can generally be represented by the dissociation constant (K_d), which is the ratio of dissociation and association rate constants (k_{off} and k_{on} , respectively). Thus, equivalent affinities may comprise different rate constants, as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. A particular method for measuring affinity is Surface Plasmon Resonance (SPR).

The terms "polypeptide", "peptide", or "protein" are used interchangeably herein to designate a linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues. The amino acid residues are usually in the natural "L" isomeric form. However, residues in the "D" isomeric form can be substituted for any L-amino acid residue, as long as the desired functional property is retained by the polypeptide.

As used herein, the term “modified antibody” includes synthetic forms of antibodies which are altered such that they are not naturally occurring, *e.g.*, antibodies that comprise at least two heavy chain portions but not two complete heavy chains (such as, domain deleted antibodies or minibodies); multispecific forms of antibodies (*e.g.*, bispecific, trispecific, etc.) altered to bind to two or more different antigens or to different epitopes on a single antigen); heavy chain molecules joined to scFv molecules and the like. ScFv molecules are known in the art and are described, *e.g.*, in U.S. Pat. No. 5,892,019. In addition, the term “modified antibody” includes multivalent forms of antibodies (*e.g.*, trivalent, tetravalent, etc., antibodies that bind to three or more copies of the same antigen).

In one embodiment, the antigen-binding molecule specifically binds to rhesus macaque ALPPL2. The rhesus macaque ALPPL2 may have a sequence as shown in Genbank ID XP_011726419.1.

In one embodiment, the antigen-binding molecule comprises: (a) a V_H amino acid sequence having at least 90% (including at least 91% to 100% and all integer percentages therebetween) sequence identity to a V_H amino acid sequence as shown in any of the rows in Table 2 or Table 3, and (b) a V_L amino acid sequence having at least 90% sequence identity (including at least 91% to 100% and all integer percentages therebetween) to a V_L amino acid sequence as shown in the same row as the V_H amino acid sequence in Table 2 or Table 3.

In one embodiment, the antigen-binding molecule specifically binds ALPPL2 and ALPP but not ALPL or ALPI.

The antigen-binding molecule may, for example, comprise:

- a) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 281 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 282,
- b) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 283 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 284,
- c) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 285 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 286,
- d) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 287 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 288,
- e) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 289 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 290,
- f) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 291 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 292, or

- g) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 293 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 294.

The phrase “at least 90% sequence identity” as referred to in the specification may include at least 91% to 100% and all integer percentages therebetween.

In one embodiment, the antigen-binding molecule does not bind to ALPP. The antigen-binding molecule may bind to ALPPL2 but not ALPP. In one embodiment, the antigen-binding molecule binds to ALPPL2 but not ALPP, ALPL or ALPI. The antigen-binding molecule may comprise:

- a) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 31, SEQ ID NO: 32 and SEQ ID NO: 33, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 34, SEQ ID NO: 35 and SEQ ID NO: 36,
- b) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 67, SEQ ID NO: 68 and SEQ ID NO: 69, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 70, SEQ ID NO: 71 and SEQ ID NO: 72,
- c) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 85, SEQ ID NO: 86 and SEQ ID NO: 87, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 88, SEQ ID NO: 89 and SEQ ID NO: 90,
- d) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 127, SEQ ID NO: 128 and SEQ ID NO: 129, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 130, SEQ ID NO: 131 and SEQ ID NO: 132,
- e) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 133, SEQ ID NO: 134 and SEQ ID NO: 135, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 136, SEQ ID NO: 137 and SEQ ID NO: 138,
- f) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 169, SEQ ID NO: 170 and SEQ ID NO: 171, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 172, SEQ ID

NO: 173 and SEQ ID NO: 174; or

- g) a heavy chain variable region (V_H) comprising the amino acid sequences of SEQ ID NO: 205, SEQ ID NO: 206 and SEQ ID NO: 207, and a light chain variable region (V_L) comprising the amino acid sequences of SEQ ID NO: 208, SEQ ID NO: 209 and SEQ ID NO: 210.

In one embodiment, the antibody comprises:

- a) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 221 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 222,
- b) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 223 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 224,
- c) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 239 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 240,
- d) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 253 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 254,
- e) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 255 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 256,
- f) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 267 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 268, or
- g) a V_H amino acid sequence having at least 90% sequence identity to SEQ ID NO: 279 and a V_L amino acid sequence having at least 90% sequence identity to SEQ ID NO: 280.

In one embodiment, the antigen-binding molecule is an antibody or antigen-binding fragment thereof or a chimeric antigen receptor (CAR).

In one embodiment, the antibody or antigen-binding fragment thereof is humanized or chimerized.

In one embodiment, the antibody or antigen-binding fragment thereof is a humanized antibody comprising:

a) a heavy chain variable region that comprises:

- i) a V_HFR1 having at least 90% sequence identity to
EVQLVESGGGLVQPGGSLRLSCAASG (SEQ ID NO: 295),
- ii) a V_HFR2 having at least 90% sequence identity to WVRQAPGKGLE (SEQ ID NO: 296),
- iii) a V_HFR3 having at least 90% sequence identity to
ASWAKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCA (SEQ ID NO: 297),
- iv) a V_HFR4 having at least 90% sequence identity to WGQGTLVTVSS (SEQ ID NO: 298), and

b) a light chain variable region that comprises:

- i) a V_LFR1 having at least 90% sequence identity to
DIQMTQSPSSLSASVGDRVTITCQAG (SEQ ID NO: 299)
- ii) a V_HFR2 having at least 90% sequence identity to WYQQKPGKVPK (SEQ ID NO: 300),
- iii) a V_HFR3 having at least 90% sequence identity to
GVPSRFSGSGSGTDFTLTISLQPEDVATYYC (SEQ ID NO: 301)
- i) a V_HFR4 having at least 90% sequence identity to FGQGTKVEIK (SEQ ID NO: 302).

In one embodiment, the antibody or antigen-binding fragment thereof comprises a C_H1 amino acid sequence having at least 90% (including at least 91% to 100% and all integer percentages therebetween) to:

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF
PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK (SEQ ID NO: 319).

In one embodiment, the antibody or antigen-binding fragment thereof comprises a C_L amino acid sequence having at least 90% (including at least 91% to 100% and all integer percentages therebetween) to:

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNS
QESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRG
EC (SEQ ID NO: 320).

Representative antigen-binding molecules contemplated by the present disclosure include full-length immunoglobulins and antigen-binding fragments, including recombinant antigen-binding molecules, which may be monovalent or multivalent, monospecific or multispecific.

In one embodiment, the antibody or antigen-binding fragment thereof is a full-length antibody, a substantially intact antibody, a Fab fragment, scFab, Fab', a single chain variable fragment (scFv) or a one-armed antibody.

In one embodiment, the antibody has an isotype selected from the group consisting of IgG1, IgG2, IgG3, and IgG4. In one embodiment, the antibody is an IgG1 antibody. The antibody may have antibody-dependent cell-mediated cytotoxicity (ADCC) activity and can induce NK cell killing. The heavy chain constant region can be a wild-type human Fc region, or a human Fc region that includes one or more amino acid substitutions. The antibodies can have mutations that stabilize the disulfide bond between the two heavy chains of an immunoglobulin, such as mutations in the hinge region of IgG4, as disclosed in the art (e.g., Angal et al., 1993. Mol. Immunol., 30:105-08). See also, e.g., U.S. 2005/0037000. The heavy chain constant region can also have substitutions that modify the properties of the antigen-binding molecule (e.g., decrease one or more of: Fc receptor binding, antigen-binding molecule glycosylation, deamidation, binding to complement, or methionine oxidation). In some instances, the antigen-binding molecules may have mutations such as those described in U.S. Pat. Nos. 5,624,821 and 5,648,260. In some embodiments, the antigen-binding molecule is modified to reduce or eliminate effector function.

In one embodiment, the antigen-binding molecule of the present invention is a monovalent antigen-binding molecule. Non-limiting monovalent antigen-binding molecules include: a Fab fragment consisting of V_L, V_H, C_L and C_{H1} domains; a Fab' fragment consisting of V_L, V_H, C_L and C_{H1} domains, as well as a portion of a C_{H2} domain; an Fd fragment consisting of V_H and C_{H1} domains; an Fv fragment consisting

of V_L and V_H domains of a single arm of an antibody; a single-chain antibody molecule (*e.g.*, scFab and scFv); a single domain antibody (dAb) fragment (Ward *et al.*, 1989 Nature 341:544-546), which consists of a V_H domain; and a one-armed antibody, such as described in US20080063641 (Genentech) or other monovalent antibody, *e.g.*, such as described in WO2007048037 (Amgen).

In one embodiment, a monovalent antigen-binding molecule comprises an Fv fragment. The Fv fragment is the smallest unit of an immunoglobulin molecule with function in antigen-binding activities. An antigen-binding molecule in scFv (single chain fragment variable) format consists of variable regions of heavy (V_H) and light (V_L) chains, which are joined together by a flexible peptide linker that can be easily expressed in functional form in an expression host such as *E. coli* and mammalian cells, allowing protein engineering to improve the properties of scFv such as increase of affinity and alteration of specificity (Ahmed *et al.*, 2012. *Clin Dev Immunol.* 2012:980250). Representative examples of linker sequences are described in Section 4.5 *infra*. In the scFv construction, the order of the domains can be either V_H-linker-V_L or V_L-linker-V_H and both orientations can be applied.

In some embodiments, the linker sequences used in scFvs are multimers of the pentapeptide GGGGS [SEQ ID NO:66] (or G4S or Gly4Ser). Those include the 15-mer (G4S)₃ (Huston *et al.*, 1988. *Proc Natl Acad Sci USA.* 85(16), 5879–83), the 18-mer GGSSRSSSSGGGSGGGG [SEQ ID NO:67] (Andris-Widhopf *et al.*, “Generation of human scFv antibody libraries: PCR amplification and assembly of light- and heavy-chain coding sequences.” Cold Spring Harbor Protocols, 2011(9)) and the 20-mer (G4S)₄ (Schaefer *et al.*, “Construction of scFv Fragments from Hybridoma or Spleen Cells by PCR Assembly.” In: Antibody Engineering, R. Kontermann and S. Dübel, Springer Verlag, Heidelberg, Germany (2010) pp. 21-44). Many other sequences have been proposed, including sequences with added functionalities, *e.g.*, an epitope tag or an encoding sequence containing a Cre-Lox recombination site or sequences improving scFv properties, often in the context of particular antibody sequences.

Cloning of the scFv is usually done by a two-step overlapping PCR (also known as Splicing by Overlap Extension or SOE-PCR), as described (Schaefer *et al.*, 2010, *supra*). The V_H and V_L domains are first amplified and gel-purified and secondarily assembled

in a single step of assembly PCR. The linker is generated either by overlap of the two inner primers or by adding a linker primer whose sequence covers the entire linker or more (three-fragment assembly PCR).

Single chain Fv (scFv) antigen-binding molecules may be recombinantly produced for example in *E. coli*, insect cells or mammalian host cells upon cloning of the protein coding sequence for the scFv in the context of appropriate expression vectors with appropriate translational, transcriptional start sites and, in the case of mammalian expression, a signal peptide sequence.

In one embodiment, the monovalent antigen-binding molecule comprises an Fab fragment. In an illustrative example of this type, the monovalent antigen-binding molecule is a one-armed antibody consisting or consisting essentially of a single antigen-binding fragment (Fab) and a Fc region, wherein the Fc region comprises a first and a second Fc polypeptide, and wherein the first and second Fc polypeptides are present in a complex.

Recombinant expression of Fc-containing monovalent antigen-binding molecules can often lead to undesirable bivalent, homodimer contaminants. Strategies to inhibit formation of homodimers are known including methods that introduce mutations into immunoglobulin constant regions to create altered structures that support unfavorable interactions between polypeptide chains and suppress unwanted Fc homodimer formation. Non-limiting examples of this strategy to promote heterodimerization include the introduction of knobs-into-holes (KIH) structures into the two polypeptides and utilization of the naturally occurring heterodimerization of the C_L and C_{H1} domains (see, Kontermann, *supra*, pp. 1 -28 (2011) Ridgway et al., 1996. *Protein Eng.* 9(7):617-21; Atwell *et al.*, 1997. *J Mol Biol.* 270(1):26-35; as described in WO 2005/063816). These KIH mutations promote heterodimerization of the knob containing Fc and the hole containing heavy chain, improving the assembly of monovalent antibody and reducing the level of undesired bivalent antibody.

Modifications in the Fc domain of an antigen-binding molecules may also be desirable to reduce Fc receptor binding and therefore reduce the potential for FcγRIIa-mediated activation of platelets. For example, the so-called 'LALA' double mutation (Leu234Ala

together with Leu235Ala) in human IgG (including IgG1) is known to significantly impair Fc receptor binding and effector function (Lund *et al.*, 1991, *J. Immunol.* 147, 2657–2662; Lund *et al.*, 1992, *Mol. Immunol.* 29:53–59). For human IgG4, engineering mutations S228P/L235E variant (SPLE) has previously demonstrated minimal Fc γ R binding (Newman *et al.*, 2001, *Clin. Immunol.* 98, 164–174). Mutations in IgG1 or IgG4 Fc domains can be combined, for instance combining the LALA mutations in human IgG1 with a mutation at P329G or combining the SPLE mutation in human IgG4 with a mutation at P329G, completely abolished Fc γ R and C1q interactions (Schlothauer *et al.*, 2016, *Protein Eng Des. Sel.* 29, 457-466).

In one embodiment, the antigen-binding molecule (*e.g.*, a MAb or an antigen-binding fragment thereof), in which each of the IgG1 Fc chains of the antibody carries P329G, L235A, L234A (P329G LALA) mutations or each of the IgG4 Fc chains carries P329G, S228P, L235E mutations, in order to reduce or abolish any undesired cross-linking, platelet activation, or immune effector function (*e.g.*, antibody-dependent cell-mediated cytotoxicity (ADCC), phagocytosis (ADCP) and complement dependent cytotoxicity (CDC)) of the antigen-binding molecule.

In one embodiment, each of the IgG1 Fc chains of the antigen-binding molecule (or antibody) carries mutations comprising a) S239D, A330L and I332E or b) F243L, R292P, Y300L, V305I and P396L, which enhance immune effector function of the antigen-binding molecule (*e.g.* ADCC).

In one embodiment, the antigen-binding molecule (or antibody) comprises a CH₂-CH₃ sequence of having at least 70% sequence identity to an amino acid sequence of SEQ ID NO: 321, SEQ ID NO: 322 or SEQ ID NO: 323.

The antigen-binding molecules may comprise a heavy chain sequence. The heavy chain sequence may, for example, comprise or consist of a V_H sequence listed in Table 3 that is fused to a C_H1 sequence (*e.g.* SEQ ID NO: 319) and a C_H2-C_H3 sequence (*e.g.* SEQ ID NO: 321, SEQ ID NO: 322 or SEQ ID NO: 33). For example, the heavy chain sequence may comprise an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 326, SEQ ID NO: 327, SEQ ID NO: 329, SEQ ID NO: 330, SEQ ID NO: 332 or SEQ ID NO: 333.

The antigen-binding molecules may comprise a light chain sequence. The light chain sequence may, for example, comprise or consist of a VL sequence listed in Table 3 that is directly fused to a CL sequence (e.g. SEQ ID NO: 320). For example, the light chain sequence may comprise an amino acid sequence having at least 70% sequence identity to SEQ ID NO: 328, SEQ ID NO: 331 or SEQ ID NO: 334.

In one embodiment, the present invention contemplates monovalent antigen-binding molecules produced by co-expression of a light chain, heavy chain and a truncated Fc domain. Suitably, the heavy chain incorporates hole mutations and P329G LALA mutations, while the truncated Fc domain incorporates knob mutations and P329G LALA mutations.

Expression of the antigen-binding molecule disclosed herein can be achieved for example in bacterial (*e.g.*, *Escherichia coli*), yeast, insect or mammalian host cells upon cloning of the protein coding sequences of the constructs in the context of appropriate expression vectors with appropriate translational, transcriptional start sites, and, where appropriate, signal peptide sequences.

In one embodiment, the antigen-binding molecule is a multivalent antigen-binding molecule, non-limiting examples of which include: immunoglobulins, F(ab')₂, tandem scFv (taFv or scFv₂), scFv-Fc, diabody, dAb₂/V_HH₂, minibodies, ZIP miniantibodies, barnase-barstar dimer, knobs-into-holes derivatives, SEED-IgG, heteroFc-scFv, Fab-scFv, Fab₂/sc(Fab)₂, scFv-(TNFα)₃, scFv-Jun/Fos, Fab'-Jun/Fos, tribody, trimerbody, tribi-minibody, barnase-barstar trimer, collabody, DNL-F(ab)₃, scFv₃-C_H1/C_L, Fab-scFv₂, IgG-scFab, IgG-scFv, scFv-IgG, scFv₂-Fc, F(ab')₂-scFv₂, scDB-Fc, scDb-C_H3, Db-Fc, scFv₂-H/L, DVD-Ig, tandAb, scFv-dhlx-scFv, dAb₂-IgG, dAb-IgG, dAb-Fc-dAb, tetrabody, streptabody (scFv-streptavidin)₄, (scFv-p53)₄, [sc(Fv)₂]₂; tandem diabody (tandab) and combinations thereof.

In one embodiment, the multivalent antigen-binding molecule is selected from IgG-like antibodies (*e.g.*, triomab/quadroma, Trion Pharma/Fresenius Biotech; knobs-into-holes, Genentech; CrossMAbs, Roche; electrostatically matched antibodies, AMGEN; LUZ-Y, Genentech; strand exchange engineered domain (SEED) body, EMD Serono; biolonic, Merus; and Fab-exchanged antibodies, Genmab), symmetric IgG-like

antibodies (*e.g.*, dual targeting (DT)-Ig, GSK/Domantis; two-in-one antibody, Genentech; crosslinked MAb, Karmanos Cancer Center; MAb₂, F-star; and Coy X-body, Coy X/Pfizer), IgG fusions (*e.g.*, dual variable domain (DVD)-Ig, Abbott; IgG-like bispecific antibodies, Eli Lilly; Ts2Ab, Medimmune/AZ; BsAb, ZymoGenetics; HERCULES, Biogen Idec; TvAb, Roche) Fc fusions (*e.g.*, scFv/Fc fusions, Academic Institution; SCORPION, Emergent BioSolutions/Trubion, ZymoGenetics/BMS; dual affinity retargeting technology (Fc-DART), MacroGenics; dual (ScFv)₂-Fab, National Research Center for Antibody Medicine) Fab fusions (*e.g.*, F(ab)₂, Medarex/AMGEN; dual-action or Bis-Fab, Genentech; Dock-and-Lock (DNL), ImmunoMedics; bivalent bispecific, Biotechnol; and Fab-Fv, UCB-Celltech), ScFv- and diabody-based antibodies (*e.g.*, bispecific T cell engagers (BiTEs), Micromet; tandem diabodies (Tandab), Affimed; DARTs, MacroGenics; Single-chain diabody, Academic; TCR-like antibodies, AIT, Receptor Logics; human serum albumin scFv fusion, Merrimack; and COMBODIES, Epigen Biotech), IgG/non-IgG fusions (*e.g.*, immunocytokins, EMDSerono, Philogen, ImmunGene, ImmunoMedics; superantigen fusion protein, Active Biotech; and immune mobilizing mTCR Against Cancer, ImmTAC) and oligoclonal antibodies (*e.g.*, Symphogen and Merus).

In one embodiment, the antibody is a bispecific or trispecific antibody. In one embodiment, the antibody is a bispecific antibody. The bispecific antibody may be one which comprises a first antigen-binding site that specifically binds ALPPL2 and a second antigen-binding site that specifically binds CD3. In one embodiment, the bispecific antibody is capable of binding to the cancer cell and recruit immune effector cells (*e.g.* T-cells) to kill the cancer cell. Antigen binding polypeptides that specifically binds CD3 are well known in the art. The second antigen-binding site may, for example, comprise CD3-specific CDR sequences or VH/VL sequences from Muromonab (Orthoclone OKT3), Foralumab, Teplizumab, Blinatumomab or Visilizumab. The bispecific antibody may, for example, comprise the VH CDR sequences of SEQ ID NO: 335-337 and the VL CDR sequences of SEQ ID NO: 338-340. Alternatively, the antibody may comprise the VH CDR sequences of SEQ ID NO: 341-343 and VL CDR sequences of SEQ ID NO: 344-346.

In one embodiment, bispecific antibodies of the invention are formed using a "protuberance-into-cavity" strategy, also referred to as "knobs into holes" that serves to engineer an interface between a first and second polypeptide for hetero-oligomerization.

The preferred interface comprises at least a part of the CH3 domain of an antibody constant domain. The "knobs into holes" mutations in the CH3 domain of an Fc sequence has been reported to greatly reduce the formation of homodimers (See, for example, Merchant et al., 1998, *Nature Biotechnology*, 16:677-681). "Protuberances" are constructed by replacing small amino acid side chains from the interface of the first polypeptide with larger side chains (e.g. tyrosine or tryptophan). Compensatory "cavities" of identical or similar size to the protuberances are optionally created on the interface of the second polypeptide by replacing large amino acid side chains with smaller ones (e.g. alanine or threonine). Where a suitably positioned and dimensioned protuberance or cavity exists at the interface of either the first or second polypeptide, it is only necessary to engineer a corresponding cavity or protuberance, respectively, at the adjacent interface. The protuberance and cavity can be made by synthetic means such as altering the nucleic acid encoding the polypeptides or by peptide synthesis. For further description of knobs into holes, see U.S. Patents 5,731,168; 5,807,706; 5,821,333.

A general method of preparing a heteromultimer using the "protuberance-into-cavity" strategy comprises expressing, in one or separate host cells, a polynucleotide encoding a first polypeptide that has been altered from an original polynucleotide to encode a protuberance, and a second polynucleotide encoding a second polypeptide that has been altered from the original polynucleotide to encode the cavity. The polypeptides are expressed, either in a common host cell with recovery of the heteromultimer from the host cell culture, or in separate host cells, with recovery and purification, followed by formation of the heteromultimer. In some embodiments, the heteromultimer formed is a multimeric antibody, for example a bispecific antibody.

Chimeric Molecule

Disclosed herein is a chimeric molecule comprising an antigen-binding molecule as defined herein and a heterologous moiety.

In one embodiment, the heterologous moiety is a detectable moiety, a half-life extending moiety, or a therapeutic moiety.

Detectable moieties contemplated by the present invention include for example any species known in the art that is appropriate for diagnostic detection, including *in vitro* detection and *in vivo* imaging. The detectable moiety may be, for example, a fluorophore, a radionuclide reporter, a metal-containing nanoparticle or microparticle, an ultrasound contrast agent (*e.g.*, a nanobubble or microbubble) or an optical imaging dye. This also includes contrast particles visible in magnetic resonance imaging (MRI) and magnetic particle imaging (MPI). Fluorophores can be detected and/or imaged, for example, by fluorescence polarization, fluorescence-activated cell sorting and fluorescence microscopy, which may or may not be in combination with electrospray ionization-mass spectrometry (ESI-MS) detection, as well as fluorescence emission computed tomography (FLECT) imaging. Radionuclide reporters can be detected and imaged by radionuclide (nuclear) detection, such as, for example, single-photon emission computed tomography (SPECT), positron emission tomography (PET) or scintigraphic imaging. Metal-containing nanoparticles or microparticles may be detected using optical imaging, including MRI, which is typically used with paramagnetic nanoparticles or microparticles, and MPI, which is generally used with superparamagnetic particles. Ultrasound contrast agents can be detected using ultrasound imaging including contrast-enhanced ultrasound (CEU).

The detectable label may also be an enzyme-substrate label. The enzyme may generally catalyze a chemical alteration of the chromogenic substrate that can be measured using various techniques. For example, the enzyme may catalyze a chemical alteration of the chromogenic substrate that can be measured using the various techniques. For example, the example may catalyze a color change in a substrate, which can be measured spectrophotometrically. Alternatively, the enzyme may alter the fluorescence or chemiluminescence of the substrate. Techniques for quantifying a change in fluorescence are described above. The chemiluminescent substrate becomes electronically excited by a chemical reaction and may then emit light that can be measured (using a chemiluminometer, for example) or donates energy to a fluorescent acceptor. Examples of enzymatic labels include luciferases (*e.g.*, firefly luciferase and bacterial luciferase; U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, malate dehydrogenase, urease, peroxidase such as horseradish peroxidase (HRPO), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases (*e.g.*, glucose oxidase, galactose oxidase, and glucose-6-

phosphate dehydrogenase), heterocyclic oxidases (such as urease and xanthine oxidase), lactoperoxidase, microperoxidase, and the like.

Examples of enzyme-substrate combinations include, for example:

- 1) Horseradish peroxidase (HRPO) utilizes hydrogen peroxide to oxidize a dye precursor (e.g., orthophenylene diamine (OPD) or 3,3',5,5'-tetramethyl benzidine hydrochloride (TMB));
- 2) alkaline phosphatase (AP) with para-Nitrophenyl phosphate as chromogenic substrate; and
- 3) β -D-galactosidase (β -D-Gal) with a chromogenic substrate (e.g., p-nitrophenyl- β -D-galactosidase) or fluorogenic substrate 4-methylumbelliferyl- β -D-galactosidase.

In another embodiment of the invention, the antigen-binding molecule need not be labeled, and the presence thereof can be detected using a labeled antibody which binds to the antigen-binding molecule. The antigen-binding molecule of the present invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, immunohistochemistry and immunoprecipitation assays.

In one embodiment, the chimeric molecule comprises at least one heterologous moiety that is a "half-life extending moiety". Half-life extending moieties, can comprise, for example, (i) XTEN polypeptides; (ii) Fc; (iii) albumin, (iv) albumin binding polypeptide or fatty acid, (v) the C-terminal peptide (CTP) of the 13 subunit of human chorionic gonadotropin, (vi) PAS; (vii) HAP; (viii) transferrin; (ix) polyethylene glycol (PEG); (x) hydroxyethyl starch (HES), (xi) polysialic acids (PSAs); (xii) a clearance receptor or fragment thereof which blocks binding of the chimeric molecule to a clearance receptor; (xiii) low complexity peptides; (xiv) or any combinations thereof. In some embodiments, the half-life extending moiety comprises an Fc region. In other embodiments, the half-life extending moiety comprises two Fc regions fused by a linker. Exemplary heterologous moieties also include, *e.g.*, FcRn binding moieties (*e.g.*, complete Fc regions or portions thereof which bind to FcRn), single chain Fc regions (scFc regions, *e.g.*, as described in U.S. Publ. No. 20080260738, WO 2008/012543 and WO 2008/1439545), or processable scFc regions. In some embodiments, a heterologous moiety can include an attachment site for a non-polypeptide moiety such as

polyethylene glycol (PEG), hydroxyethyl starch (HES), polysialic acid, or any derivatives, variants, or combinations of these moieties.

In some embodiments, at least one heterologous moiety is a therapeutic moiety. In certain embodiments, the therapeutic moiety is selected from an anti-cancer moiety (*e.g.*, cytostatic/toxic, and/or anti-proliferative drugs), an immunotherapeutic moiety and an anti-inflammatory moiety. In some embodiments, the therapeutic agent is useful in the treatment of cancer. Useful classes of anti-cancer agents include chemotherapeutic agents, representative examples of which include antitubulin agents, auristatins, DNA minor groove binders, DNA replication inhibitors, alkylating agents (*e.g.*, platinum complexes such as *cis*-platin, mono(platinum), bis(platinum) and tri-nuclear platinum complexes and carboplatin), anthracyclines, antibiotics, antifolates, antimetabolites, calmodulin inhibitors, chemotherapy sensitizers, duocarmycins, etoposides, fluorinated pyrimidines, ionophores, lexitropsins, maytansinoids, nitrosoureas, platinols, pore-forming compounds, purine antimetabolites, puromycins, radiation sensitizers, rapamycins, steroids, taxanes, topoisomerase inhibitors, vinca alkaloids, or the like.

In one embodiment, the therapeutic moiety is an auristatin such as monomethyl auristatin F (MMAF) or monomethyl auristatin E (MMAE).

In one embodiment, the antigen-binding molecule is joined to the therapeutic moiety via a valine-citrulline (Vc) linker.

Polynucleotides, Constructs and Host Cells

Disclosed herein is an isolated polynucleotide comprising a nucleic acid sequence encoding the antigen-binding molecule as defined herein, or the chimeric molecule as defined herein.

The term “polynucleotide” or “nucleic acid” are used interchangeably herein to refer to a polymer of nucleotides, which can be mRNA, RNA, cRNA, cDNA or DNA. The term typically refers to polymeric form of nucleotides of at least 10 bases in length, either ribonucleotides or deoxynucleotides or a modified form of either type of nucleotide. The

term includes single and double stranded forms of DNA.

Also disclosed herein is a vector that comprises a nucleic acid encoding the antigen-binding molecule as described herein.

By “vector” is meant a nucleic acid molecule, preferably a DNA molecule derived, for example, from a plasmid, bacteriophage, or virus, into which a nucleic acid sequence may be inserted or cloned. A vector preferably contains one or more unique restriction sites and may be capable of autonomous replication in a defined host cell including a target cell or tissue or a progenitor cell or tissue thereof, or be integrable with the genome of the defined host such that the cloned sequence is reproducible. Accordingly, the vector may be an autonomously replicating vector, i.e., a vector that exists as an extrachromosomal entity, the replication of which is independent of chromosomal replication, *e.g.*, a linear or closed circular plasmid, an extrachromosomal element, a minichromosome, or an artificial chromosome. The vector may contain any means for assuring self-replication. Alternatively, the vector may be one which, when introduced into the host cell, is integrated into the genome and replicated together with the chromosome(s) into which it has been integrated. A vector system may comprise a single vector or plasmid, two or more vectors or plasmids, which together contain the total DNA to be introduced into the genome of the host cell, or a transposon. The choice of the vector will typically depend on the compatibility of the vector with the host cell into which the vector is to be introduced. The vector may also include a selection marker such as an antibiotic resistance gene that can be used for selection of suitable transformants. Examples of such resistance genes are well known to those of skill in the art.

Disclosed herein is a construct comprising a nucleic acid sequence encoding the antigen-binding molecule as defined herein, or the chimeric molecule as defined herein in operable connection with one or more control sequences.

The term “construct” refers to a recombinant genetic molecule including one or more isolated nucleic acid sequences from different sources. Thus, constructs are chimeric molecules in which two or more nucleic acid sequences of different origin are assembled into a single nucleic acid molecule and include any construct that contains (1) nucleic

acid sequences, including regulatory and coding sequences that are not found together in nature (i.e., at least one of the nucleotide sequences is heterologous with respect to at least one of its other nucleotide sequences), or (2) sequences encoding parts of functional RNA molecules or proteins not naturally adjoined, or (3) parts of promoters that are not naturally adjoined. Representative constructs include any recombinant nucleic acid molecule such as a plasmid, cosmid, virus, autonomously replicating polynucleotide molecule, phage, or linear or circular single stranded or double stranded DNA or RNA nucleic acid molecule, derived from any source, capable of genomic integration or autonomous replication, comprising a nucleic acid molecule where one or more nucleic acid molecules have been operably linked. Constructs of the present invention will generally include the necessary elements to direct expression of a nucleic acid sequence of interest that is also contained in the construct, such as, for example, a target nucleic acid sequence or a modulator nucleic acid sequence. Such elements may include control elements or regulatory sequences such as a promoter that is operably linked to (so as to direct transcription of) the nucleic acid sequence of interest, and often includes a polyadenylation sequence as well. Within certain embodiments of the invention, the construct may be contained within a vector. In addition to the components of the construct, the vector may include, for example, one or more selectable markers, one or more origins of replication, such as prokaryotic and eukaryotic origins, at least one multiple cloning site, and/or elements to facilitate stable integration of the construct into the genome of a host cell. Two or more constructs can be contained within a single nucleic acid molecule, such as a single vector, or can be contained within two or more separate nucleic acid molecules, such as two or more separate vectors. An "expression construct" generally includes at least a control sequence operably linked to a nucleotide sequence of interest. In this manner, for example, promoters in operable connection with the nucleotide sequences to be expressed are provided in expression constructs for expression in an organism or part thereof including a host cell. For the practice of the present invention, conventional compositions and methods for preparing and using constructs and host cells are well known to one skilled in the art, see for example, *Molecular Cloning: A Laboratory Manual*, 3rd edition Volumes 1, 2, and 3. J. F. Sambrook, D. W. Russell, and N. Irwin, Cold Spring Harbor Laboratory Press, 2000.

By "control element", "control sequence", "regulatory sequence" and the like, as used herein, mean a nucleic acid sequence (e.g., DNA) necessary for expression of an

operably linked coding sequence in a particular host cell. The control sequences that are suitable for prokaryotic cells for example, include a promoter, and optionally a cis-acting sequence such as an operator sequence and a ribosome binding site. Control sequences that are suitable for eukaryotic cells include transcriptional control sequences such as promoters, polyadenylation signals, transcriptional enhancers, translational control sequences such as translational enhancers and internal ribosome binding sites (IRES), nucleic acid sequences that modulate mRNA stability, as well as targeting sequences that target a product encoded by a transcribed polynucleotide to an intracellular compartment within a cell or to the extracellular environment.

Disclosed herein is a host cell that contains the construct as defined herein.

The terms “host”, “host cell”, “host cell line” and “host cell culture” are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include “transformants” and “transformed cells”, which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are included herein. A host cell is any type of cellular system that can be used to generate the antigen-binding molecules of the present invention. Host cells include cultured cells, *e.g.*, mammalian cultured cells, such as CHO cells, BHK cells, NS0 cells, SP2/0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, to name only a few, but also cells comprised within a transgenic animal, transgenic plant or cultured plant or animal tissue.

Pharmaceutical Composition

Disclosed herein is a pharmaceutical composition comprising the antigen-binding molecule as defined herein, or the chimeric molecule as defined herein, and a pharmaceutically acceptable carrier.

By “pharmaceutically acceptable carrier” is meant a pharmaceutical vehicle comprised of a material that is not biologically or otherwise undesirable, *i.e.*, the material may be

administered to a subject along with the selected active agent without causing any or a substantial adverse reaction. Carriers may include excipients and other additives such as diluents, detergents, coloring agents, wetting or emulsifying agents, pH buffering agents, preservatives, and the like.

Representative pharmaceutically acceptable carriers include any and all solvents, dispersion media, coatings, surfactants, antioxidants, preservatives (*e.g.*, antibacterial agents, antifungal agents), isotonic agents, absorption delaying agents, salts, preservatives, drugs, drug stabilizers, gels, binders, excipients, disintegration agents, lubricants, sweetening agents, flavoring agents, dyes, such like materials and combinations thereof, as would be known to one of ordinary skill in the art (see, for example, Remington's Pharmaceutical Sciences, 18th Ed. Mack Printing Company, 1990, pp. 1289-1329, incorporated herein by reference). Except insofar as any conventional carrier is incompatible with the active ingredient(s), its use in the pharmaceutical compositions is contemplated.

The pharmaceutical compositions may be in a variety of forms. These include, for example, liquid, semi-solid and solid dosage forms, such as liquid solutions (*e.g.*, injectable and infusible solutions), dispersions or suspensions, liposomes and suppositories. The preferred form depends on the intended mode of administration and therapeutic application. Suitable pharmaceutical compositions may be administered intravenously, subcutaneously or intramuscularly. In some embodiments, the compositions are in the form of injectable or infusible solutions. A preferred mode of administration is parenteral (*e.g.*, intravenous, subcutaneous, intraperitoneal, intramuscular). In specific embodiments, the pharmaceutical composition is administered by intravenous infusion or injection. In other embodiments, the pharmaceutical composition is administered by intramuscular or subcutaneous injection.

The phrases "parenteral administration" and "administered parenterally" as used herein means modes of administration other than enteral and topical administration, usually by injection, and includes, without limitation, intravenous, intramuscular, intraarterial, intrathecal, intracapsular, intraorbital, intracardiac, intradermal, intraperitoneal, transtracheal, subcutaneous, subcuticular, intraarticular, subcapsular, subarachnoid,

intraspinal, epidural and intrasternal injection and infusion.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. In the subject invention, pharmaceutically acceptable carriers include, but are not limited to, 0.01-0.1M and preferably 0.05M phosphate buffer or 0.8% saline. Other common parenteral vehicles include sodium phosphate solutions, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's, or fixed oils. Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives can also be present such as for example, antimicrobials, antioxidants, chelating agents, and inert gases and the like.

More particularly, pharmaceutical compositions suitable for injectable use include sterile aqueous solutions (where water soluble) or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In such cases, the composition must be sterile and should be fluid to the extent that easy syringability exists. It should be stable under the conditions of manufacture and storage and will preferably be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (*e.g.*, glycerol, propylene glycol, and liquid polyethylene glycol, and the like), and suitable mixtures thereof. The proper fluidity can be maintained, for example, by the use of a coating such as lecithin and/or by the maintenance of the required particle size. In specific embodiments, an agent of the present disclosure may be conjugated to a vehicle for cellular delivery. In these embodiments, the agent may be encapsulated in a suitable vehicle to either aid in the delivery of the agent to target cells, to increase the stability of the agent, or to minimize potential toxicity of the agent. As will be appreciated by a skilled artisan, a variety of vehicles are suitable for delivering an agent of the present disclosure. Non-limiting examples of suitable structured fluid delivery systems may include nanoparticles, liposomes, microemulsions, micelles, dendrimers and other phospholipid-containing systems. Methods of incorporating agents of the present disclosure into delivery

vehicles are known in the art. Although various embodiments are presented below, it will be appreciated that other methods known in the art to incorporate an antigen-binding molecule, as described herein, into a delivery vehicle are contemplated.

Dosage regimens are adjusted to provide the optimum desired response (*e.g.*, a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. An antigen-binding molecule of the present disclosure can be administered on multiple occasions. Intervals between single dosages can be daily, weekly, monthly or yearly. Intervals can also be irregular as indicated by measuring blood levels of modified polypeptide or antigen in the patient. Alternatively, the antigen-binding molecule can be administered as a sustained release formulation, in which case less frequent administration is required. Dosage and frequency vary depending on the half-life of the polypeptide in the patient.

It may be advantageous to formulate compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutically acceptable carrier. The specification for the dosage unit forms of the invention are dictated by and directly dependent on (a) the unique characteristics of the active compound and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active compound for the treatment of sensitivity in individuals.

Dosages and therapeutic regimens of the antigen-binding molecule can be determined by a skilled artisan. In certain embodiments, the antigen-binding molecule is administered by injection (*e.g.*, subcutaneously or intravenously) at a dose of about 0.01 to 50 mg/kg, *e.g.*, 0.01 to 0.1 mg/kg, *e.g.*, about 0.1 to 1 mg/kg, about 1 to 5 mg/kg, about 5 to 25 mg/kg, about 10 to 50 mg/kg. The dosing schedule can vary from *e.g.*, once a week to once every 2, 3, or 4 weeks.

It is to be noted that dosage values may vary with the type and severity of the condition to be alleviated. It is to be further understood that for any particular subject, specific

dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that dosage ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed composition.

Methods of Treatment

Provided herein is a method for reducing the expression or activity of ALPPL2 in a cell (such as a cancer cell). Provided herein is a method for reducing the expression or activity of ALPPL2 in a cancer cell, the method comprising contacting the cancer cell with an antigen-binding molecule, a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition as defined herein.

Disclosed herein is a method for reducing the expression or activity of ALPPL2 in a cancer cell, the method comprising contacting the cancer cell with an antigen-binding molecule as defined herein or a chimeric molecule as defined herein.

The term “tumor,” as used herein, refers to any neoplastic cell growth and proliferation, whether malignant or benign, and all pre-cancerous and cancerous cells and tissues. The terms “cancer” and “cancerous” refer to or describe the physiological condition in mammals that is typically characterized in part by unregulated cell growth. As used herein, the term “cancer” refers to non-metastatic and metastatic cancers, including early stage and late stage cancers. The term “precancerous” refers to a condition or a growth that typically precedes or develops into a cancer. By “non-metastatic” is meant a cancer that is benign or that remains at the primary site and has not penetrated into the lymphatic or blood vessel system or to tissues other than the primary site. Generally, a non-metastatic cancer is any cancer that is a Stage 0, I, or II cancer, and occasionally a Stage III cancer. By “early stage cancer” is meant a cancer that is not invasive or metastatic or is classified as a Stage 0, I, or II cancer. The term “late stage cancer” generally refers to a Stage III or Stage IV cancer, but can also refer to a Stage II cancer or a substage of a Stage II cancer. One skilled in the art will appreciate that the classification of a Stage II cancer as either an early stage cancer or a late stage cancer depends on the particular type of cancer. Illustrative examples of cancer include, but are not limited to, breast cancer, prostate or testicular cancer, ovarian cancer, cervical

cancer, pancreatic cancer, colorectal cancer, lung cancer, hepatocellular cancer, gastric cancer, liver cancer, bladder cancer, cancer of the urinary tract, thyroid cancer, renal cancer, carcinoma, melanoma, brain cancer, non-small cell lung cancer, squamous cell cancer of the head and neck, endometrial cancer, multiple myeloma, rectal cancer, mesothelioma, endometrial cancer and esophageal cancer. In an exemplary embodiment, the cancer is colorectal, endometrial, gastric, mesothelioma, ovarian, pancreatic or testicular cancer.

Provided herein is a method for reducing or inhibiting proliferation, survival and viability of a tumor in a subject, the method comprising administering an antigen-binding molecule, a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition as defined herein to the subject.

Disclosed herein is a method for reducing or inhibiting proliferation, survival and viability of a tumor in a subject, the method comprising administering an antigen-binding molecule as defined herein or a chimeric molecule as defined herein to the subject.

The term "patient" includes human and other mammalian subjects that receive either prophylactic or therapeutic treatment. As used herein, the term "subject" includes any human or non-human animal. For example, the methods of the present invention can be used to treat a subject having cancer. In one embodiment, the subject is a human. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc. For example, the methods of the present invention can be used to treat a subject having cancer. In one embodiment, the subject is a human. The term "non-human animal" includes all vertebrates, e.g., mammals and non-mammals, such as non-human primates, sheep, dog, cow, chickens, amphibians, reptiles, etc.

The methods as disclosed herein may comprises the administration of a "therapeutically effective amount" of an agent (e.g. an antigen-binding molecule, a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition) to a subject. As used herein the term "therapeutically effective amount" includes within its meaning a non-toxic but sufficient amount of an agent or compound to provide the

desired therapeutic effect. The exact amount required will vary from subject to subject depending on factors such as the species being treated, the age and general condition of the subject, the severity of the condition being treated, the particular agent being administered and the mode of administration and so forth. Thus, it is not possible to specify an exact “effective amount”. However, for any given case, an appropriate “effective amount” may be determined by one of ordinary skill in the art using only routine experimentation.

In one embodiment, there is provided a method of treating cancer in a subject, wherein the method comprises administering an antigen-binding molecule, a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition as defined herein to the subject

Disclosed herein is a method of treating cancer in a subject, wherein the method comprises administering an antigen-binding molecule as defined herein or a chimeric molecule as defined herein to the subject.

The term “treating” as used herein may refer to (1) preventing or delaying the appearance of one or more symptoms of the disorder; (2) inhibiting the development of the disorder or one or more symptoms of the disorder; (3) relieving the disorder, i.e., causing regression of the disorder or at least one or more symptoms of the disorder; and/or (4) causing a decrease in the severity of one or more symptoms of the disorder.

In one embodiment, the cancer is gastric, ovarian or pancreatic cancer.

Disclosed herein is an antigen-binding molecule, a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition as defined herein for use as a medicament.

Disclosed herein is an antigen-binding molecule as defined herein or a chimeric molecule as defined herein for use in the treatment of cancer.

Disclosed herein is the use of an antigen-binding molecule, a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition in the manufacture of a medicament for the treatment of a subject in need. The subject may be a subject suffering from cancer.

Disclosed herein is the use of an antigen-binding molecule as defined herein or a chimeric molecule as defined herein in the manufacture of a medicament for the treatment of cancer.

Disclosed herein is a method of treating a disorder or condition associated with the undesired expression of ALPPL2 in a subject, wherein the method comprises administering an antigen-binding molecule a chimeric molecule, a polynucleotide, a construct, a vector, a host cell or a pharmaceutical composition as defined herein to the subject.

Disclosed herein is a method of treating a disorder or condition associated with the undesired expression of ALPPL2 in a subject, wherein the method comprises administering an antigen-binding molecule as defined herein or a chimeric molecule as defined herein to the subject.

In one embodiment, the disorder or condition associated with the undesired expression of ALPPL2 is a cancer.

In one embodiment, the cancer is a solid cancer.

In one embodiment, the cancer is cervical, colon, endometrial, gastric, ovarian or pancreatic cancer.

Kits

Disclosed herein is a kit for detecting cancer, the kit comprising an antigen-binding molecule or a chimeric molecule as defined herein

Methods of Diagnosis

Disclosed herein is a method of determining the likelihood of a cancer in a subject, wherein the method comprises detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 in the sample as compared to a reference indicates the likelihood of cancer in the subject.

In one embodiment, the method comprises detecting ALPPL2 with an antigen-binding

molecule as defined herein or a chimeric molecule as defined herein.

Disclosed herein is a method of treating a cancer in a subject, wherein the method comprises a) detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 in the sample as compared to a reference indicates an increased likelihood of cancer in the subject; and b) treating a subject found to have an increased likelihood of cancer.

In one embodiment, the method comprises detecting ALPPL2 with an antigen-binding molecule as defined herein or a chimeric molecule as defined herein.

In one embodiment, the method comprises treating the subject with an antigen-binding molecule as defined herein or a chimeric molecule as defined herein.

Disclosed herein is a method of identifying a subject who is likely to be responsive to treatment with an anti-ALPPL2 antibody, the method comprising detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 indicates that the subject is likely to be responsive to treatment with the ALPPL2 antibody.

In one embodiment, the method comprises detecting ALPPL2 with an antigen-binding molecule as defined herein or a chimeric molecule as defined herein.

Disclosed herein is a method of identifying and treating a subject who is likely to be responsive to treatment with an anti-ALPPL2 antibody, the method comprising a) detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 indicates that the subject is likely to be responsive to treatment with the ALPPL2 antibody; and b) treating the subject found likely to be responsive to treatment with the ALPPL2 antibody.

As used herein, "and/or" refers to and encompasses any and all possible combinations of one or more of the associated listed items, as well as the lack of combinations when interpreted in the alternative (or).

As used in this application, the singular form "a," "an," and "the" include plural references unless the context clearly dictates otherwise. For example, the term "an agent" includes a plurality of agents, including mixtures thereof.

By “about” is meant a quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length that varies by as much 15, 14, 13, 12, 11, 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 % to a reference quantity, level, value, number, frequency, percentage, dimension, size, amount, weight or length.

Throughout this specification and the statements which follow, unless the context requires otherwise, the word "comprise", and variations such as "comprises" and "comprising", will be understood to imply the inclusion of a stated integer or step or group of integers or steps but not the exclusion of any other integer or step or group of integers or steps.

The reference in this specification to any prior publication (or information derived from it), or to any matter which is known, is not, and should not be taken as an acknowledgment or admission or any form of suggestion that that prior publication (or information derived from it) or known matter forms part of the common general knowledge in the field of endeavour to which this specification relates.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications which fall within the spirit and scope. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification, individually or collectively, and any and all combinations of any two or more of said steps or features.

Certain embodiments of the invention will now be described with reference to the following examples which are intended for the purpose of illustration only and are not intended to limit the scope of the generality hereinbefore described.

EXAMPLES

Target ID and Background

Gastric cancer is an East Asia prevalent disease, in which 79% of patients are diagnosed at stage IV with a five-year survival rate is less than 5%. A novel cell surface biomarker, ALPPL2, was identified as a target for therapeutic antibodies and companion diagnostics. Biomarker identification was performed on RNA-sequencing data from 19 gastric cancer patients through rigorous bioinformatics analysis.

ALPPL2 protein expression was validated in 6 gastric cancer cell lines using a commercial anti-ALPPL2 antibody in immunohistochemical staining. Strong membranous staining was observed in gastric cancer cell lines overexpressing ALPPL2 mRNA while no obvious staining was seen in cell lines which do not overexpress ALPPL2 transcript. Clinical prevalence was also assessed by immunohistochemical staining of 2 gastric tumour microarrays. A total of 198 tumour cores of various stages of the disease and different regions of the stomach were stained. The results indicate that 32 out of 198 cases showed ALPPL2 membranous staining which amounts to 16%. No obvious membranous staining was observed in both adjacent matched and unmatched normal tissues.

Antibody Generation

Antibodies against human ALPPL2 were generated by immunizing rabbits with the antigen. The rabbit antibodies were isolated by cloning the antibody genes directly from rabbit single B cells.

During the screening process, clones that bind to ALPPL2 but not the related ALPI, which is expressed in normal intestinal tissue, were selected (Figures 1 and 2). In total 36 clones with high affinity to human ALPP/ALPPL2 were isolated. The amino acid sequences of the variable regions and complementarity determining regions are shown in Table 1 and 2.

Affinity and Specificity

Specific clones were screened and identified by ELISA and high throughput flow cytometry (Figure 3). Rabbit kidney cells were transfected with either truncated (for ELISA screen) or full-length (for FACS screen) ALPI and ALPPL2.

A subset of clones with specificity towards ALPPL2/ALPP but not ALPI were selected further for affinity measurement using Biolayer Interferometry analysis (Figure 3). In this technique, single concentration of different supernatant clones from rabbit B cells were immobilized on protein A biosensors. The biosensors were then incubated with analyte to measure affinity.

A comparable humanized monoclonal antibody disclosed in a prior art was engineered by grafting the CDR to the same framework and to evaluate binding to both ALPPL2 and ALPI by ELISA. The comparable humanized monoclonal antibody has the following V_H and V_L sequences:

V _H	V _L
QVQLQQSGGGLVKPGGSLRLSCAAS GFTFSSYDMHWVRQAPGKGLEWVA VISYDGSNKYYADSVKGRFTISRDN KNTLYLQMDSLRAEDTAVYFCAKE GDSSRWSYDLWGRGTLVTVSS (SEQ ID NO: 324)	QSALTQPASVSGSPGQSITISCTGTS SDVGGYNYVSWYQQHPGKAPKV MIYDVTNRPSGVSNRFSGSKSGNT ASLTISGLQAEDEADYYCSSYTSTS TLVVFGGGTKLTVLG (SEQ ID NO: 325)

The gene was synthesized and cloned into the expression vector for recombinant antibody production. The surface plasmon resonance data in Figure 4 shows that the antibody disclosed in prior art exhibits non-specific binding to ALPI but not the antibodies of the present invention.

Immunohistochemistry (IHC) activity,

To enable development of a companion diagnostic, the IHC activity of the antibodies was evaluated (Figure 5). Antigen retrieval by Proteinase-K digestion, but not heat mediated antigen retrieval, enabled detection. C36, C45 and C130 enabled detection in ALPPL2 +ve cell lines (SCH) and formalin fixed paraffin embedded (FFPE) human tumor tissues by IHC. This shows that the antibodies may have diagnostic applications in patient stratification and therapeutic applications for the treatment of ALPPL2/ALPP +ve tumors, including gastric cancer, ovarian cancer, colorectal cancer, pancreatic

cancer, endometrial cancer, mesothelioma and testicular cancer. C36 shows negative staining in all normal tissues except placenta, suggesting ALPPL/ALPP has no/low expression in normal tissues. This is also indicative the optimal therapeutic window of these antibodies in the clinic.

Non-Human Primate (NHP) Cross-reactivity

The antibodies were further evaluated for cross-reactivity to non-human primate orthologs (Figure 6). Select clones showed reactivity to rhesus macaque ortholog.

Humanized Clones (affinity, selectivity and specificity)

Select clones (C4, C15, C131, C12, C18, C36 and C53) were humanized by grafting the CDRs to a human IgG1 framework. These humanized clones were shown to retain high ALPP/ALPPL2 affinity using surface plasmon resonance (Figure 7). Surface plasmon resonance was studied using Biacore T200. Ligands (e.g. ALPPL2 or ALPP) were immobilized on biosensors CM5 chips captured with the streptavidin. Ligands-loaded sensors were then incubated with different concentrations of analyte (recombinant expressed humanized antibody clones) to measure affinity.

Humanized clones (C4, C36 and C53) maintained the selectivity towards cancer-specific ALPPL2 and/or ALPP, but not towards the widely expressed ALPI and ALPL (Figure 13). Humanized clones were also specific to the cancer cells but not the normal naïve and stimulated immune cells (Figure 13).

Humanized Clones (ADCC)

The therapeutic efficacy of the humanized clones was tested by first evaluating antibody-dependent cellular toxicity by co-culture of reporter or primary NK cells with cancer cell lines (Figure 8). C4 resulted in the most potent ADCC induction in both gastric cancer cell lines with high and low target expression, when compared to the other clones. The potency of C4 was confirmed in a co-culture assay of primary NK cells with different gastric cancer cell lines. C4 achieved near complete killing of a high expressing cell line, and showed potency (maximum % kill and EC50) that was proportional to the

target expression level. In addition, C4 was also tested in a reporter assay and induction of ADCC with different ovarian and pancreatic cancer cell lines was confirmed.

The Fc region of humanized C4 was further engineered to enhance ADCC. Reporter assay confirmed more the humanized C4 with engineered Fc more potently induced ADCC with a gastric cancer cell line-

Humanized Clones (ADC)

The suitability of using these humanized antibodies as antibody-drug conjugate was evaluated. First, killing of gastric cancer cell lines by these antibodies was tested in the presence of secondary antibodies conjugated with vc-MMAF (Figure 9). Secondary ADC assay revealed some differences in potency among the clones; killing was only seen in select gastric cancer cell lines with high target expression but not others. These results were confirmed using the same antibodies conjugated with vc-MMAE. Primary conjugation of the antibodies with vc-MMAE potentiated killing of the same gastric cancer cell lines observed in the secondary ADC assay.

Humanized Clones (T-cell engagers)

It was further exemplified that these humanized antibodies can be successfully adapted for use as T-cell engagers to induce potent T-cell mediated killing of cancer cells (Figure 10, Figure 11 and Figure 12). Bispecific antibodies by heterodimerisation of the humanized clones with anti-CD3 antibodies achieved potent and specific killing of gastric, ovarian and pancreatic cancer cell lines irrespective of target expression level. In particular, C4 achieved near-complete killing of multiple cancer cell lines at pM concentrations.

ALPPL2 specific clone

Chimerized and humanized C53 clone demonstrated binding specificity towards ALPPL2 but not ALPP (Figure 12). Chimerized C53 is also cross-reactive towards rhesus macaque ortholog. Binding affinity of humanized C53 as compared to humanized C36 to ALPPL and ALPP was performed using Biolayer Interferometry. In this

technique, biotinylated ligands (i.e. ALPPL2 or ALPP) were immobilized on SA biosensors. Ligands-loaded sensors were then incubated with different concentrations of analyte (recombinantly expressed humanized antibody clones) in the buffer. Humanized C53 antibody demonstrated nM binding affinity towards ALPPL but not ALPP as determined Biolayer Interferometry, whereas humanized C36 demonstrated similar binding affinity towards ALPPL2 and ALPP.

It was further exemplified that humanized C53 antibody maintained its killing potency in both ADCC and adapted for use as T-cell engager to induce potent T-cell mediated killing of cancer cells.

Claims

1. An antigen-binding molecule that specifically binds ALPPL2 and/or ALPP but not ALPL or ALPI, comprising:
 - a) a heavy chain variable region (V_H) comprising VHCDR1, VHCDR2 and VHCDR3 amino acid sequences; and
 - b) a light chain variable region (V_L) comprising VLCDR1, VLCDR2 and VLCDR3 amino acid sequences; wherein the combination of VHCDR1, VHCDR2, VHCDR3, VLCDR1, VLCDR2 and VLCDR3 amino acid sequences are shown in any of the rows in Table 1.
2. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule specifically binds to ALPPL2 and/or ALPP or a cell expressing ALPPL2 and/or ALPP with an affinity of between about 14 pM to about 10 nM.
3. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule specifically binds to rhesus macaque ALPPL2/ALPP ortholog.
4. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule comprises a) a heavy chain variable region (V_H) comprising SEQ ID NO: 115, SEQ ID NO: 116 and SEQ ID NO: 117; and b) a light chain variable region (V_L) comprising SEQ ID NO: 118, SEQ ID NO: 119 and SEQ ID NO: 120.
5. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule comprises:
 - a) a V_H amino acid sequence having at least 90% (including at least 91% to 100% and all integer percentages therebetween) sequence identity to a V_H amino acid sequence as shown in any of the rows in Table 2 or Table 3, and
 - b) a V_L amino acid sequence having at least 90% sequence identity (including at least 91% to 100% and all integer percentages therebetween) to a V_L amino acid sequence as shown in the same row as the V_H amino acid sequence in Table 2 or Table 3.
6. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule

comprises:

- a) a VH amino acid sequence having at least 90% (including at least 91% to 100% and all integer percentages therebetween) sequence identity to SEQ ID NO: 291, and
- b) a VL amino acid sequence having at least 90% sequence identity (including at least 91% to 100% and all integer percentages therebetween) to SEQ ID NO: 292.

7. The antigen-binding molecule of claim 1, wherein the antigen-binding molecule does not bind to ALPP.
8. The antigen binding molecule of claim 1, wherein the antigen-binding molecule is an antibody or antigen-binding fragment thereof or a chimeric antigen receptor (CAR).
9. The antigen binding molecule of claim 8, wherein the antibody or antigen-binding fragment thereof is humanized or chimerized.
10. The antigen-binding molecule of claim 8, wherein the antibody or antigen-binding fragment thereof is a full-length antibody, a substantially intact antibody, a Fab fragment, scFab, Fab', a single chain variable fragment (scFv) or a one-armed antibody.
11. The antigen-binding molecule of claim 8, wherein the antibody is a bispecific or trispecific antibody.
12. The antigen-binding molecule of claim 11, wherein the bispecific antibody comprises a first antigen-binding site that specifically binds ALPPL2 and a second antigen-binding site that specifically binds CD3.
13. A chimeric molecule comprising an antigen-binding molecule according to any one of claim 1 to 12 and a heterologous moiety.
14. The chimeric molecule of claim 13, wherein the heterologous moiety is a detectable moiety, a half-life extending moiety, or a therapeutic moiety.

15. The chimeric molecule of claim 14, wherein the therapeutic moiety is monomethyl auristatin F (MMAF) or monomethyl auristatin E (MMAE).
16. An isolated polynucleotide comprising a nucleic acid sequence encoding the antigen-binding molecule according to any one of claims 1 to 10, or the chimeric molecule of any one of claims 13 to 15.
17. A construct comprising a nucleic acid sequence encoding the antigen-binding molecule according to any one of claims 1 to 12, or the chimeric molecule of any one of claims 13 to 15 in operable connection with one or more control sequences.
18. A host cell that contains the construct of claim 17.
19. A pharmaceutical composition comprising the antigen-binding molecule according to any one of claims 1 to 12, or the chimeric molecule of any one of claims 13 to 15, and a pharmaceutically acceptable carrier.
20. A method for reducing the expression or activity of ALPPL2 in a cancer cell, the method comprising contacting the cancer cell with an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15.
21. A method for reducing or inhibiting proliferation, survival and viability of a tumor in a subject, the method comprising administering an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15 to the subject.
22. A method of treating cancer in a subject, wherein the method comprises administering an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15 to the subject.
23. The method of claim 22, wherein the cancer is colorectal, endometrial, gastric, mesothelioma, ovarian, pancreatic or testicular cancer.
24. An antigen-binding molecule according to any one of claim 1 to 12 or a chimeric


molecule according to any one of claims 13 to 15 for use in the treatment of cancer.

25. Use of an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15 in the manufacture of a medicament for the treatment of cancer.
26. A method of treating a disease or condition associated with the undesired expression of ALPPL2 in a subject, wherein the method comprises administering an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15 to the subject.
27. A kit for detecting cancer, the kit comprising an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15.
28. A method of determining the likelihood of a cancer in a subject, wherein the method comprises detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 in the sample as compared to a reference indicates the likelihood of cancer in the subject.
29. The method of claim 28, wherein the method comprises detecting ALPPL2 with an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15.
30. A method of treating a cancer in a subject, wherein the method comprises a) detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 in the sample as compared to a reference indicates an increased likelihood of cancer in the subject; and b) treating a subject found to have an increased likelihood of cancer.
31. The method of claim 30, wherein the method comprises detecting ALPPL2 with an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15.
32. The method of claim 31, wherein the method comprises treating the subject with an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric

molecule according to any one of claims 13 to 15.


33. A method of identifying a subject who is likely to be responsive to treatment with an anti-ALPPL2 antibody, the method comprising detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 indicates that the subject is likely to be responsive to treatment with the ALPPL2 antibody.
34. The method of claim 33, wherein the method comprises detecting ALPPL2 with an antigen-binding molecule according to any one of claims 1 to 12 or a chimeric molecule according to any one of claims 13 to 15.
35. A method of identifying and treating a subject who is likely to be responsive to treatment with an anti-ALPPL2 antibody, the method comprising a) detecting ALPPL2 in a sample obtained from the subject, wherein an increased level of ALPPL2 indicates that the subject is likely to be responsive to treatment with the ALPPL2 antibody; and b) treating the subject found likely to be responsive to treatment with the ALPPL2 antibody.
36. A method for preparing an antigen-binding molecule that specifically binds ALPPL2 but not ALPL or ALPI, the method comprising:
 - a) immunizing an animal, preferentially a rabbit, with ALPPL2,
 - b) isolating from the animal a B-cell that binds specifically to ALPPL2 but not ALPL or ALPI, and
 - c) determining the amino acid sequence of the antibody that is expressed by the B-cell.

1/20



Gene	FPKM normal	FPKM tumour	Fold change	Frequency		Expression in normal tissues
				Tumour >1 , normal <0.5	Tumour >5 , normal <0.5	
TM4SF19	0.19	1.21	6.28	9/19	0/19	no/low expression
ALPPL2	0.026	7.74	292.79	4/19	2/19	placenta
TMFRSS13	0.18	2.84	16.02	6/19	4/19	brain, small intestine, duodenum, prostate, skin
CDH12	0.092	2.19	23.71	4/19	2/19	brain, adrenal gland, fallopian tube
CLDN8	0.02	4.88	233.50	4/19	2/19	no/low expression, embryonic/pluripotent stem cells
CEACAM7	1.58	9.34	5.99	7/19	4/19	appendix, colon, rectum
SLCO1A2	0.030	1.43	48.05	6/19	2/19	brain, salivary gland
SLCO1B3	0.29	2.26	7.89	3/19	2/19	liver
SSTR5	0.27	1.42	5.30	6/19	2/19	no/low expression
IL13RA2	0.24	1.94	8.07	6/19	2/19	testis, brain, kidney

Figure 1



% positive cells: 1-9% (1); 10-50% (2); >50% (3)
Staining intensity: weak (1); moderate (2); strong (3)
Score = % positive cells x staining intensity

Score	Number of cases
0	166 (85%)
1 – 2	9
3 – 6	18
9	5
1 – 9	32 (15%)






Figure 2

3/20

ELISA**FACS**

Clone	Kd(nM)	R ²
C4	0.001	100
C129	0.001	0.9984
C130	0.001	0.92864
C136	0.1	99.9
C10	0.15	99.9
C29	0.2	99.7
C138	0.2	99.8
C31	0.4	99.5
C102	0.5	0.99754
C15	0.6	0.99577
C12	0.8	0.98874
C133	1	0.92345
C18	1.4	0.97532
C25	1.4	0.97532
C21	1.4	0.93144
C36	1.6	98.5
C124	1.6	0.91724
C19	1.69	0.92002
C127	1.7	0.99172
C39	2	0.88134
C35	4.1	0.92625
C131	8	0.99968

Figure 3

ELISA (reactivity against ALPPL2 and ALPI)









Figure 4 (continued)

5/20


SPR (reactivity against ALPI)**Competitor mAb (K_d=3.63nM)****C12 (no binding)****C4 (no binding)****C18 (no binding)****Figure 4 (end)**

6/20

(A)



(B)




Representative images taken with OLYMPUS bright field microscope with 40X magnification under same light intensity

H Score = $[(1 \times (\% \text{ A cells } 1+)) + 2 \times (\% \text{ B cells } 2+)) + 3 \times (\% \text{ C cells } 3+)]$ and A, B, C are the % cells (to nearest 5%) at intensity 1, 2, 3 respectively; H-Score: 0-100 = IHC1+, 101-200 = IHC2+, 201-300 = IHC3+


Figure 5 (Continued)

(C)

Anatomic site	Result	Number of cores	H-Score	IHC
Adrenal gland	Negative	3		
Bladder	Negative	3		
Bone marrow	Negative	1		
Eye	Negative	3		
Breast	Negative	3		
Cerebellum	Negative	3		
Cerebral cortex	Negative	2		
Fallopian tube	Negative	3		
GI-Esophagus	Negative	3		
GI-Stomach	Negative	3		
GI-Small intestine	Negative	3		
GI-Colon	Negative	3		
GI-Rectum	Negative	3		
Heart	Negative	3		
Kidney	Negative	6		
Liver	Negative	3		
Lung	Negative	2		
Ovary	Negative	3		
Pancreas	Negative	3		
Parathyroid	Negative	1		
Pituitary gland	Negative	2		
Placenta	Positive	3	75-195	IHC2+
Prostate	Negative	3		
Skin	Negative	2		
Spinal cord	Negative	2		
Spleen	Negative	2		
Striated muscle	Negative	3		
Testis	Negative	3		
Thymus	Negative	3		
Thyroid	Negative	3		
Tonsil	Negative	3		
Ureter	Negative	3		
Uterus-cervix	Negative	3		
Uterus-endometrium	Negative	3		



IHC2+, placenta tissues



IHC2+, placenta tissues

Figure 5 (End)






Figure 6

SPR (ALPPL2)
C4



C12



C18




Figure 7 (continued)





Figure 7 (continued)

Affinity (K_D) measurements

	ALPP2	ALPP
C4	14 pM	0.1 pM
C12	80 pM	235 pM
C18	144 pM	526pM

Figure 7 (end)

12/20



Fc-1 mutations (S239D, A330L, I332E)
 Fc-2 mutations (F243L, R292P, Y300L, V305I, P396L)

Figure 8

13/20




Figure 9




Figure 10




Figure 11

(A)






Figure 12 (continued)

(B)



(C)



(D)





Figure 12 (continued)

(E)



(F)






Figure 12 (continued)


(A)



(B)



(C)



(D)




Figure 13

SEQUENCE LISTING

<110> Agency for Science, Technology and Research

<120> Antigen-Binding Moleculees and Uses Thereof

<130> S61015030

<160> 346

<170> PatentIn version 3.5

<210> 1

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 1

Phe Thr Ile Ser Asn Asn Tyr Trp Ile Cys
1 5 10

<210> 2

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 2

Trp Ile Gly Cys Ile Ala Thr Gly Asp Gly Ser Thr Tyr Tyr
1 5 10

<210> 3

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 3

Arg Gly Ala Ala Gly Ser Ser Trp Thr Thr Tyr Phe Asp Phe
1 5 10

<210> 4

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 4

Gln Asn Ile Asp Asn Tyr Leu Ser
1 5

<210> 5
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 5

Leu Leu Ile Tyr Arg Ala Ser Thr Leu Ala Ser
1 5 10

<210> 6
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 6

Gln Asn Asn Asn Gly Gly Ser Thr Phe Thr Gly Phe Pro
1 5 10

<210> 7
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 7

Phe Asp Phe Ser Ser Asn Gly Met Cys
1 5

<210> 8
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 8

Trp Ile Ala Cys Ile Tyr Val Asp Ser Ser Asp Asn Thr Asn Tyr
1 5 10 15

<210> 9
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 9

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu
1 5 10

<210> 10
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 10

Gln Ser Ile Asn Asn Glu Leu Ser
1 5

<210> 11
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 11

Leu Leu Ile Tyr Gly Ala Ser Thr Leu Glu Ser
1 5 10

<210> 12
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 12

Gln Ser Ala Tyr Tyr Ser Ser Ser Ser Ser Tyr Ala Asn Thr
1 5 10

<210> 13
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 13

Phe Thr Ile Ser Ser Ile Trp Ile Cys
1 5

<210> 14
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 14

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Asp Gly Gly Ser Tyr Tyr
1 5 10 15

<210> 15
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 15

Arg Ala Ser Asn Ser Trp Gln Tyr Gly Tyr Ala Gly Tyr Gly Asn Tyr
1 5 10 15

Lys Asp Tyr Phe Asn Leu
20

<210> 16
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 16

Glu Ser Ile Ser Asn Leu Leu Ala
1 5

<210> 17
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 17

Val Leu Ile Tyr Lys Ala Ser Ala Leu Pro Ser
1 5 10

<210> 18
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 18

Gln Ser Tyr Tyr Gly Ser Ser Asp Thr Gly Asn Thr
1 5 10

<210> 19
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 19

Phe Ser Phe Ser Ser Ser Tyr Trp Ile Ser
1 5 10

<210> 20

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CD2

<400> 20

Trp Ile Ala Cys Ile Ala Ile Gly Ser Ser Gly Thr Thr Tyr Tyr
1 5 10 15

<210> 21

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CD3

<400> 21

Arg Ser Gly Asp Gly Tyr Thr Tyr Val Glu Leu
1 5 10

<210> 22

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 22

Gln Ser Ile Ser Ser Tyr Leu Ala
1 5

<210> 23

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 23

Leu Leu Ile Tyr Arg Ala Ser Thr Leu Ala Ser
1 5 10

<210> 24

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 24

Gln Asn Tyr Tyr Asp Ile Asp Asp Ser Asp Asn Thr
1 5 10

<210> 25

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 25

Phe Ser Phe Ser Trp Ile Cys
1 5

<210> 26

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 26

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Ser Ala Lys Thr Tyr Tyr
1 5 10 15

<210> 27

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 27

Arg Ala Ser Asn Tyr Tyr Arg Tyr Gly Val Ala Gly Tyr Ala Asp Tyr
1 5 10 15

Thr Gly Tyr Phe Asn Leu
20

<210> 28

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 28

Gln Ser Ile Ser Ser Trp Leu Ala
1 5

<210> 29

<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 29

Leu Leu Ile Tyr Gly Thr Ser Thr Leu Ala Ser
1 5 10

<210> 30
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 30

Gln Asn Tyr Gly Gly Ser Ser Ser Gly Asp Ala
1 5 10

<210> 31
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 31

Phe Ser Phe Ser Ser Asn Tyr Trp Ile Cys
1 5 10

<210> 32
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 32

Trp Ile Ala Cys Ile Ala Thr Gly Ser Ser Gly Ser Thr Tyr Tyr
1 5 10 15

<210> 33
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 33

Arg Gly Glu Tyr Thr Tyr Gly Tyr Val Glu Tyr Ala Ile Val Thr Gln
1 5 10 15

Tyr Tyr Phe Asp Leu
20

<210> 34
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 34

Gln Asn Ile Tyr Ser Asn Leu Ala
1 5

<210> 35
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 35

Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser
1 5 10

<210> 36
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 36

Gln Ser Ala Asp Tyr Ile Gly Ser Ala Tyr Asn Ala
1 5 10

<210> 37
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 37

Phe Ser Phe Ser Ser Tyr Tyr Met Cys
1 5 10

<210> 38
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 38

Trp Ile Ala Cys Ile Tyr Thr Thr Tyr Gly Gly Thr Trp Tyr
1 5 10

<210> 39
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 39

Arg Ser Ser Ile Ser Asp Val Thr Tyr Phe Asn Leu
1 5 10

<210> 40
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 40

Gln Ser Ile Ser Asn Tyr Leu Ala
1 5

<210> 41
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 41

Leu Leu Ile Tyr Arg Ala Ser Thr Leu Glu Ser
1 5 10

<210> 42
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 42

Gln Ser Tyr Tyr Asp Asn Asn Asn Tyr Ala
1 5 10

<210> 43
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 43

Phe Thr Leu Ser Thr Tyr Trp Val Cys
1 5

<210> 44

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 44

Trp Ile Gly Cys Ile Asp Thr Val Ser Ser Gly Asp Thr Tyr Phe
1 5 10 15

<210> 45

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 45

Arg Arg Thr Gly Ser Gly Trp Thr Leu
1 5

<210> 46

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 46

Gln Ser Val Tyr Asn Asn Asn Tyr Leu Ala
1 5 10

<210> 47

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 47

Leu Leu Ile Tyr Trp Ala Ser Lys Leu Ala Ser
1 5 10

<210> 48

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 48

Leu Gly Ala Tyr Val Ser Asn Gly Trp Tyr Phe Ala
1 5 10

<210> 49

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 49

Phe Ser Phe Ser Ser Tyr Trp Thr Cys
1 5

<210> 50

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 50

Trp Leu Gly Cys Thr Asp Gly Gly Ser Ser Gly Asp Thr Tyr Tyr
1 5 10 15

<210> 51

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 51

Arg Asn Leu Ile Thr Trp Asp Leu
1 5

<210> 52

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 52

Glu Ser Val Tyr Asn Asn Asn Gln Leu Ser
1 5 10

<210> 53

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 53

Leu Leu Ile Tyr Trp Ala Ser Lys Leu Ala Ser
1 5 10

<210> 54

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 54

Ala Gly Tyr Lys Ser Ser Ile Thr Asp Gly Asn Ala
1 5 10

<210> 55

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 55

Phe Asp Phe Ser Thr Asn Ile Met Cys
1 5

<210> 56

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 56

Trp Ile Ala Cys Ile Tyr Ala Gly Asp Gly Ser Thr Tyr Tyr
1 5 10

<210> 57

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 57

Arg Ala Ser Thr Tyr Trp Asn Tyr Gly Tyr Ala Gly Tyr Gly Tyr Tyr
1 5 10 15

Pro Gly Tyr Phe Asn Leu
20

<210> 58

<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 58

Gln Ser Ile Ile Ser Ala Leu Ala
1 5

<210> 59
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 59

Leu Leu Ile Tyr Ala Ala Ser Thr Leu Ala Ser
1 5 10

<210> 60
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 60

Gln Thr Tyr Ala Tyr Ser Thr Lys Ser Asn Tyr Gly Ser Val
1 5 10

<210> 61
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 61

Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys
1 5 10

<210> 62
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 62

Trp Ile Ala Cys Ile Tyr Thr Gly Asp Gly Ser Thr Tyr Tyr
1 5 10

<210> 63
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 63

Arg Glu Asp Val Ser Ser Gly Asp Tyr Thr Phe Asn Leu
1 5 10

<210> 64
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 64

Glu Asp Ile Tyr Ser Gly Leu Ala
1 5

<210> 65
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 65

Leu Leu Ile Tyr Lys Ala Ser Asn Leu Ala Ser
1 5 10

<210> 66
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 66

Gln Gln Gly Val Thr Tyr Ser Asn Val Asp Asn Thr
1 5 10

<210> 67
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 67

Phe Ser Phe Ser Ser Thr Tyr Tyr Met Cys
1 5 10

<210> 68
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 68

Trp Ile Ala Cys Ile Tyr Thr Gly Ser Thr Gly Ser Thr Tyr Tyr
1 5 10 15

<210> 69
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 69

Arg Gly Asp Tyr Thr Tyr Ala Tyr Ala Gly Gly Ala His Val Thr Asn
1 5 10 15

Tyr Tyr Phe Asp Leu
20

<210> 70
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 70

Gln Asn Ile Tyr Ser Asn Leu Ala
1 5

<210> 71
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 71

Leu Leu Ile Phe Gly Ala Ser Asn Leu Glu Ser
1 5 10

<210> 72
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 72

Gln Thr Ala Asp Tyr Ser Ser Ser Thr Asp Trp Gly Ala
1 5 10

<210> 73

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 73

Phe Asp Phe Ser Ser Asn Gly Met Cys
1 5

<210> 74

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 74

Trp Ile Ala Cys Ile Tyr Val Asp Ser Ser Asp Ser Thr Tyr Tyr
1 5 10 15

<210> 75

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 75

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu
1 5 10

<210> 76

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 76

Gln Ser Ile Ser Asn Glu Leu Ser
1 5

<210> 77

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 77

Leu Leu Ile Tyr Gly Ala Ser Thr Leu Glu Ser
1 5 10

<210> 78

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 78

Gln Ser Ala Tyr Tyr Ser Ser Ser Ser Ser Tyr Ala Asn Thr
1 5 10

<210> 79

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 79

Phe Thr Leu Ser Thr Tyr Trp Val Cys
1 5

<210> 80

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 80

Trp Ile Gly Cys Ile Asp Thr Val Ser Ser Gly Asp Thr Tyr Phe
1 5 10 15

<210> 81

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 81

Arg Arg Thr Gly Ser Gly Trp Thr Leu
1 5

<210> 82

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 82

Gln Ser Val Tyr Asn Asn Asn Tyr Leu Ala
1 5 10

<210> 83

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 83

Leu Leu Ile Tyr Trp Ala Ser Lys Leu Ala Ser
1 5 10

<210> 84

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 84

Leu Gly Ala Tyr Val Ser Asn Gly Trp Tyr Phe Ala
1 5 10

<210> 85

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 85

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys
1 5 10

<210> 86

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 86

Trp Ile Ala Cys Ile Tyr Pro Asp Asp Gly Asn Thr Tyr Tyr
1 5 10

<210> 87

<211> 22

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 87

Arg Ala Leu Ala Tyr Tyr Ala Tyr Val Asp Gly Gly His Ser Tyr Ala
1 5 10 15

Ile Asn Asp Phe Asp Leu
20

<210> 88

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 88

Gln Ser Val Phe Ser Asn Asp Tyr Phe Ser
1 5 10

<210> 89

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 89

Leu Leu Ile Tyr Asp Ala Ser Arg Leu Ala Ser
1 5 10

<210> 90

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 90

Gln Gly Thr Tyr Tyr Ser Ser Ala Trp Tyr Asn Ala
1 5 10

<210> 91

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 91

Phe Asp Phe Ser Ser Asn Gly Met Cys
1 5

<210> 92
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 92

Trp Ile Ala Cys Ile Tyr Val Asp Ser Ser Asp Asn Thr Asn Tyr
1 5 10 15

<210> 93
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 93

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu
1 5 10

<210> 94
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 94

Gln Ser Ile Ser Asn Glu Leu Ser
1 5

<210> 95
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 95

Leu Leu Ile Tyr Gly Ala Ser Thr Leu Glu Ser
1 5 10

<210> 96
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 96

Gln Ser Ala Tyr Tyr Ser Ser Ser Ser Tyr Ala Asn Thr
1 5 10

<210> 97
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 97

Ile Asp Phe Ser Ser Asp Tyr Tyr Met Cys
1 5 10

<210> 98
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 98

Trp Ile Ala Cys Ile Tyr Thr Gly Ser Ser Asp Asp Thr Tyr Tyr
1 5 10 15

<210> 99
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 99

Arg Gly Gly Tyr Gly Gly Lys Asp Leu
1 5

<210> 100
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 100

Gln Ser Ile Gly Ser Leu Leu Ala
1 5

<210> 101
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 101

Leu Leu Ile Tyr Trp Ala Ser Thr Leu Ala Ser
1 5 10

<210> 102
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 102

Gln Cys Thr Tyr Gly Ser Ser Gly Ser Ser Ser Tyr Leu Asn Ala
1 5 10 15

<210> 103
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 103

Phe Asp Phe Ser Ser Asn Gly Met Cys
1 5

<210> 104
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 104

Trp Ile Ala Cys Ile Tyr Val Asp Ser Ser Asp Ser Thr Tyr Tyr
1 5 10 15

<210> 105
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 105

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu
1 5 10

<210> 106
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 106

Gln Ser Ile Ser Asn Glu Leu Ala

1 5

<210> 107
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 107

Leu Leu Ile Tyr Gly Ala Ser Thr Leu Glu Ser
1 5 10

<210> 108
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 108

Gln Ser Ala Tyr Tyr Ser Ser Ser Ser Tyr Ala Asn Thr
1 5 10

<210> 109
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 109

Phe Thr Leu Ser Thr Tyr Trp Val Cys
1 5

<210> 110
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 110

Trp Ile Gly Cys Ile Asp Thr Val Ser Ser Gly Asp Thr Tyr Phe
1 5 10 15

<210> 111
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 111

Arg Arg Thr Gly Ser Arg Trp Thr Leu
1 5

<210> 112
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 112

Glu Ser Val Tyr Asn Asn Asn Tyr Leu Ser
1 5 10

<210> 113
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 113

Leu Leu Ile Tyr Gln Ala Ser Thr Leu Ala Ser
1 5 10

<210> 114
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 114

Leu Gly Ala Phe Val Ser Asn Gly Trp Tyr Phe Ala
1 5 10

<210> 115
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 115

Phe Ser Phe Ser Ser Gly Tyr Asn Ile Cys
1 5 10

<210> 116
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 116

Leu Ile Ala Cys Ile Tyr Thr Ser Ser Ser Gly Ser Thr Tyr Tyr
1 5 10 15

<210> 117
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 117

Arg Gly Glu Ala Tyr Tyr Ala Tyr Gly Tyr Val Gly Tyr Ala Tyr Tyr
1 5 10 15

His Gly Ala Phe Asp Pro
20

<210> 118
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 118

His Ser Ile Ser Lys Tyr Phe Ser
1 5

<210> 119
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 119

Leu Leu Ile Tyr Glu Ala Ser Thr Leu Ala Ser
1 5 10

<210> 120
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 120

Gln Ser Tyr Tyr Tyr Gly Thr Ser Ser Ser Tyr Ala
1 5 10

<210> 121
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 121

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys
1 5 10

<210> 122
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 122

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Ser Gly Gly Thr Tyr Tyr
1 5 10 15

<210> 123
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 123

Arg Ala Phe Ser Tyr Tyr Tyr Ser Asp Gly Tyr Thr Gly Tyr Ala Tyr
1 5 10 15

Gly Leu

<210> 124
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 124

Gln Ser Ile Ser Ser Tyr Leu Ala
1 5

<210> 125
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 125

Leu Leu Ile Tyr Arg Ala Ser Thr Leu Ala Ser
1 5 10

<210> 126
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 126

Gln Gly Ala Tyr Tyr Ser Ser Ser Ser Ser Tyr Gly
1 5 10

<210> 127
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 127

Phe Ser Phe Ser Gly Tyr Asp Met
1 5

<210> 128
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 128

Trp Ile Ala Cys Ile His Ser Ser Ser Gly Thr Tyr Tyr
1 5 10

<210> 129
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 129

Arg Asp Phe Ser Tyr Thr Asp Asp Tyr Ile Ser Tyr Val Tyr Ala Thr
1 5 10 15

Asp

<210> 130
<211> 6
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 130

Gln Gly Ser Ser Leu Ala
1 5

<210> 131

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 131

Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Ala
1 5 10

<210> 132

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 132

Gln Ser Thr Tyr Tyr Ser Ser Ser Thr Asp Ile Arg Ala
1 5 10

<210> 133

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 133

Phe Ser Phe Ser Ser Tyr Trp Ile Cys
1 5

<210> 134

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 134

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Ser Gly Thr Tyr Tyr
1 5 10

<210> 135

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 135

Arg Ala Glu Tyr Ile Asp Gly Tyr Ala Asp Tyr Thr Tyr Thr Thr Leu
1 5 10 15

Tyr Phe Asp Leu
20

<210> 136

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 136

Gln Ile Tyr Asn Asn Leu Ala
1 5

<210> 137

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 137

Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu
1 5 10

<210> 138

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 138

Gln Ser Ala Asp Leu Thr Ser Ser Ile Asn Val
1 5 10

<210> 139

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 139

Phe Ser Phe Asn Ser Asn Tyr Trp Met Cys
1 5 10

<210> 140

<211> 14

<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 140

Trp Ile Gly Cys Ile Leu Phe Gly Asn Thr Asp Thr Tyr Tyr
1 5 10

<210> 141
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 141

Arg Ser Val Ser Gly Val Gly Ser Ala Trp Asn Leu
1 5 10

<210> 142
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 142

Glu Ser Val Tyr Asn Asn Asn His Leu Ala
1 5 10

<210> 143
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 143

Leu Leu Ile Tyr Leu Ala Ser Ile Leu Asp Ser
1 5 10

<210> 144
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 144

Ala Gly Tyr Lys Gly Ile Thr Ile Asp Gly Ser Ala
1 5 10

<210> 145

<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 145

Phe Asp Phe Ser Ser Tyr Tyr Trp Ile Cys
1 5 10

<210> 146
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 146

Trp Ile Ala Cys Ile Tyr Gly Gly Ser Ser Gly Ser Thr Tyr Tyr
1 5 10 15

<210> 147
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 147

Arg Ser Leu Tyr Thr Trp Arg Tyr Ala Asp Tyr Ala Ala Ser Thr Leu
1 5 10 15

Asn Leu

<210> 148
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 148

Gln Ser Val Tyr Asn Val Asn Leu Leu Ala
1 5 10

<210> 149
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 149

Leu Leu Ile Tyr Glu Thr Ser Lys Leu Glu Ser
1 5 10

<210> 150
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 150

Ala Gly Gly Tyr Ser Ser Ser Lys Asp Asn Ser
1 5 10

<210> 151
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 151

Phe Ser Phe Ser Ser Ser Tyr Phe Met Cys
1 5 10

<210> 152
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 152

Trp Ile Ala Cys Ile Tyr Thr Gly Asp Gly Asn Asn Tyr Tyr
1 5 10

<210> 153
<211> 22
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 153

Arg Gly Gly Ser Tyr Tyr Ala Tyr Gly Tyr Ala Gly Tyr Asp Tyr Tyr
1 5 10 15

Pro Asp Ala Phe Asp Tyr
20

<210> 154
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 154

Gln Ser Ile Ser Ser Tyr Leu Ser
1 5

<210> 155
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 155

Leu Leu Ile Tyr Arg Ala Ser Thr Leu Ala Ser
1 5 10

<210> 156
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 156

Gln Ser Tyr Tyr Tyr Ser Ser Ser Gly Ser Tyr Gly
1 5 10

<210> 157
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 157

Phe Ser Phe Asn Ser Tyr Tyr Met Cys
1 5

<210> 158
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 158

Trp Ile Ala Cys Ile Ser Gly Gly Ser Ser Asp Asn Thr Tyr Tyr
1 5 10 15

<210> 159
<211> 13
<212> PRT
<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 159

Arg Asp Ile Pro Arg Ser Gly Tyr Phe Gly Cys Asp Leu
1 5 10

<210> 160

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 160

Gln Asn Ile Tyr Ser Asn Leu Ala
1 5

<210> 161

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 161

Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser
1 5 10

<210> 162

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 162

Gln Ser Thr Val Tyr Asn Ser Asn Tyr Ala Asn Thr
1 5 10

<210> 163

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 163

Phe Ser Phe Ser Ser Ser Tyr Trp Ile Tyr
1 5 10

<210> 164

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 164

Trp	Ile	Ala	Cys	Ile	Tyr	Thr	Ala	Ser	Arg	Gly	Ser	Ile	Tyr	Tyr
1				5					10				15	

<210> 165

<211> 19

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 165

Arg	Gly	Pro	Asp	Tyr	Thr	Tyr	Gly	Tyr	Ile	Gly	Asp	Ala	Leu	Thr	Arg
1				5					10				15		

Leu Asp Leu

<210> 166

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 166

Gln	Ser	Val	Tyr	Asp	Asn	Asn	Trp	Leu	Ala
1				5				10	

<210> 167

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 167

Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Thr	Leu	Ser	Ser
1				5				10		

<210> 168

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 168

Ala	Gly	Gly	Tyr	Ser	Ser	Thr	Ser	Asp	Ile	Glu	Asp	Asn	Thr
1				5					10				

<210> 169
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 169

Phe Ser Phe Ser Ser Ser Tyr Trp Ile Cys
1 5 10

<210> 170
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 170

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Ser Gly Asp Thr Tyr Tyr
1 5 10 15

<210> 171
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 171

Arg Ala Glu Tyr Ile Asp Gly Tyr Ala Asp Tyr Thr Tyr Thr Thr Leu
1 5 10 15

Tyr Tyr Phe Asp Leu
20

<210> 172
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 172

Glu Ser Ile Asn Ser Trp Leu Ala
1 5

<210> 173
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 173

Leu Leu Ile Tyr Ser Ala Ser Thr Leu Ala Ser
1 5 10

<210> 174

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 174

Gln Ser Tyr Tyr Ser Phe Ser Arg Phe Ala
1 5 10

<210> 175

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 175

Phe Ser Phe Ser Ser Gly Tyr Trp Ile Cys
1 5 10

<210> 176

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 176

Trp Ile Ala Cys Ile Tyr Thr Gly Val Gly Ala Thr Tyr Tyr
1 5 10

<210> 177

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 177

Arg Asp Phe Gly Gly Ser Ser Gly Phe Tyr Phe Asn Leu
1 5 10

<210> 178

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 178

Gln Ser Ile Ser Asn Ala Leu Ala
1 5

<210> 179

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 179

Leu Leu Ile Tyr Ser Ala Ser Thr Leu Glu Ser
1 5 10

<210> 180

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 180

Gln Asn Tyr Tyr Gly Ser Thr Ser Ser Ser Tyr Gly Val Ala
1 5 10

<210> 181

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 181

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys
1 5 10

<210> 182

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 182

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Thr Phe Ser Thr Tyr Tyr
1 5 10 15

<210> 183

<211> 20

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 183

Arg Ser Asp Ser Tyr Tyr Thr Tyr Gly Tyr Ala Gly Tyr Ala Tyr Ala
1 5 10 15

Ile Phe Asn Leu
20

<210> 184

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 184

Glu Ser Ile Tyr Ser Asn Leu Ala
1 5

<210> 185

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 185

Leu Leu Ile Tyr Leu Ala Ser Thr Leu Ala Ser
1 5 10

<210> 186

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 186

Gln Ser Ala Tyr Tyr Ser Ser Ser Ala Asp Ile Ala
1 5 10

<210> 187

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 187

Leu Asp Phe Ser Ser Ser Tyr Trp Ile Cys
1 5 10

<210> 188
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 188

Trp Ile Gly Cys Ile Lys Thr Ala Thr Glu Thr Thr Val Tyr
1 5 10

<210> 189
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 189

Lys Thr Tyr Ala Asp Asn Gly Gly Tyr Ile Asn Leu
1 5 10

<210> 190
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 190

Gln Asn Ile Tyr Asn Asn Leu Ala
1 5

<210> 191
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 191

Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser
1 5 10

<210> 192
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 192

Gln Ser Ala Asp Leu Thr Ser Ser Ile Asn Val
1 5 10

<210> 193
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR1

<400> 193

Phe Ser Phe Ser Ser Ser Tyr Trp Ile Cys
1 5 10

<210> 194
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR2

<400> 194

Trp Ile Ala Cys Ile Tyr Thr Ala Ser Arg Asp Ser Ile Tyr Tyr
1 5 10 15

<210> 195
<211> 19
<212> PRT
<213> Artificial Sequence

<220>
<223> VH CDR3

<400> 195

Arg Gly Pro Tyr Tyr Ser Tyr Ala Tyr Ile Gly Asp Ala Leu Thr Arg
1 5 10 15

Leu Asp Leu

<210> 196
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 196

Gln Ser Val Tyr Asp Asn Asn Trp Leu Ala
1 5 10

<210> 197
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 197

Leu Leu Ile Tyr Glu Ala Ser Lys Leu Ala Ser
1 5 10

<210> 198

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 198

Ala Gly Gly Tyr Ser Ser Ser Ser Asp Ile Glu Asp Asn Thr
1 5 10

<210> 199

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 199

Phe Ser Phe Asn Ser Asn Tyr Tyr Met Cys
1 5 10

<210> 200

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 200

Trp Ile Ala Cys Ile Tyr Thr Gly Ile Val Val Pro Thr Tyr Tyr
1 5 10 15

<210> 201

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 201

Arg Asp Pro Tyr Val Gly Ser Ser Tyr Ile Tyr Asn Leu
1 5 10

<210> 202

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 202

Gln Ser Val Tyr Asn Asn Asn Asn Leu Ala
1 5 10

<210> 203

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 203

Leu Leu Ile Tyr Ser Ala Ser Ser Leu Ala Ser
1 5 10

<210> 204

<211> 12

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 204

Ala Gly Tyr Lys Thr Tyr Ser Asn Asn Glu Asn Ala
1 5 10

<210> 205

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 205

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys
1 5 10

<210> 206

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 206

Trp Ile Ala Cys Ile Tyr Ala Gly Ser Ser Ser Thr Tyr Tyr
1 5 10 15

<210> 207

<211> 21

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 207

Arg Ala Gly Tyr Ile Asp Ser Tyr Val Asp Tyr Thr Tyr Ala Ala Trp
1 5 10 15

Tyr Tyr Phe Asp Leu
20

<210> 208

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 208

Glu Asn Ile Tyr Ser Asn Leu Ala Trp
1 5

<210> 209

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 209

Leu Leu Ile Tyr Gly Ala Ser Asn Leu Glu Ser
1 5 10

<210> 210

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 210

Gln Ser Ala Asp Leu Ser Ser Ser Ile Asn Val
1 5 10

<210> 211

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 211

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Pro Ser
1 5 10 15

Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Thr Ile Ser Asn Asn Tyr

20

25

30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Cys Ile Ala Thr Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp Ala
 50 55 60

Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
 65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
 85 90 95

Arg Gly Ala Ala Gly Ser Ser Trp Thr Thr Tyr Phe Asp Phe Trp Gly
 100 105 110

Pro Gly Thr Pro Val Thr Val Ser Ser
 115 120

<210> 212
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL

<400> 212

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
 1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Gly Gln Asn Ile Asp Asn Tyr
 20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
 35 40 45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
 50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
 65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Asn Asn Gly Gly Ser Thr
 85 90 95

Phe Thr Gly Phe Pro Phe Gly Gly Gly Thr Glu Val Val Val Lys
 100 105 110

<210> 213
 <211> 119
 <212> PRT
 <213> Artificial Sequence

<220>

<223> VH

<400> 213

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Asp Phe Ser Ser Asn Gly
20 25 30

Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
35 40 45

Cys Ile Tyr Val Asp Ser Ser Asp Asn Thr Asn Tyr Ala Ser Trp Val
50 55 60

Asn Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 214

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 214

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Asn Asn Glu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser

85

90

95

Ser Ser Tyr Ala Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
 100 105 110

<210> 215

<211> 129

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 215

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
 1 5 10 15

Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Thr Ile Ser Ser Ile Trp
 20 25 30

Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
 35 40 45

Cys Ile Tyr Ala Gly Ser Asp Gly Gly Ser Tyr Tyr Ala Ser Trp Ala
 50 55 60

Arg Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
 65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
 85 90 95

Arg Ala Ser Asn Ser Trp Gln Tyr Gly Tyr Ala Gly Tyr Gly Asn Tyr
 100 105 110

Lys Asp Tyr Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser
 115 120 125

Ser

<210> 216

<211> 109

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 216

Phe Glu Leu Thr Gln Thr Pro Ser Ser Val Glu Ala Val Val Gly Gly
 1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Ser Asn Leu Leu
 20 25 30

Ala Trp Tyr Gln Gln Lys Ser Gly Gln Pro Pro Lys Val Leu Ile Tyr
35 40 45

Lys Ala Ser Ala Leu Pro Ser Gly Val Ser Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Gly Ser Ser Asp Thr
85 90 95

Gly Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 217
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 217

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Trp Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Ala Ile Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ser Gly Asp Gly Tyr Thr Tyr Val Glu Leu Trp Gly Pro Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 218
<211> 110
<212> PRT
<213> Artificial Sequence

<220>

<223> VL

<400> 218

Asp Val Val Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Tyr Tyr Asp Ile Asp Asp
85 90 95

Ser Asp Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 219

<211> 128

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 219

Gln Glu Gln Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Trp Ile
20 25 30

Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala Cys
35 40 45

Ile Tyr Ala Gly Ser Ser Ala Lys Thr Tyr Tyr Ala Ser Trp Ala Lys
50 55 60

Gly Arg Phe Thr Ile Ser Lys Ala Ser Ser Thr Thr Val Thr Leu Gln
65 70 75 80

Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg
85 90 95

Ala Ser Asn Tyr Tyr Arg Tyr Gly Val Ala Gly Tyr Ala Asp Tyr Thr
100 105 110

Gly Tyr Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 220
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 220

Phe Glu Leu Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Trp Leu
20 25 30

Ala Trp Tyr His Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
35 40 45

Gly Thr Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Tyr Gly Gly Ser Ser Ser Gly
85 90 95

Asp Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 221
<211> 129
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 221

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Asn Tyr
20 25 30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Ala Thr Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Gly Glu Tyr Thr Tyr Gly Tyr Val Glu Tyr Ala Ile Val Thr
100 105 110

Gln Tyr Tyr Phe Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser
115 120 125

Ser

<210> 222
<211> 109
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 222

Phe Glu Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Asn Ile Tyr Ser Asn Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
35 40 45

Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Asp Tyr Ile Gly Ser Ala
85 90 95

Tyr Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 223
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 223

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Thr Thr Tyr Gly Gly Thr Trp Tyr Ala Ser Trp Ala
50 55 60

Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Asp Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Ser Ser Ile Ser Asp Val Thr Tyr Phe Asn Leu Trp Gly Pro Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 224
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 224

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asn Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Glu Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Gly Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Asp Asn Asn Asn
85 90 95

Tyr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 225
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 225

Gln Glu Gln Leu Lys Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Thr Leu Ser Thr Tyr
20 25 30

Trp Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Cys Ile Asp Thr Val Ser Ser Gly Asp Thr Tyr Phe Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Gly Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Arg Thr Gly Ser Gly Trp Thr Leu Trp Gly Pro Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 226
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 226

Leu Val Met Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asn Asn Asn
20 25 30

Tyr Leu Ala Trp Phe Gln Gln Asn Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Trp Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Gln
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Ala Tyr Val Ser Asn
85 90 95

Gly Trp Tyr Phe Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 227
<211> 115
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 227

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Tyr Trp
20 25 30

Thr Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu Gly
35 40 45

Cys Thr Asp Gly Gly Ser Ser Gly Asp Thr Tyr Tyr Ala Thr Trp Ala
50 55 60

Lys Gly Arg Val Ala Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Val Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Asn Leu Ile Thr Trp Asp Leu Trp Gly Pro Gly Thr Leu Val Thr
100 105 110

Val Ser Ser
115

<210> 228
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 228

Ile Val Met Thr Gln Thr Pro Ser Ser Lys Ser Val Pro Val Gly Asp
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Val Tyr Asn Asn Asn

20

25

30

Gln Leu Ser Trp Phe Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
 35 40 45

Ile Tyr Trp Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
 50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Val
 65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Ser Ser Ile
 85 90 95

Thr Asp Gly Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
 100 105 110

<210> 229

<211> 128

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 229

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Gln Pro Glu Gly Ser
 1 5 10 15

Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Asp Phe Ser Thr Asn Ile
 20 25 30

Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
 35 40 45

Cys Ile Tyr Ala Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp Val Asn
 50 55 60

Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln
 65 70 75 80

Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg
 85 90 95

Ala Ser Thr Tyr Trp Asn Tyr Gly Tyr Ala Gly Tyr Gly Tyr Tyr Pro
 100 105 110

Gly Tyr Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
 115 120 125

<210> 230

<211> 112

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 230

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ile Ser Ala
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Thr Tyr Ala Tyr Ser Thr Lys
85 90 95

Ser Asn Tyr Gly Ser Val Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 231

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 231

Gln Gln Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Lys Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Arg Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Glu Asp Val Ser Ser Gly Asp Tyr Thr Phe Asn Leu Trp Gly

100

105

110

Pro Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 232
<211> 109
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 232

Tyr Asp Met Thr Gln Thr Pro Ala Ser Val Glu Val Thr Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Glu Asp Ile Tyr Ser Gly Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
35 40 45

Lys Ala Ser Asn Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Gly Val Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Gln Gly Val Thr Tyr Ser Asn Val
85 90 95

Asp Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 233
<211> 129
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 233

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Thr Tyr
20 25 30

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Thr Gly Ser Thr Gly Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Gly Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Gly Asp Tyr Thr Tyr Ala Tyr Ala Gly Gly Ala His Val Thr
100 105 110

Asn Tyr Tyr Phe Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser
115 120 125

Ser

<210> 234
<211> 110
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 234

Leu Val Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Asn Ile Tyr Ser Asn Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Phe
35 40 45

Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Thr Ala Asp Tyr Ser Ser Ser Thr
85 90 95

Asp Trp Gly Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 235
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 235

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Asp Phe Ser Ser Asn Gly
20 25 30

Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
35 40 45

Cys Ile Tyr Val Asp Ser Ser Asp Ser Thr Tyr Tyr Ala Ser Trp Val
50 55 60

Asn Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 236
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 236

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asn Glu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser
85 90 95

Ser Ser Tyr Ala Asn Thr Phe Gly Gly Gly Thr Glu Val Val Ala Ala
100 105 110

<210> 237
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 237

Gln Glu Gln Leu Lys Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Thr Leu Ser Thr Tyr
20 25 30

Trp Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Cys Ile Asp Thr Val Ser Ser Gly Asp Thr Tyr Phe Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Gly Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Arg Thr Gly Ser Gly Trp Thr Leu Trp Gly Pro Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 238
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 238

Leu Val Met Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asn Asn Asn
20 25 30

Tyr Leu Ala Trp Phe Gln Gln Asn Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Trp Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Gln
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Ala Tyr Val Ser Asn
85 90 95

Gly Trp Tyr Phe Ala Phe Gly Gly Gly Ile Glu Val Val Val Lys
100 105 110

<210> 239
<211> 130
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 239

Gln Glu His Leu Glu Glu Ser Gly Gly Gly Leu Val Lys Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Pro Asp Asp Gly Asn Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ala Leu Ala Tyr Tyr Ala Tyr Val Asp Gly Gly His Ser Tyr
100 105 110

Ala Ile Asn Asp Phe Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val
115 120 125

Ser Ser
130

<210> 240
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 240

Gln Val Leu Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ser Ser Gln Ser Val Phe Ser Asn Asp
20 25 30

Tyr Phe Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Asp Ala Ser Arg Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Thr Tyr Tyr Ser Ser
85 90 95

Ala Trp Tyr Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 241
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 241

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Asp Phe Ser Ser Asn Gly
20 25 30

Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
35 40 45

Cys Ile Tyr Val Asp Ser Ser Asp Asn Thr Asn Tyr Ala Ser Trp Val
50 55 60

Asn Gly Arg Phe Thr Ile Ser Arg Thr Ser Ser Thr Thr Val Asp Leu
65 70 75 80

Lys Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 242
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 242

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asn Glu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser
85 90 95

Ser Ser Tyr Ala Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 243
<211> 118
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 243

Gln Glu Gln Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Gly
1 5 10 15

Thr Leu Thr Leu Thr Cys Lys Ala Ser Gly Ile Asp Phe Ser Ser Asp
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Gly Ser Ser Asp Asp Thr Tyr Tyr Ala Ser
50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Pro Thr Val
65 70 75 80

Ala Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe
85 90 95

Cys Ala Arg Gly Gly Tyr Gly Gly Lys Asp Leu Trp Gly Pro Gly Thr
100 105 110

Leu Val Thr Val Ser Ser
115

<210> 244
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 244

Val Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Gly Ser Leu Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Asn Leu Leu Ile Tyr
35 40 45

Trp Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Cys Thr Tyr Gly Ser Ser Gly Ser
85 90 95

Ser Ser Tyr Leu Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 245
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 245

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Asp Phe Ser Ser Asn Gly
20 25 30

Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala

35

40

45

Cys Ile Tyr Val Asp Ser Ser Asp Ser Thr Tyr Tyr Ala Ser Trp Val
50 55 60

Asn Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu Trp Gly Gln Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 246
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 246

Asn Ile Val Met Thr Gln Thr Pro Ser Pro Val Ser Gly Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asn Glu
20 25 30

Leu Ala Trp Phe Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser
85 90 95

Ser Ser Tyr Ala Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 247
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 247

Gln Glu Gln Leu Lys Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Thr Leu Ser Thr Tyr
20 25 30

Trp Val Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Cys Ile Asp Thr Val Ser Ser Gly Asp Thr Tyr Phe Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Gly Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Arg Thr Gly Ser Arg Trp Thr Leu Trp Gly Pro Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 248

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 248

Gln Val Leu Thr Gln Thr Pro Ser Ser Val Ser Ala Gly Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Val Tyr Asn Asn Asn
20 25 30

Tyr Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Gln Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Gln
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gly Ala Phe Val Ser Asn
85 90 95

Gly Trp Tyr Phe Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys

100

105

110

<210> 249
 <211> 130
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VH

<400> 249

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
 1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr
 20 25 30

Asn Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu Ile
 35 40 45

Ala Cys Ile Tyr Thr Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser Trp
 50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
 65 70 75 80

Leu Gln Met Thr Ser Leu Thr Val Ala Asp Thr Ala Thr Tyr Phe Cys
 85 90 95

Ala Arg Gly Glu Ala Tyr Tyr Ala Tyr Gly Tyr Val Gly Tyr Ala Tyr
 100 105 110

Tyr His Gly Ala Phe Asp Pro Trp Gly Pro Gly Thr Leu Val Thr Val
 115 120 125

Ser Ser
 130

<210> 250
 <211> 110
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL

<400> 250

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Gly Val Gly
 1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser His Ser Ile Ser Lys Tyr
 20 25 30

Phe Ser Trp Tyr Gln Gln Lys Ile Gly Gln Pro Pro Lys Leu Leu Ile
 35 40 45

Tyr Glu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Tyr Gly Thr Ser
85 90 95

Ser Ser Tyr Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 251
<211> 126
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 251

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Ala Gly Ser Ser Gly Gly Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ala Phe Ser Tyr Tyr Tyr Ser Asp Gly Tyr Thr Gly Tyr Ala
100 105 110

Tyr Gly Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 252
<211> 110
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 252

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Gly Ala Tyr Tyr Ser Ser Ser
85 90 95

Ser Ser Tyr Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 253
<211> 122
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 253

Gln Glu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Gly Tyr
20 25 30

Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile His Ser Ser Ser Gly Thr Tyr Tyr Ala Asn Trp Ala Lys
50 55 60

Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln
65 70 75 80

Met Thr Ser Leu Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Asp
85 90 95

Phe Ser Tyr Thr Asp Asp Tyr Ile Ser Tyr Val Tyr Ala Thr Asp Trp
100 105 110

Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 254
<211> 107
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 254

Ala Ile Glu Met Thr Gln Thr Pro Ala Ser Val Ser Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Gly Ser Ser Leu Ala
20 25 30

Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr Ala
35 40 45

Ala Ser Tyr Leu Ala Ser Val Pro Ser Arg Phe Lys Gly Ser Gly Ser
50 55 60

Gly Thr Glu Tyr Thr Leu Thr Ile Ser Gly Val Gln Cys Ala Asp Ala
65 70 75 80

Ala Tyr Tyr Cys Gln Ser Thr Tyr Tyr Ser Ser Ser Thr Asp Ile Arg
85 90 95

Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 255
<211> 125
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 255

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Tyr Trp
20 25 30

Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
35 40 45

Cys Ile Tyr Ala Gly Ser Ser Gly Thr Tyr Tyr Ala Ser Trp Ala Lys
50 55 60

Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu Gln
65 70 75 80

Thr Thr Ser Leu Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala Arg Ala
85 90 95

Glu Tyr Ile Asp Gly Tyr Ala Asp Tyr Thr Tyr Thr Thr Leu Tyr Phe
100 105 110

Asp Leu Trp Gly Pro Gly Thr Pro Val Thr Val Ser Ser
115 120 125

<210> 256
<211> 106
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 256

Ala Leu Val Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Ile Tyr Asn Asn Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
35 40 45

Gly Ala Ser Asn Leu Glu Gly Val Pro Ser Arg Phe Lys Gly Ser Gly
50 55 60

Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp Asp
65 70 75 80

Ala Ala Tyr Tyr Cys Gln Ser Ala Asp Leu Thr Ser Ser Ile Asn Val
85 90 95

Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 257
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 257

Gln Gln Gln Leu Glu Glu Ser Gly Gly Asp Leu Val Gln Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Asn Ser Asn
20 25 30

Tyr Trp Met Cys Trp Gly Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Gly Cys Ile Leu Phe Gly Asn Thr Asp Thr Tyr Tyr Ala Asn Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ser Val Ser Gly Val Gly Ser Ala Trp Asn Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 258
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 258

Ile Val Met Thr Gln Thr Pro Ser Ser Lys Ser Val Pro Val Gly Asp
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Val Tyr Asn Asn Asn
20 25 30

His Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu
35 40 45

Ile Tyr Leu Ala Ser Ile Leu Asp Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Val
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Gly Ile Thr
85 90 95

Ile Asp Gly Ser Ala Phe Gly Gly Gly Thr Glu Leu Val Val Lys
100 105 110

<210> 259
<211> 126
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 259

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Asp Phe Ser Ser Tyr Tyr
20 25 30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Gly Gly Ser Ser Gly Ser Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Glu Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Met Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ser Leu Tyr Thr Trp Arg Tyr Ala Asp Tyr Ala Ala Ser Thr
100 105 110

Leu Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 260

<211> 110

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 260

Ala Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Ser Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asn Val Asn
20 25 30

Leu Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Glu Thr Ser Lys Leu Glu Ser Gly Val Pro Ser Arg Phe Ser
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Gln
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Ser Ser
85 90 95

Lys Asp Asn Ser Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 261
<211> 130
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 261

Gln Glu Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Phe Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Gly Asp Gly Asn Asn Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ser Arg Gly Gly Ser Tyr Tyr Ala Tyr Gly Tyr Ala Gly Tyr Asp Tyr
100 105 110

Tyr Pro Asp Ala Phe Asp Tyr Trp Gly Pro Gly Thr Leu Val Thr Val
115 120 125

Ser Ser
130

<210> 262
<211> 110
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 262

Asp Ile Val Met Thr Gln Thr Pro Ala Ser Val Glu Val Ala Val Gly
1 5 10 15

Gly Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile

35

40

45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Tyr Ser Ser Ser
85 90 95

Gly Ser Tyr Gly Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 263

<211> 120

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 263

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Asn Ser Tyr Tyr
20 25 30

Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile Ala
35 40 45

Cys Ile Ser Gly Gly Ser Ser Asp Asn Thr Tyr Tyr Ala Ser Trp Ala
50 55 60

Lys Gly Arg Phe Thr Thr Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Asp Ile Pro Arg Ser Gly Tyr Phe Gly Cys Asp Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 264

<211> 109

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 264

Val Val Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly Gly
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Asn Ile Tyr Ser Asn Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
35 40 45

Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asn Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Thr Val Tyr Asn Ser Asn Tyr
85 90 95

Ala Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 265

<211> 127

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 265

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30

Trp Ile Tyr Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Thr Ala Ser Arg Gly Ser Ile Tyr Tyr Ala Ser Trp
50 55 60

Thr Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Gly Pro Asp Tyr Thr Tyr Gly Tyr Ile Gly Asp Ala Leu Thr
100 105 110

Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser

115

120

125

<210> 266
 <211> 113
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL

<400> 266

Ala Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
 1 5 10 15

Thr Val Ser Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn
 20 25 30

Trp Leu Ala Trp Tyr Gln Gln Lys Ala Gly Gln Pro Pro Lys Leu Leu
 35 40 45

Ile Tyr Ala Ala Ser Thr Leu Ser Ser Gly Val Pro Ser Arg Phe Lys
 50 55 60

Gly Ser Gly Ser Gly Ile Glu Phe Thr Leu Thr Ile Ser Asp Val Gln
 65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Ser Thr
 85 90 95

Ser Asp Ile Glu Asp Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val
 100 105 110

Lys

<210> 267
 <211> 129
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VH

<400> 267

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
 1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Tyr
 20 25 30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Ala Cys Ile Tyr Ala Gly Ser Ser Gly Asp Thr Tyr Tyr Ala Ser Trp
 50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Thr Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ala Glu Tyr Ile Asp Gly Tyr Ala Asp Tyr Thr Tyr Thr Thr
100 105 110

Leu Tyr Tyr Phe Asp Leu Trp Gly Pro Gly Thr Pro Val Thr Val Ser
115 120 125

Ser

<210> 268
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 268

Asp Val Val Met Thr Gln Thr Pro Ala Ser Val Ser Glu Pro Val Gly
1 5 10 15

Gly Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Asn Ser Trp
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
35 40 45

Tyr Ser Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly
50 55 60

Ser Gly Ser Gly Ile Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys
65 70 75 80

Ala Asp Ala Ala Thr Tyr Phe Cys Gln Ser Tyr Tyr Ser Phe Ser Arg
85 90 95

Phe Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 269
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 269

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Gly Tyr
20 25 30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Thr Gly Val Gly Ala Thr Tyr Tyr Ala Ser Trp Ala
50 55 60

Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys Ala
85 90 95

Arg Asp Phe Gly Gly Ser Ser Gly Phe Tyr Phe Asn Leu Trp Gly Pro
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 270
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 270

Phe Glu Leu Thr Gln Thr Pro Ser Ser Val Glu Ala Ala Val Gly Ala
1 5 10 15

Thr Val Thr Ile Lys Cys Gln Ala Ser Gln Ser Ile Ser Asn Ala Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
35 40 45

Ser Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Asn Tyr Tyr Gly Ser Thr Ser Ser
85 90 95

Ser Tyr Gly Val Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 271
<211> 128
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 271

Gln Ser Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Glu Gly Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Ala Gly Ser Thr Phe Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Ser Asp Ser Tyr Tyr Thr Tyr Gly Tyr Ala Gly Tyr Ala Tyr
100 105 110

Ala Ile Phe Asn Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 272
<211> 109
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 272

Leu Val Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Tyr Ser Asn Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile Tyr
35 40 45

Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Phe Thr Leu Thr Ile Ser Asp Leu Glu Cys Ala
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser Ala
85 90 95

Asp Ile Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 273
<211> 119
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 273

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Leu Asp Phe Ser Ser Ser Tyr
20 25 30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Gly Cys Ile Lys Thr Ala Thr Glu Thr Thr Val Tyr Ala Ser Trp Ala
50 55 60

Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr Leu
65 70 75 80

Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Leu Cys Ala
85 90 95

Lys Thr Tyr Ala Asp Asn Gly Gly Tyr Ile Asn Leu Trp Gly Pro Gly
100 105 110

Thr Leu Val Thr Val Ser Ser
115

<210> 274
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 274

Leu Val Met Thr Gln Thr Pro Ser Ser Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Gln Asn Ile Tyr Asn Asn Leu
20 25 30

Ala Trp Tyr Gln Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
35 40 45

Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
50 55 60

Gly Ser Gly Thr Glu Tyr Thr Leu Thr Ile Ser Asp Leu Glu Cys Asp
65 70 75 80

Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Asp Leu Thr Ser Ser Ile
85 90 95

Asn Val Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105

<210> 275
<211> 127
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 275

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Thr Ala Ser Arg Asp Ser Ile Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Gly Pro Tyr Tyr Ser Tyr Ala Tyr Ile Gly Asp Ala Leu Thr
100 105 110

Arg Leu Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 276
<211> 113
<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 276

Ala Val Leu Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Gly
1 5 10 15

Thr Val Ser Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asp Asn Asn
20 25 30

Trp Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Glu Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Gln
65 70 75 80

Cys Asp Asp Ala Ser Thr Tyr Tyr Cys Ala Gly Gly Tyr Ser Ser Ser
85 90 95

Ser Asp Ile Glu Asp Asn Thr Phe Gly Gly Gly Thr Glu Val Val Val
100 105 110

Lys

<210> 277

<211> 122

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 277

Gln Glu Gln Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Asn Ser Asn
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Gly Ile Val Val Pro Thr Tyr Tyr Ala Ser
50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val
65 70 75 80

Thr Leu Gln Met Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe
85 90 95

Cys Ala Arg Asp Pro Tyr Val Gly Ser Ser Tyr Ile Tyr Asn Leu Trp
100 105 110

Gly Pro Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 278
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 278

Leu Val Met Thr Gln Thr Pro Ser Pro Val Ser Ala Ala Val Gly Ser
1 5 10 15

Thr Val Thr Ile Ser Cys Gln Ser Ser Gln Ser Val Tyr Asn Asn Asn
20 25 30

Asn Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Ser Ala Ser Ser Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Gly Val Glu
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Thr Tyr Ser
85 90 95

Asn Asn Glu Asn Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 279
<211> 129
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 279

Gln Ser Leu Glu Glu Ser Gly Gly Asp Leu Val Lys Pro Gly Ala Ser
1 5 10 15

Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser Tyr
20 25 30

Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile

35

40

45

Ala Cys Ile Tyr Ala Gly Ser Ser Ser Ser Thr Tyr Tyr Ala Ser Trp
 50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Lys Thr Ser Ser Thr Thr Val Thr
 65 70 75 80

Leu Gln Thr Thr Ser Leu Thr Ala Ala Asp Thr Ala Thr Tyr Phe Cys
 85 90 95

Ala Arg Ala Gly Tyr Ile Asp Ser Tyr Val Asp Tyr Thr Tyr Ala Ala
 100 105 110

Trp Tyr Tyr Phe Asp Leu Trp Gly Pro Gly Thr Leu Val Thr Val Ser
 115 120 125

Ser

<210> 280
 <211> 111
 <212> PRT
 <213> Artificial Sequence

<220>
 <223> VL

<400> 280

Gln Val Leu Thr Gln Thr Pro Ser Ser Val Ser Glu Pro Val Gly Gly
 1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Asn Ile Tyr Ser Asn Leu
 20 25 30

Ala Trp Tyr His Gln Lys Pro Gly Gln Arg Pro Lys Leu Leu Ile Tyr
 35 40 45

Gly Ala Ser Asn Leu Glu Ser Gly Val Pro Ser Arg Phe Lys Gly Ser
 50 55 60

Gly Ser Gly Thr Glu Tyr Thr Leu Tyr His Gln Thr Ile Ser Asp Leu
 65 70 75 80

Glu Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Gln Ser Ala Asp Leu Ser
 85 90 95

Ser Ser Ile Asn Val Phe Gly Gly Gly Thr Glu Val Val Val Lys
 100 105 110

<210> 281
 <211> 123
 <212> PRT
 <213> Artificial Sequence

<220>

<223> VH

<400> 281

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Asn Asn
20 25 30

Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Gly Cys Ile Ala Thr Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gly Ala Ala Gly Ser Ser Trp Thr Thr Tyr Phe Asp Phe
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 282

<211> 111

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 282

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Gly Gln Asn Ile Asp Asn Tyr
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Asn Asn Gly Gly Ser Thr

85

90

95

Phe Thr Gly Phe Pro Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
 100 105 110

<210> 283

<211> 121

<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 283

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
 1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Ser
 20 25 30

Tyr Trp Ile Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
 35 40 45

Ile Ala Cys Ile Ala Ile Gly Ser Ser Gly Thr Thr Tyr Tyr Ala Ser
 50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
 65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
 85 90 95

Tyr Cys Ala Arg Ser Gly Asp Gly Tyr Thr Tyr Val Glu Leu Trp Gly
 100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
 115 120

<210> 284

<211> 110

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 284

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
 1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Ser Tyr
 20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
 35 40 45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Tyr Tyr Asp Ile Asp Asp
85 90 95

Ser Asp Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 285
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 285

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Thr Thr Tyr Gly Gly Thr Trp Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Ser Ser Ile Ser Asp Val Thr Tyr Phe Asn Leu Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 286
<211> 108
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 286

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Asn Tyr
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Asp Asn Asn Asn
85 90 95

Tyr Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105

<210> 287
<211> 117
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 287

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Tyr
20 25 30

Trp Thr Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Leu
35 40 45

Gly Cys Thr Asp Gly Gly Ser Ser Gly Asp Thr Tyr Tyr Ala Thr Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Asn Leu Ile Thr Trp Asp Leu Trp Gly Gln Gly Thr Leu
100 105 110

Val Thr Val Ser Ser
115

<210> 288
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 288

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Ser Val Tyr Asn Asn
20 25 30

Asn Gln Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu
35 40 45

Leu Ile Tyr Trp Ala Ser Lys Leu Ala Ser Gly Val Pro Ser Arg Phe
50 55 60

Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu
65 70 75 80

Gln Pro Glu Asp Val Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Ser Ser
85 90 95

Ile Thr Asp Gly Asn Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 289
<211> 121
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 289

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Asp Phe Ser Ser Asn
20 25 30

Gly Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

Ala Cys Ile Tyr Val Asp Ser Ser Asp Asn Thr Asn Tyr Ala Ser Trp
50 55 60

Val Asn Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gly Tyr Gly Tyr Val Gly Ser Ala Met Asp Leu Trp Gly
100 105 110

Gln Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 290
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 290

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Ser Asn Glu
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Gly Ala Ser Thr Leu Glu Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser
85 90 95

Ser Ser Tyr Ala Asn Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 291
<211> 132
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 291

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asn Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser
50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Ala Arg Gly Glu Ala Tyr Tyr Ala Tyr Gly Tyr Val Gly Tyr
100 105 110

Ala Tyr Tyr His Gly Ala Phe Asp Pro Trp Gly Gln Gly Thr Leu Val
115 120 125

Thr Val Ser Ser
130

<210> 292
<211> 110
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 292

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser His Ser Ile Ser Lys Tyr
20 25 30

Phe Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Glu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Tyr Gly Thr Ser
85 90 95

Ser Ser Tyr Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 293
<211> 130
<212> PRT

<213> Artificial Sequence

<220>

<223> VH

<400> 293

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile Tyr Ala Gly Ser Thr Phe Ser Thr Tyr Tyr Ala Ser
50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Ala Arg Ser Asp Ser Tyr Tyr Thr Tyr Gly Tyr Ala Gly Tyr
100 105 110

Ala Tyr Ala Ile Phe Asn Leu Trp Gly Gln Gly Thr Leu Val Thr Val
115 120 125

Ser Ser
130

<210> 294

<211> 110

<212> PRT

<213> Artificial Sequence

<220>

<223> VL

<400> 294

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Glu Ser Ile Tyr Ser Asn
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Leu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Ala Tyr Tyr Ser Ser Ser
85 90 95

Ala Asp Ile Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 295
<211> 26
<212> PRT
<213> Artificial Sequence

<220>
<223> VHFR1

<400> 295

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly
20 25

<210> 296
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VHFR2

<400> 296

Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
1 5 10

<210> 297
<211> 37
<212> PRT
<213> Artificial Sequence

<220>
<223> VHFR3

<400> 297

Ala Ser Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys
1 5 10 15

Asn Thr Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala
20 25 30

Val Tyr Tyr Cys Ala
35

<210> 298
<211> 11
<212> PRT

<213> Artificial Sequence

<220>

<223> VHFR4

<400> 298

Trp	Gly	Gln	Gly	Thr	Leu	Val	Thr	Val	Ser	Ser
1				5					10	

<210> 299

<211> 26

<212> PRT

<213> Artificial Sequence

<220>

<223> VLFR1

<400> 299

Asp	Ile	Gln	Met	Thr	Gln	Ser	Pro	Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly
1				5					10					15	

Asp	Arg	Val	Thr	Ile	Thr	Cys	Gln	Ala	Gly
			20					25	

<210> 300

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VLFR2

<400> 300

Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Lys	Val	Pro	Lys
1				5					10	

<210> 301

<211> 32

<212> PRT

<213> Artificial Sequence

<220>

<223> VLFR3

<400> 301

Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
1				5					10					15	

Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Val	Ala	Thr	Tyr	Tyr	Cys
			20					25					30		

<210> 302

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VLFR4

<400> 302

Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
1 5 10

<210> 303

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 303

Phe Ser Phe Ser Ser Ser Tyr Tyr Met Cys
1 5 10

<210> 304

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 304

Trp Ile Gly Cys Ile Tyr Thr Gly Asn Asp Asp Thr Trp Tyr
1 5 10

<210> 305

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 305

Arg Gly Leu Ser Pro Ile Asp Leu
1 5

<210> 306

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR1

<400> 306

Glu Ser Ile Tyr Asn Asn Asn Asn Leu Gly
1 5 10

<210> 307

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR2

<400> 307

Leu Leu Ile Tyr Trp Ala Ser Thr Leu Ala Ser
1 5 10

<210> 308

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> VL CDR3

<400> 308

Ala Gly Tyr Lys Ser Arg Thr Thr Asp Gly Ser Ala Phe
1 5 10

<210> 309

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR1

<400> 309

Phe Ser Phe Ser Ser Gly Tyr Asp Met Cys
1 5 10

<210> 310

<211> 14

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR2

<400> 310

Trp Ile Ala Cys Ile His Ser Ser Ser Gly Thr Thr Tyr Tyr
1 5 10

<210> 311

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> VH CDR3

<400> 311

Arg Asp Phe Ser Tyr Thr Asp Asp Tyr Ile Ser Tyr Val Tyr Ala Thr
1 5 10 15

Asp Leu

<210> 312

<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR1

<400> 312

Gln Ser Ile Gly Ser Ser Leu Ala
1 5

<210> 313
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR2

<400> 313

Leu Leu Ile Tyr Ala Ala Ser Tyr Leu Ala Ser
1 5 10

<210> 314
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> VL CDR3

<400> 314

Gln Ser Thr Tyr Tyr Ser Ser Ser Thr Asp Ile Arg Ala
1 5 10

<210> 315
<211> 116
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 315

Gln Glu Arg Leu Glu Glu Ser Gly Gly Gly Leu Val Gln Pro Glu Gly
1 5 10 15

Ser Leu Thr Leu Thr Cys Thr Ala Ser Gly Phe Ser Phe Ser Ser Ser
20 25 30

Tyr Tyr Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Met Glu Trp
35 40 45

Ile Gly Cys Ile Tyr Thr Gly Asn Asp Asp Thr Trp Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Val Ser Lys Thr Ser Ser Thr Thr Val Thr
65 70 75 80

Leu Gln Met Thr Ser Leu Thr Ala Thr Asp Thr Ala Thr Tyr Phe Cys
85 90 95

Ala Arg Gly Leu Ser Pro Ile Asp Leu Trp Gly Pro Gly Thr Leu Val
100 105 110

Thr Val Ser Ser
115

<210> 316
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 316

Ile Val Met Thr Gln Thr Pro Ser Ser Lys Ser Val Pro Val Gly Asp
1 5 10 15

Thr Val Thr Ile Asn Cys Gln Ala Ser Glu Ser Ile Tyr Asn Asn Asn
20 25 30

Asn Leu Gly Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu
35 40 45

Ile Tyr Trp Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Lys
50 55 60

Gly Ser Gly Ser Gly Thr Gln Phe Thr Leu Thr Ile Ser Asp Val Glu
65 70 75 80

Cys Asp Asp Ala Ala Thr Tyr Tyr Cys Ala Gly Tyr Lys Ser Arg Thr
85 90 95

Thr Asp Gly Ser Ala Phe Gly Gly Gly Thr Glu Val Val Val Lys
100 105 110

<210> 317
<211> 127
<212> PRT
<213> Artificial Sequence

<220>
<223> VH

<400> 317

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile His Ser Ser Ser Gly Thr Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Asp Phe Ser Tyr Thr Asp Asp Tyr Ile Ser Tyr Val Tyr
100 105 110

Ala Thr Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser
115 120 125

<210> 318
<211> 111
<212> PRT
<213> Artificial Sequence

<220>
<223> VL

<400> 318

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Gly Ser Ser
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Tyr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Thr Tyr Tyr Ser Ser Ser
85 90 95

Thr Asp Ile Arg Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys
100 105 110

<210> 319
<211> 97
<212> PRT
<213> Artificial Sequence

<220>
<223> CH1 domain

<400> 319

Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys
1 5 10 15

Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr
20 25 30

Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser
35 40 45

Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser
50 55 60

Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr
65 70 75 80

Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys
85 90 95

Lys

<210> 320

<211> 107

<212> PRT

<213> Artificial Sequence

<220>

<223> CL domain

<400> 320

Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu
1 5 10 15

Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe
20 25 30

Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln
35 40 45

Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser
50 55 60

Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu
65 70 75 80

Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser
85 90 95

Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys
100 105

<210> 321
<211> 227
<212> PRT
<213> Artificial Sequence

<220>
<223> WT CH2CH3

<400> 321

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15

Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220

Pro Gly Lys
225

<210> 322
<211> 227
<212> PRT
<213> Artificial Sequence

<220>
<223> FC1 CH2CH3

<400> 322

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15

Gly Pro Asp Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
65 70 75 80

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Leu Pro Glu
100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220

Pro Gly Lys
225

<210> 323
<211> 227
<212> PRT
<213> Artificial Sequence

<220>
<223> FC2 CH2CH3

<400> 323

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
1 5 10 15

Gly Pro Ser Val Phe Leu Leu Pro Pro Lys Pro Lys Asp Thr Leu Met
20 25 30

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
35 40 45

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
50 55 60

His Asn Ala Lys Thr Lys Pro Pro Glu Glu Gln Tyr Asn Ser Thr Leu
65 70 75 80

Arg Val Val Ser Ile Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
85 90 95

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
100 105 110

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
115 120 125

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
130 135 140

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
145 150 155 160

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Leu
165 170 175

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
180 185 190

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
195 200 205

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
210 215 220

Pro Gly Lys

225

<210> 324
<211> 120
<212> PRT
<213> Artificial Sequence

<220>
<223> VH of comparator antibody

<400> 324

Gln Val Gln Leu Gln Gln Ser Gly Gly Gly Leu Val Lys Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr
20 25 30

Asp Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val
50 55 60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65 70 75 80

Leu Gln Met Asp Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Phe Cys
85 90 95

Ala Lys Glu Gly Asp Ser Ser Arg Trp Ser Tyr Asp Leu Trp Gly Arg
100 105 110

Gly Thr Leu Val Thr Val Ser Ser
115 120

<210> 325
<211> 112
<212> PRT
<213> Artificial Sequence

<220>
<223> VL of comparator antibody

<400> 325

Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln
1 5 10 15

Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp Val Gly Gly Tyr
20 25 30

Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Val
35 40 45

Met Ile Tyr Asp Val Thr Asn Arg Pro Ser Gly Val Ser Asn Arg Phe
50 55 60

Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu
65 70 75 80

Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser Tyr Thr Ser Thr
85 90 95

Ser Thr Leu Val Val Phe Gly Gly Gly Thr Lys Leu Thr Val Leu Gly
100 105 110

<210> 326

<211> 456

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized C36 heavy chain with FC-1 mutations

<400> 326

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asn Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser
50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Ala Arg Gly Glu Ala Tyr Tyr Ala Tyr Gly Tyr Val Gly Tyr
100 105 110

Ala Tyr Tyr His Gly Ala Phe Asp Pro Trp Gly Gln Gly Thr Leu Val
115 120 125

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
130 135 140

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
145 150 155 160

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
165 170 175

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser

180

185

190

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
 195 200 205

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
 210 215 220

Lys Val Asp Lys Lys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala
 225 230 235 240

Pro Glu Leu Leu Gly Gly Pro Asp Val Phe Leu Phe Pro Pro Lys Pro
 245 250 255

Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val
 260 265 270

Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val
 275 280 285

Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln
 290 295 300

Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln
 305 310 315 320

Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala
 325 330 335

Leu Pro Leu Pro Glu Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro
 340 345 350

Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr
 355 360 365

Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser
 370 375 380

Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr
 385 390 395 400

Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr
 405 410 415

Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe
 420 425 430

Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys
 435 440 445

Ser Leu Ser Leu Ser Pro Gly Lys
 450 455

<210> 327
<211> 456
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized C36 heavy chain with FC-2 mutations

<400> 327

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asn Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Leu
35 40 45

Ile Ala Cys Ile Tyr Thr Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Ser
50 55 60

Trp Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65 70 75 80

Leu Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr
85 90 95

Tyr Cys Ala Arg Gly Glu Ala Tyr Tyr Ala Tyr Gly Tyr Val Gly Tyr
100 105 110

Ala Tyr Tyr His Gly Ala Phe Asp Pro Trp Gly Gln Gly Thr Leu Val
115 120 125

Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala
130 135 140

Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu
145 150 155 160

Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly
165 170 175

Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser
180 185 190

Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu
195 200 205

Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr
210 215 220

Lys Val Asp Lys Lys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala

225	230	235	240
Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Leu Pro Pro Lys Pro	245	250	255
Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val	260	265	270
Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val	275	280	285
Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Pro Glu Glu Gln	290	295	300
Tyr Asn Ser Thr Leu Arg Val Val Ser Ile Leu Thr Val Leu His Gln	305	310	315
Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala	325	330	335
Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro	340	345	350
Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr	355	360	365
Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser	370	375	380
Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr	385	390	395
Lys Thr Thr Pro Leu Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr	405	410	415
Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe	420	425	430
Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys	435	440	445
Ser Leu Ser Leu Ser Pro Gly Lys	450	455	

<210> 328

<211> 217

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized C36 light chain

<400> 328

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser His Ser Ile Ser Lys Tyr
20 25 30

Phe Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Glu Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Tyr Tyr Tyr Gly Thr Ser
85 90 95

Ser Ser Tyr Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr
100 105 110

Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu
115 120 125

Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro
130 135 140

Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly
145 150 155 160

Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr
165 170 175

Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His
180 185 190

Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val
195 200 205

Thr Lys Ser Phe Asn Arg Gly Glu Cys
210 215

<210> 329

<211> 447

<212> PRT

<213> Artificial Sequence

<220>

<223> Humanized C4 heavy chain with FC-1 mutations

<400> 329

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Asn Asn
20 25 30

Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Gly Cys Ile Ala Thr Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gly Ala Ala Gly Ser Ser Trp Thr Thr Tyr Phe Asp Phe
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Asp Lys Thr His
210 215 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Asp Val
225 230 235 240

Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285

Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser
290 295 300

Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320

Cys Lys Val Ser Asn Lys Ala Leu Pro Leu Pro Glu Glu Lys Thr Ile
325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser
385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 330
<211> 447
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized C4 heavy chain with FC-2 mutations

<400> 330

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Ile Ser Asn Asn
20 25 30

Tyr Trp Ile Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Gly Cys Ile Ala Thr Gly Asp Gly Ser Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Gly Ala Ala Gly Ser Ser Trp Thr Thr Tyr Phe Asp Phe
100 105 110

Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly
115 120 125

Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly
130 135 140

Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val
145 150 155 160

Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe
165 170 175

Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val
180 185 190

Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val
195 200 205

Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Asp Lys Thr His
210 215 220

Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val
225 230 235 240

Phe Leu Leu Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr
245 250 255

Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu
260 265 270

Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys
275 280 285

Thr Lys Pro Pro Glu Glu Gln Tyr Asn Ser Thr Leu Arg Val Val Ser
290 295 300

Ile Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys
305 310 315 320

Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile
325 330 335

Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro
340 345 350

Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu
355 360 365

Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn
370 375 380

Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Leu Val Leu Asp Ser
385 390 395 400

Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg
405 410 415

Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu
420 425 430

His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys
435 440 445

<210> 331
<211> 217
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized C4 light chain

<400> 331

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Gly Gln Asn Ile Asp Asn Tyr
20 25 30

Leu Ser Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Arg Ala Ser Thr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Asn Asn Asn Gly Gly Ser Thr
85 90 95

Phe Thr Gly Phe Pro Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu
210 215

<210> 332
<211> 451
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized C53 with FC-1 mutations

<400> 332

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile His Ser Ser Ser Gly Thr Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Asp Phe Ser Tyr Thr Asp Asp Tyr Ile Ser Tyr Val Tyr
100 105 110

Ala Thr Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
115 120 125

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
130 135 140

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
145 150 155 160

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
 165 170 175

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
 180 185 190

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
 195 200 205

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
 210 215 220

Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240

Gly Pro Asp Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255

Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270

Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285

His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr
 290 295 300

Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320

Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Leu Pro Glu
 325 330 335

Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350

Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365

Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380

Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro
 385 390 395 400

Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415

Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430

His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
435 440 445

Pro Gly Lys
450

<210> 333
<211> 451
<212> PRT
<213> Artificial Sequence

<220>
<223> Humanized C53 with FC-2 mutations

<400> 333

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly
1 5 10 15

Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Ser Gly
20 25 30

Tyr Asp Met Cys Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35 40 45

Ile Ala Cys Ile His Ser Ser Ser Gly Thr Thr Tyr Tyr Ala Ser Trp
50 55 60

Ala Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65 70 75 80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
85 90 95

Cys Ala Arg Asp Phe Ser Tyr Thr Asp Asp Tyr Ile Ser Tyr Val Tyr
100 105 110

Ala Thr Asp Leu Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala
115 120 125

Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Ser Ser Lys Ser
130 135 140

Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe
145 150 155 160

Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly
165 170 175

Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu
180 185 190

Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr
195 200 205

Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys Lys
 210 215 220
 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly
 225 230 235 240
 Gly Pro Ser Val Phe Leu Leu Pro Pro Lys Pro Lys Asp Thr Leu Met
 245 250 255
 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His
 260 265 270
 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val
 275 280 285
 His Asn Ala Lys Thr Lys Pro Pro Glu Glu Gln Tyr Asn Ser Thr Leu
 290 295 300
 Arg Val Val Ser Ile Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly
 305 310 315 320
 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile
 325 330 335
 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val
 340 345 350
 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser
 355 360 365
 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu
 370 375 380
 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Leu
 385 390 395 400
 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val
 405 410 415
 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met
 420 425 430
 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser
 435 440 445
 Pro Gly Lys
 450

<210> 334
 <211> 217
 <212> PRT

<213> Artificial Sequence

<220>

<223> Humanized C53 light chain

<400> 334

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly
1 5 10 15

Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Ser Ile Gly Ser Ser
20 25 30

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Val Pro Lys Leu Leu Ile
35 40 45

Tyr Ala Ala Ser Tyr Leu Ala Ser Gly Val Pro Ser Arg Phe Ser Gly
50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Pro
65 70 75 80

Glu Asp Val Ala Thr Tyr Tyr Cys Gln Ser Thr Tyr Tyr Ser Ser Ser
85 90 95

Thr Asp Ile Arg Ala Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg
100 105 110

Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln
115 120 125

Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr
130 135 140

Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser
145 150 155 160

Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr
165 170 175

Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys
180 185 190

His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro
195 200 205

Val Thr Lys Ser Phe Asn Arg Gly Glu
210 215

<210> 335

<211> 5

<212> PRT

<213> Artificial Sequence

<220>

<223> CD3 VH CDR1

<400> 335

Gly Tyr Gly Met His
1 5

<210> 336

<211> 17

<212> PRT

<213> Artificial Sequence

<220>

<223> CD3 VH CDR2

<400> 336

Val Ile Trp Tyr Asp Gly Ser Lys Lys Tyr Tyr Val Asp Ser Val Lys
1 5 10 15

Gly

<210> 337

<211> 9

<212> PRT

<213> Artificial Sequence

<220>

<223> CD3 VH CDR3

<400> 337

Gln Met Gly Tyr Trp His Phe Asp Leu
1 5

<210> 338

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CD3 VL CDR1

<400> 338

Arg Ala Ser Gln Ser Val Ser Ser Tyr Leu Ala
1 5 10

<210> 339

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> CD3 VL CDR2

<400> 339

Asp Ala Ser Asn Arg Ala Thr
1 5

<210> 340

<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CD3 VL CDR3

<400> 340

Gln Gln Arg Ser Asn Trp Pro Pro Leu Thr
1 5 10

<210> 341
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR VH CDR1

<400> 341

Gly Tyr Thr Phe Thr Arg Tyr Thr
1 5

<210> 342
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CD3 VH CDR2

<400> 342

Ile Asn Pro Ser Arg Gly Tyr Thr
1 5

<210> 343
<211> 12
<212> PRT
<213> Artificial Sequence

<220>
<223> CD3 VH CDR3

<400> 343

Ala Arg Tyr Tyr Asp Asp His Tyr Cys Leu Asp Tyr
1 5 10

<210> 344
<211> 5
<212> PRT
<213> Artificial Sequence

<220>
<223> CD3 VL CDR1

<400> 344

Ser Ser Val Ser Tyr
1 5

<210> 345
<211> 3
<212> PRT
<213> Artificial Sequence

<220>
<223> CD3 VL CDR2

<400> 345

Asp Thr Ser
1

<210> 346
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CD3 VL CDR3

<400> 346

Gln Gln Trp Ser Ser Asn Pro
1 5